

**MFT TRUST FORMULARY****Manchester University**  
NHS Foundation Trust

	<b>BNF Chapter</b>
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

**Version 9.6 (July 2024)**

Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

## Formulary status definitions

**Formulary** (OK to be prescribed - but after any 1<sup>st</sup> or 2<sup>nd</sup> line options)

1<sup>st</sup> line formulary (when there are few formulary options, this is the 1<sup>st</sup> choice)

2<sup>nd</sup> line formulary (when there are few formulary options, this is the 2<sup>nd</sup> choice)

Where there is no preferred 1<sup>st</sup> line agent provided, the drug choice appears in alphabetical order.

1<sup>st</sup> line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



## PCT Red/Amber/Green classifications



### Adult RAG, DNP & Grey list Paediatric RAG, DNP & Grey list

#### Red

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

#### Amber

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP). [See here for a list of GMMMG approved SCPs.](#)

#### Green

Drugs that are suitable for initiation and ongoing prescribing within primary care.

#### Green

specialist initiation

Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

#### Green

following specialist recommendation

Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

**Do Not Prescribe:** DNP

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

**Grey:** Grey

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

**Unlicensed:** U

Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be highlighted in the template as follows: drug name<sup>U</sup>

### MMC Medicines Management Committee decision tables

Summary of Product Characteristics

Bluetec Enabled Forms

British National Formulary (BNF)

Controlled Drug

British National Formulary for Children (BNFC)

High Cost Medicine

NICE guidance

Payment by Results high cost excluded drug

**NOT STOCKED** Not routinely stocked, can be ordered if existing patient supply is exhausted

## PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY



GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Paediatric **Red/Amber/Green**; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

## Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (**No password required**)

British National Formulary for Children (**No password required**)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

# Section 1: Gastro-Intestinal System

Supported by the  
formulary ([click here](#))



## 1.1 Dyspepsia & gastro-oesophageal reflux disease

1.1.1 Antacids & Simeticone

1.1.2 Compound Alginates & Proprietary Indigestion Preparations

## 1.2 Anti-spasmodics & other drugs altering gut motility

Antimuscarinics

Other Antispasmodics

Motility Stimulants

## 1.3 Antisecretory drugs & mucosal protectants

1.3.1 H<sub>2</sub>-Receptor Antagonists

1.3.3 Chelates & Complexes

1.3.5 Proton Pump Inhibitors

## 1.4 Acute diarrhoea

1.4.2 Antimotility Drugs

## 1.5 Chronic bowel disorders

1.5.1 Aminosalicylates

1.5.2 Corticosteroids & Enemas

1.5.3 Drugs Affecting the Immune Response

Advanced therapies (biologic and targeted synthetic treatments)

## 1.6 Laxatives

1.6.1 Bulk-forming Laxatives

1.6.2 Stimulant Laxatives

1.6.3 Faecal Softeners

1.6.4 Osmotic Laxatives

1.6.5 Bowel Cleansing Preparation

1.6.6 Peripheral opioid-receptor antagonists

1.6.7 Other drugs used in constipation

## 1.7 Local preparations for anal & rectal disorders

1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids

1.7.4 Management of anal fissures

## 1.9 Drugs affecting intestinal secretions

1.9.1 Drugs affecting biliary composition & flow

1.9.2 Bile acid sequestrants

1.9.4 Pancreatin

## 1.10 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines





GASTRO / ENDOSCOPY - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)
















## NICE Guidance
























Biosimilar Medicines (KTT15)  
 Faecal Incontinence (CG49)  
 Irritable Bowel Syndrome (CG61)  
 Diarrhoea and vomiting in children under 5 (CG84)  
 Constipation in children and young people (CG99)  
 Acute upper GI bleeding (CG141)  
 Dyspepsia and gastro-oesophageal reflux disease (CG184)  
 Coeliac disease: recognition, assessment and management (NG20)  
 Crohn's disease: management (NG129)  
 Ulcerative colitis: management (NG130)  
 Ulcerative colitis (acute exacerbations) - infliximab (TA163)  
 Crohn's disease - infliximab & adalimumab (TA187)  
 Constipation (women) - prucalopride (TA211)  
 Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)  
 Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)  
 Naloxegol for treating opioid induced constipation (TA345)  
 Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)  
 Obeticholic acid for treating primary biliary cholangitis (TA443)  
 Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)  
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)  
 Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)  
 Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)  
 Naldemedine for treating opioid-induced constipation (TA651)  
 Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)  
 Filgotinib for treating moderately to severely active ulcerative colitis (TA792)  
 Teduglutide for treating short bowel syndrome (TA804)  
 Ozanimod for treating moderately to severely active ulcerative colitis (TA828)  
 Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)  
 Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)  
 Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)  
 Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)  
 Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

## GMMMG Formulary

Formulary Homepage  
 Chapter 1: Gastro-Intestinal system (Complete)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

1.1 Dyspepsia & gastro-oesophageal reflux disease		GMMMG
<b>1.1.1 Antacids &amp; Simeticone</b>		
<b>Aluminium &amp; Magnesium Containing Antacids</b>		
<b>Co-magaldrox</b>	 195/220 suspension <sup>SF</sup>	<b>1<sup>st</sup> line use</b>
<b>Magnesium Trisilicate</b>	 suspension	
<b>Simeticone alone (activated dimeticone)</b>		
<b>Simeticone</b>	 DNP Infacol® 40mg/mL liquid	<b>RESTRICTED</b> Paediatric use only
<b>1.1.2 Compound Alginates &amp; Proprietary Indigestion Preparations</b>		
<b>Alginate raft-forming oral suspensions<sup>SF</sup></b>	 DNP suspension	

1.2 Anti-spasmodics & other drugs altering gut motility		GMMMG
<b>Antimuscarinics</b>		
<b>Hyoscine Butylbromide</b>		
tablets; injection	 	
MHRA Drug Safety Update (Feb-17): Hyoscine butylbromide (Buscopan) injection: risk of serious adverse effects in patients with underlying cardiac disease		
<b>Glycopyrronium Bromide (Glycopyrrolate)</b>		
	  	
(Robinul®, Sialanar®) tablets; injection; oral solution; cream		
<b>Other Antispasmodics</b>		
<b>Mebeverine Hydrochloride</b>		
135mg tablets	 	<b>1<sup>st</sup> line use</b>
<b>Peppermint oil</b>		
capsules	 	
<b>Motility Stimulants</b>		
<b>Metoclopramide</b>		
10mg tablets ( <a href="#">see also section 4.6</a> )	 	<b>1<sup>st</sup> line use</b>
MHRA (Aug-13): Metoclopramide: risk of neurological adverse effects		
<b>Domperidone</b>		
	 	<b>Use where 1<sup>st</sup> line unsuitable</b>
10mg tablets ( <a href="#">see also section 4.6</a> )		
MHRA Drug Safety Update (Dec19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents		
MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects		
MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects		

1.3 Antisecretory drugs & mucosal protectants		
<b>1.3.1 H<sub>2</sub>-receptor antagonists</b>		
<b>Famotidine</b>		
<p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>20mg; 40mg tablets</p>	  	
<b>Ranitidine</b>		
<p>150mg; 300mg tablets</p>	 	
<b>1.3.3 Chelates &amp; Complexes</b>		
<b>Sucralfate</b>		
<p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>1g tablets; oral suspension</p>	  	
<b>Bismuth Subsalicylate (Pepto-Bismol®)</b>		
<p>262.5mg chewable tablets</p>	  	<p><b>RESTRICTED</b> Adults, H. Pylori eradication regime</p>
<b>1.3.5 Proton Pump Inhibitors</b>		
<b>Omeprazole</b>		
<p>10mg; 20mg; 40mg capsules; 40mg infusion</p>	  	
<b>Lansoprazole</b>		
<p>15mg &amp; 30mg capsules; 15mg &amp; 30mg orodispersible tablets</p>	   	<p><b>RESTRICTED</b> tablets - enteral feeding tubes / dysphagia</p>
<b>Esomeprazole</b>		
<p>40mg infusion</p>	  	<p><b>RESTRICTED</b> PPI indicated / enteral route not available/appropriate</p>
<p>MHRA (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice                      MHRA Drug Safety Update (Sep-15): Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus</p>		
<p><b>Other PPIs are not available at this Trust</b></p>		



# 1.4 Acute diarrhoea



## 1.4.2 Antimotility Drugs

### Loperamide hydrochloride

DNP

2mg capsules; 1mg/5mL syrup<sup>SF</sup>



**1<sup>st</sup> line use**

### Codeine Phosphate

15mg; 30mg & 60mg tablets



**RESTRICTED**  
Adults - high output stomas

























































































### Teduglutide




























































Revestive ® injection



**RESTRICTED** Gastro. Consultants  
only in line with NICE TA804

1.5 Chronic bowel disorders		GMMMG
<b>1.5.1 Aminosalicylates</b>		
<b>Mesalazine</b>  tablets; M/R tablets; M/R granules; enema; foam enema; suppositories	 	<b>PRESCRIBE BY BRAND NAME</b>
<b>Balsalazide Sodium</b> 750mg capsules	  	
<b>1.5.2 Corticosteroids &amp; Enemas</b>		
<b>Prednisolone</b> 5mg tablets	 	<b>1<sup>st</sup> line use</b>
<b>Budesonide (Budenofalk®)</b> 3mg capsules; rectal foam	  	
<b>Budesonide (Jorveza®)</b>  1mg orodispersible tablets	   	<b>RESTRICTED</b> Adults - eosinophilic esophagitis
<b>Budesonide</b>  3mg CR capsules	  	<b>RESTRICTED</b> Adults - Gastro. Consultants only
<b>Hydrocortisone</b> foam enema	 	
<b>Short chain fatty acid enema</b>  Nutricol® enema	  	<b>RESTRICTED</b> Adults - Gastro. Consultants only
<b>1.5.3 Drugs Affecting the Immune Response</b>		
<b>Azathioprine</b>  tablets; oral solution (see also sections 8.2.1; 10.1.3 & 13.5.3)	 	<b>1<sup>st</sup> line use</b>
<b>Ciclosporin (oral and I.V. preparations)</b>  capsules; infusion; oral solution (see also section 8.2.2)	  	
<b>Mercaptopurine</b>  tablets; oral suspension (see also section 8.1.3)	 	
<b>Methotrexate (s/c and oral preparations)</b>  tablets; injection; oral solution (see also section 10.1.3)	  	
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing		
<b>Advanced therapies (biologic and targeted synthetic treatments)</b>		
<b>Adalimumab</b>   injection (see also sections 10.1.3, 11.4.2 & 13.5.3)	     	<b>RESTRICTED</b> Gastro. Consultants for IBD as per NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
<b>Infliximab</b>   infusion (see also sections 10.1.3 & 13.5.3)	     	<b>RESTRICTED</b> Gastro. Consultants for IBD as per NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
<b>Etrasimod</b>   Velsipity® tablets	     	<b>RESTRICTED</b> Gastro. Consultants in line with NICE TA956
<b>Filgotinib</b>   100mg; 200mg tablets (see also section 10.1.3)	     	<b>RESTRICTED</b> Gastro. Consultants for Ulcerative colitis as per NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality		
<b>Golimumab</b>   injection (see also section 10.1.3)	     	<b>RESTRICTED</b> Gastro. Consultants for IBD as per NICE
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors: risk of TB — screen all patients before starting treatment and monitor them closely		
<b>Mirikizumab</b>   Omvoh® injection; infusion	     	<b>RESTRICTED</b> Gastro. Consultants in line with NICE TA925

<p><b>Ozanimod</b>                         Zeposia® capsules       </p>	<p><b>RESTRICTED</b> Gastro. Consultants in line with NICE TA828</p>
<p><b>Risankizumab</b>                         75mg; 150mg injection       </p>	<p><b>RESTRICTED</b>                      Specialist use only in line with NICE TA888</p>
<p><b>Tofacitinib</b>                         tablets (see also section 10.1.3)       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality                      MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies                      MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of VTE and of serious and fatal infections                      MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing</p>	
<p><b>Upadacitinib</b>                         MR tablet (see also section 10.1.3)       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE TA856 / TA905</p>
<p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality</p>	
<p><b>Ustekinumab</b>                         injection (see also sections 10.1.3)       </p>	<p><b>RESTRICTED</b> Gastro. Consultants as per NICE</p>
<p><b>Vedolizumab</b>                         infusion       </p>	<p><b>RESTRICTED</b> Gastro. Consultants for IBD as per NICE</p>
<p><b>ICAM-1 Inhibitor</b></p>	
<p><b>Alicaforsen</b>                         enema     </p>	<p><b>RESTRICTED</b>                      Gastro. Consultants only - pouchitis</p>

1.6 Laxatives		GMMMG
<b>1.6.1 Bulk-forming Laxatives</b>		
<b>Ispaghula husk</b>		<b>1<sup>st</sup> line use</b>
3.5g sachets	 	
<b>1.6.2 Stimulant Laxatives</b>		
<b>Docusate Sodium</b>		<b>1<sup>st</sup> line use</b>
capsules; oral solution	 	
<b>Senna</b>		<b>1<sup>st</sup> line use</b>
 tablets; oral solution	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
<b>Bisacodyl</b>		
tablets; suppositories	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
<b>Glycerol</b>		
suppositories	 	
<b>Sodium Picosulfate</b>		
oral solution	 	
MHRA Drug Safety Update (Aug-20): Stimulant laxatives (bisacodyl, senna and sennosides, sodium picosulfate) available OTC: new measures to support safe use		
<b>Co-Danthramer</b>		<b>RESTRICTED</b> Adults, Palliative Care only
oral suspension	 	
<b>Co-Danthrusate</b>		<b>RESTRICTED</b> Adults, Palliative Care only
oral suspension	 	
<b>1.6.3 Faecal Softeners</b>		
<b>Arachis oil</b>		
enema	 	
<b>1.6.4 Osmotic Laxatives</b>		
<b>Lactulose</b>		<b>1<sup>st</sup> line use</b>
 oral solution	 	
<b>Macrogols (Polyethylene glycols)</b>		<b>2<sup>nd</sup> / 3<sup>rd</sup> line use</b> Rehab patients / paediatrics
 sachets	  	
<b>Phosphates (Rectal)</b>		
128mL enema	 	
<b>Sodium Citrate (Rectal)</b>		
450mg micro-enema	 	
<b>1.6.5 Bowel Cleansing Preparations</b>		
NPSA RRR (Feb-09): Reducing risk of harm from oral bowel cleansing solutions		
<b>Sodium Picosulfate with Magnesium Citrate</b>		<b>1<sup>st</sup> line use</b>
<i>Picolax</i> ® oral powder	 	
<b>Macrogols (<i>Klean-Prep</i>® &amp; <i>Moviprep</i>®) oral powder</b>		
oral powder	 	
<b>1.6.6 Peripheral opioid-receptor antagonists</b>		
<b>Methylnaltrexone Bromide</b>		<b>RESTRICTED</b> Adults, Palliative Care only
injection	 	
<b>Naldemedine</b>		<b>RESTRICTED</b> Adults only in line with TA651
 200 microgram tablets	   	
<b>Naloxegol</b>		<b>RESTRICTED</b> Adults only in line with TA345
 12.5mg; 25mg tablets	   	

**1.6.7 Other drugs used in constipation****Prucalopride**

Green

1mg; 2mg tablets

NICE MMC BNF emc














**RESTRICTED - Adult women, Gastro.  
Consultants only****Linaclootide**

Green

290 micrograms capsules

MMC BNF emc

**RESTRICTED - 3<sup>rd</sup> line use Adults  
Gastro. Consultants only**

1.7 Local preparations for anal & rectal disorders		GMMMG
<b>1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids</b>		
<b>Anusol®</b>		
DNP	 	
ointment		
<b>Proctosedyl®</b>		
	 	
ointment		
<b>Scheriproct®</b>		
	 	
ointment; suppositories		
<b>1.7.4 Management of anal fissures</b>		
<b>Glyceryl Trinitrate</b>		<b>1<sup>st</sup> line for anal fissure</b>
<i>Rectogesic</i> ® 0.4% ointment	  	
<b>Diltiazem Hydrochloride</b>		
 		
2% cream; ointment	 	

1.9 Drugs affecting intestinal secretions		GMMG
<b>1.9.1 Drugs affecting biliary composition &amp; flow</b>		
<p><b>Ursodeoxycholic acid</b></p> <p>150mg tablets</p> <p style="text-align: right;">MMC BNF emc</p>		<b>1<sup>st</sup> line use</b>
<p><b>Obeticholic acid</b></p> <p><span style="border: 1px solid black; border-radius: 50%; padding: 2px;">££</span></p> <p>Ocaliva® 5mg; 10mg tablets</p> <p style="text-align: right;">PbR X NICE MMC BNF blueiteq emc</p>		<b>RESTRICTED</b> Hepatology Consultants only 2 <sup>nd</sup> line per TA443
<b>1.9.2 Bile acid sequestrants</b>		
<p><b>Colestyramine</b></p> <p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>powder 4g sachet (see also section 2.12)</p> <p style="text-align: right;">BNF emc</p>		<b>1<sup>st</sup> line use</b>
<p><b>Colesevelam Hydrochloride</b></p> <p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>625mg tablets (see also section 2.12)</p> <p style="text-align: right;">MMC BNF emc</p>		<b>RESTRICTED</b> adults. Gastro & Lipid Clinic Consultants only
<b>1.9.4 Pancreatin</b>		
<p><b>Pancreatin</b></p> <p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>capsules</p> <p style="text-align: right;">BNF emc</p>		<b>NOT STOCKED</b>

# 1.10 Miscellaneous preparations



## Glucarpidase













Voraxaze® 1,000 unit injection (see also sections 8.4, 10.4 & 13.14)



**RESTRICTED**  
2<sup>nd</sup> line rescue therapy





Non-Formulary Items		
<p><b>Darvadstrocel</b></p> <p>DNP</p> <p><i>Alofisel</i>® 5 million cells/mL injection</p>	  	<p><b>REJECTED in line with NICE TA556</b></p>
<p><b>OTC haemorrhoid preparations</b></p> <p>DNP</p>	  	<p><b>in line with GMMMG</b></p>
<p><b>Rifaximin</b></p> <p>DNP</p> <p>200mg tablets (<a href="#">see also section 5.1.7</a>)</p>	   	<p><b>in line with GMMMG for Traveller's diarrhoea</b></p>

## Section 2: Cardiovascular System

Supported by the  
formulary (click here)



### 2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

### 2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

### 2.3 Anti-arrhythmic drugs

- 2.3.2 Drugs for Arrhythmias

### 2.4 Beta-adrenoceptor blocking drugs

### 2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
  - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
  - 2.5.5.2 Angiotensin-II Receptor Antagonists
  - 2.5.5.3 Renin Inhibitors
  - 2.5.5.4 Heart Failure

### 2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

### 2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

### 2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

### 2.9 Antiplatelet drugs

### 2.10 Stable angina, acute coronary syndromes & fibrinolysis

- 2.10.2 Fibrinolytic Drugs

### 2.11 Antifibrinolytic drugs & haemostatics

### 2.12 Lipid-regulating drugs

### 2.13 Local sclerosants

### 2.14 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines















CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)


























## NICE Guidance































Prophylaxis against infective endocarditis (CG64)  
 Familial hypercholesterolaemia (CG71)  
 Chest pain of recent onset (CG95)  
 Stable angina (CG126)  
 Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)  
 Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)  
 Chronic heart failure in adults: diagnosis and management (NG106)  
 Hypertension in pregnancy: diagnosis and management (NG133)  
 Hypertension in adults: diagnosis and management (NG136)  
 Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)  
 Acute coronary syndromes (NG185)  
 Atrial fibrillation: diagnosis and management (NG196)  
 Volanesorsen for treating familial chylomicronaemia syndrome (HST13)  
 Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47)  
 Myocardial infarction - thrombolysis (TA52)  
 Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)  
 Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated by TA95 & TA126)  
 Hypercholesterolaemia - Ezetimibe (TA132)  
 Coronary artery disease - drug eluting stents (TA152)  
 Venous thromboembolism - dabigatran (TA157)  
 Rivaroxaban for the prevention of VTE (TA170)  
 Atrial Fibrillation - dronedarone (TA197)  
 Vascular disease - clopidogrel and dipyridamole (TA210)  
 Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)  
 Acute coronary syndromes - ticagrelor (TA236)  
 Venous thromboembolism - apixaban (hip and knee surgery) (TA245)  
 Atrial fibrillation - dabigatran etexilate (TA249)  
 Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)  
 Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)  
 Stroke (acute, ischaemic) - alteplase (TA264)  
 Chronic heart failure - ivabradine (TA267)  
 Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)  
 Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)  
 Prasugrel with PCI for treating ACS (review of TA182) (TA317)  
 Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)  
 Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)  
 Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)  
 Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)  
 Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)  
 Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)  
 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)  
 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)  
 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)  
 Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)  
 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)  
 Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)  
 Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)  
 andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)  
 Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)  
 Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)  
 Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)  
 Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)  
 Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)  
 Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)  
 Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)  
 Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)
























## GMMMG Formulary

































































Formulary Homepage  
 Chapter 2: Cardiovascular system (Complete)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

2.1 Positive inotropic drugs		GMMMG
<b>2.1.1 Cardiac Glycosides</b>		
<b>Digoxin</b>		<b>1<sup>st</sup> line use</b>
tablets; elixir; injection	 	
<b>Digoxin-specific antibody</b>		
 		
infusion	 	
<b>2.1.2 Phosphodiesterase Inhibitors</b>		
<b>Enoximone</b>		
<i>Perfan</i> ® 5mg/1mL injection	 	
<b>Milrinone</b>		<b>1<sup>st</sup> line use Paediatrics</b>
<i>Primacor</i> ® 10mg/10mL injection	  	
<b>Levosimendan</b>		<b>RESTRICTED adults.</b> Cardiology ITU Consultant only
<i>Simdax</i> ® 12.5mg/5mL Injection	  	





























2.2 Diuretics		GMMMG
<b>2.2.1 Thiazides &amp; Related Diuretics</b>		
<b>Bendroflumethiazide</b>		<b>1<sup>st</sup> line use</b>
tablets	 	
<b>Chlortalidone</b>		
tablets	 	
<b>Metolazone</b>		<b>2<sup>nd</sup> line use with loop diuretic</b>
 tablets	<b>MMC</b>  	
MHRA Drug Safety Update (Jan-23): Xaqu (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations		
<b>2.2.2 Loop Diuretics</b>		
<b>Furosemide</b>		<b>1<sup>st</sup> line use</b>
tablets; liquid; injection	 	
<b>Bumetanide</b>		<b>2<sup>nd</sup> line use</b>
tablets; oral solution	 	
<b>2.2.3 Potassium-sparing Diuretics &amp; Aldosterone Antagonists</b>		
<b>Amiloride hydrochloride</b>		<b>1<sup>st</sup> line use</b>
tablets; oral solution	 	
<b>Spirolactone</b>		<b>1<sup>st</sup> line use</b>
tablets	 	
MHRA Drug Safety Update (Feb-16): Spirolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
<b>Eplerenone</b>		<b>RESTRICTED adults. Cardiology Consultant only</b>
 tablets	<b>MMC</b>  	
<b>Finerenone</b>		<b>RESTRICTED adults. Diabetes / Renal Consultant only</b>
 <i>Kerendia</i> ® tablets	<b>NICE</b> <b>MMC</b>  	
<b>2.2.4 Potassium-sparing Diuretics with other Diuretics</b>		
<b>Co-amilofruse</b>		<b>1<sup>st</sup> line use</b>
tablets	 	
<b>2.2.5 Osmotic Diuretics</b>		
<b>Mannitol</b>		
infusion	 	


































2.3 Anti-arrhythmic drugs		GMMMG
<b>2.3.2 Drugs for Arrhythmias</b>		
<b>Adenosine</b>		
injection	 	
<b>Amiodarone Hydrochloride</b>		
 	tablets; injection	 
MHRA Drug Safety Update (Mar-22): Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision		
<b>Disopyramide</b>		
capsules; tablets	 	
<b>Flecainide Acetate</b>		
 Paeds - until stabilised then 	tablets; injection	 
<b>Lidocaine (Lignocaine) Hydrochloride</b>		
injection	 	
<b>Mexiletine</b>		
	<i>NaMuscla</i> ® 167mg capsules	   
<b>Mexiletine Hydrochloride</b>		
	<i>Mexitil</i> ® 50mg; 100mg; 200mg capsules	  
<b>Propafenone Hydrochloride</b>		
tablets	 	
<b>Dronedaron</b>		
	tablets	   
MHRA Drug Safety Update (Oct-11): Dronedaron (Multaq ▼): cardiovascular, hepatic and pulmonary adverse events – new restrictions and monitoring requirements		
		<b>RESTRICTED</b> Neurology only
		<b>RESTRICTED</b> Cardiology / Neurology only
		<b>RESTRICTED</b> adults. Cardiology Consultant only, in line with TA197




























2.4 Beta-adrenoceptor blocking drugs		GMMMG
		NICE NG106
		NICE NG136
		NICE NG196
<b>2.4 Beta-Adrenoceptor Blocking Drugs</b>		
<b>Atenolol</b>		
tablets; liquid; injection	 	
<b>Bisoprolol Fumarate</b>		<b>RESTRICTED</b> adults. Cardiology Consultant only
tablets	MMC  	
<b>Carvedilol</b>		<b>RESTRICTED</b> adults. Cardiology Consultant only <b>ALSO 2ND LINE FOR VARICEAL BLEED</b>
tablets	MMC  	
<b>Esmolol Hydrochloride</b>		<b>RESTRICTED</b> I.V. only
injection	 	
<b>Etilefrine Hydrochloride</b>		<b>RESTRICTED</b> Haematology Consultants - SCD
 tablets	MMC  	
<b>Labetalol Hydrochloride</b>		<b>RESTRICTED</b> oral preps in pregnancy
tablets; injection	 	
<b>Metoprolol Tartrate</b>		
tablets; injection	 	
<b>Nadolol</b>		<b>RESTRICTED</b> paed. ventricular arrhythmias in long QT syndrome
tablets	MMC  	
<b>Nebivolol</b>		
tablets	 	
<b>Propranolol Hydrochloride</b>		<b>RESTRICTED</b> not in Cardiology
tablets; capsules; oral solution; injection	 	
<b>Sotalol Hydrochloride</b>		
tablets	 	

2.5 Hypertension & heart failure		GMMMG
		NICE NG106
		NICE NG136
		NICE NG196
2.5.1 Vasodilator Antihypertensive Drugs		NHSE PAH
<b>Hydralazine Hydrochloride</b>		<b>1<sup>st</sup> line use</b>
tablets; injection	 	
<b>Minoxidil</b>		
tablets	 	
<b>Ambrisentan</b>		<b>RESTRICTED</b> PAH in line with NHSE
 	   	
tablets		
<b>Bosentan</b>		<b>RESTRICTED</b> PAH in line with NHSE
 	   	
tablets		
<b>Sildenafil</b>		<b>RESTRICTED</b> PAH in line with NHSE
 	  	
Revatio® tablets; injection (see also section 7.4.5)		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio and Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
<b>Macitentan</b>		<b>RESTRICTED</b> PAH in line with NHSE
 	   	
Opsumit® tablets		
<b>Tadalafil</b>		<b>RESTRICTED</b> PAH in line with NHSE
 	   	
Adcirca® tablets (see also section 7.4.5)		
2.5.2 Centrally Acting Antihypertensive Drugs		
<b>Clonidine Hydrochloride</b>		
tablets; oral solution; injection; patches	  	
<b>Methyldopa</b>		
tablets	 	
<b>Moxonidine</b>		<b>RESTRICTED 3<sup>rd</sup> line use</b> after other treatments fail
	  	
tablets		
2.5.4 Alpha-Adrenoceptor Blocking Drugs		
<b>Doxazosin</b>		<b>1<sup>st</sup> line use</b>
	 	
1mg; 2mg & 4mg tablets		
<b>Phenoxybenzamine Hydrochloride</b>		<b>RESTRICTED adults.</b> Specialist initiation only
10mg capsules	 	
<b>Phentolamine Mesilate</b>		<b>RESTRICTED adults.</b> Specialist use, theatres only
injection	 	
2.5.5 Drugs Affecting the Renin-Angiotensin System		
2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
<b>Ramipril</b>		
1.25mg; 2.5mg; 5mg & 10mg capsules	 	
<b>Captopril</b>		<b>RESTRICTED</b> Paediatrics only
12.5mg; 25mg & 50mg tablets	 	
<b>Lisinopril</b>		<b>1<sup>st</sup> line use</b>
2.5mg; 5mg; 10mg & 20mg tablets	  	GMMMG
<b>Perindopril</b>		
	 	
2mg; 4mg & 8mg tablets		













































<b>2.5.5.2 Angiotensin-II Receptor Antagonists</b>		
<b>MHRA Drug Safety Update (Feb-16):</b> Spironolactone and renin-angiotensin system drugs in heart failure: risk of potentially fatal hyperkalaemia		
<b>Candesartan Cilexetil</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> 2mg; 4mg; 8mg; 16mg & 32mg tablets   		<b>1<sup>st</sup> line use</b> hypertension 
<b>Losartan Potassium</b> 12.5mg; 25mg; 50mg & 100mg tablets   		<b>2<sup>nd</sup> line use</b> hypertension
<b>Irbesartan</b> 75mg; 150mg & 300mg tablets   		<b>2<sup>nd</sup> line use</b> hypertension
<b>Valsartan</b> 40mg; 80mg & 160mg capsules   		<b>2<sup>nd</sup> line use</b> hypertension
<b>Sacubitril / Valsartan</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> 24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets    		<b>RESTRICTED</b> use in line with NICE TA388
<b>2.5.5.3 Renin inhibitors</b>		
<b>Aliskiren</b> <span style="background-color: #cccccc; color: #333; padding: 2px;">DNP</span> 150mg; 300mg tablets   		<b>RESTRICTED</b> adults. Specialist initiation only
<b>MHRA Drug Safety Update (Mar-12):</b> Aliskiren (Rasilez ▼): risk of cardiovascular and renal adverse reactions		
<b>2.5.5.4 Heart Failure</b>		
<b>Dapagliflozin</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> Forxiga ® tablets    		<b>RESTRICTED</b> adults. Specialist initiation in line with TA679
<b>Empagliflozin</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> Jardiance ® tablets    		<b>RESTRICTED</b> adults. Specialist initiation in line with TA773



















2.6 Nitrates, calcium-channel blockers & other antianginals		GMMMG
<b>2.6.1 Nitrates</b>		
<b>Glyceryl Trinitrate</b>	 	
S/L tablets; S/L spray; patches; Injection; ointment		
<b>Isosorbide Mononitrate</b>	 	
tablets; capsules		
<b>2.6.2 Calcium-channel Blockers</b>		
<b>Amlodipine</b>	 	<b>1<sup>st</sup> choice dihydropyridine</b>
tablets; oral solution		
<b>Diltiazem</b>	 	<b>1<sup>st</sup> choice non-dihydropyridine</b> <b>PRESCRIBE BY BRAND NAME</b>
tablets; capsules; ointment		
<b>Nifedipine</b>	 	<b>2<sup>nd</sup> choice dihydropyridine</b> <b>PRESCRIBE BY BRAND NAME</b>
tablets; capsules; oral drops		
<b>Verapamil Hydrochloride</b>	 	<b>2<sup>nd</sup> choice non-dihydropyridine</b>
tablets; injection; oral solution		
<b>Nimodipine</b>	 	<b>RESTRICTED</b> subarachnoid haemorrhage / <i>V.</i> then oral
tablets; infusion		
<b>2.6.3 Other Antianginal Drugs</b>		
<b>Nicorandil</b>	 	<b>1<sup>st</sup> line use</b>
tablets		
MHRA Drug Safety Update (Jan-16): Nicorandil (Ikorel): now 2nd-line treatment for angina - risk of ulcer complications		
<b>Ivabradine</b>	   	<b>RESTRICTED</b> adults 2 <sup>nd</sup> line. Cardiology Consultant only
tablets		
MHRA Drug Safety Update (Dec-14): Ivabradine (Procoralan) in the symptomatic treatment of angina: risk of cardiac side effects		
<b>Ranolazine</b>	  	<b>RESTRICTED</b> adults 3 <sup>rd</sup> line angina patients not suitable for surgery
M/R tablets		
<b>2.6.4 Peripheral Vasodilators &amp; Related Drugs</b>		
<b>Naftidrofuryl Oxalate</b>	  	
capsules		
<b>Defibrotide</b>	    	<b>RESTRICTED</b> Specialist use only in line with NHSE
infusion		





















2.7 Sympathomimetics		GMMMG
<b>2.7.1 Inotropic Sympathomimetics</b>		
<b>Dobutamine</b>		<b>RESTRICTED / V.</b> Specialist use only
infusion	 	
<b>Dopamine Hydrochloride</b>		<b>RESTRICTED / V.</b> Specialist use only
infusion	 	
<b>Dopexamine</b>		<b>RESTRICTED / V.</b> Specialist use only
infusion	 	
<b>Isoprenaline</b>		<b>RESTRICTED / V.</b> Specialist use only
injection	 	
<b>2.7.2 Vasoconstrictor Sympathomimetics</b>		
<b>Adrenaline acid tartrate</b>		<b>Specialist use endoscopic sinus surgery</b>
 1 in 1000 (0.1%w/v) cutaneous solution)	  	
<b>Ephedrine Hydrochloride</b>		<b>RESTRICTED / V.</b> Specialist use only
injection	 	
<b>Metaraminol</b>		
 injection	 	
<b>Midodrine</b>		<b>Specialist use Cardiology / Healthcare of the elderly</b>
 tablets	  	
<b>Noradrenaline acid tartrate</b>		<b>RESTRICTED / V.</b> Specialist use only
infusion	 	
<b>Phenylephrine Hydrochloride</b>		<b>RESTRICTED / V.</b> Specialist use only
injection	 	
<b>2.7.3 Cardiopulmonary Resuscitation</b>		
<b>Adrenaline / Epinephrine</b>		
injection	 	

2.8 Anticoagulants & protamine		GMMMG
2.8.1 Parenteral Anticoagulants		NICE NG89
ACD-A Anticoagulant Citrate Dextrose		<b>RESTRICTED</b> Specialist use only CRRT
solution	MMC BNF emc	
Dalteparin Sodium		1 <sup>st</sup> line LMWH
injection	MMC BNF emc	
Epoprostenol		<b>RESTRICTED</b> / V. Specialist use only
infusion	PbR X BNF emc	
MHRA Drug Safety Update (Dec-14): Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices		
Heparin		
injection; infusion	BNF emc	
Bivalirudin		<b>RESTRICTED</b> adults. Cardiac Catheter Lab only.
infusion	NICE MMC BNF emc	
Fondaparinux Sodium		<b>RESTRICTED</b> adults. Haematology Consultants only.
injection	MMC BNF emc	
Tinzaparin Sodium		<b>RESTRICTED</b> Obs & Gynae; ACS & VTE in Renal impairment only. Paeds: haemodialysis
injection	MMC BNF emc	
Enoxaparin Sodium		<b>RESTRICTED</b> ACS & VTE in Renal impairment only.
injection	MMC BNF emc	
Argatroban monohydrate		<b>RESTRICTED</b> adults. Treatment of HIT
infusion	MMC BNF emc	
2.8.2 Oral Anticoagulants		
Acenocoumarol		<b>RESTRICTED</b> warfarin intolerant patients only.
tablets	BNF emc	
Phenindione		
tablets	BNF emc	
Warfarin Sodium		
tablets	PbR X BNF emc	
MHRA Drug Safety Update (Jun-24): Warfarin: be alert to the risk of drug interactions with tramadol		
MHRA Drug Safety Update (Oct-20): Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic		
MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR		
MHRA Drug Safety Update (Jul-16): Warfarin: reports of calciphylaxis		
Apixaban		<b>RESTRICTED</b> in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
Dabigatran Etexilte		<b>RESTRICTED</b> in line with NICE
capsules	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
MHRA Drug Safety Update (Jul-12): Dabigatran (Pradaxa ▼): risk of serious haemorrhage		
Edoxaban		<b>RESTRICTED</b> in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
Rivaroxaban		<b>RESTRICTED</b> in line with NICE
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (May-23): Direct-acting oral anticoagulants (DOACs): paediatric formulations; reminder of dose adjustments in patients with renal impairment		
MHRA Drug Safety Update (Jul-19): Rivaroxaban (Xarelto ▼): reminder that 15 mg and 20 mg tablets should be taken with food		
MHRA Drug Safety Update (Oct-18): Rivaroxaban (Xarelto ▼) after TAVR: increase in all-cause mortality, thromboembolic and bleeding events in a clinical trial		

<b>Antidotes</b>	
<p><b>Andexanet Alfa</b></p> <p> </p> <p><i>Ondexxya</i>® infusion</p> <p>   </p>	<b>RESTRICTED</b> in line with NICE
<p><b>Idarucizumab</b></p> <p> </p> <p><i>Praxbind</i>® infusion</p> <p>  </p>	<b>RESTRICTED</b> reversal of dabigatran in emergency surgery
<b>2.8.3 Protamine Sulfate</b>	
<p><b>Protamine Sulfate</b></p> <p>injection</p> <p>  </p>	

2.9 Antiplatelet drugs		GMMMG
		NICE NG185
<p><b>Aspirin</b></p> <p>tablets (dispersible &amp; E/C); suppositories</p>	 	
<p><b>Clopidogrel</b></p> <p>tablets</p> <p>MHRA Drug Safety Update (Dec-13): Clopidogrel: risk of acquired haemophilia                      MHRA Drug Safety Update (Apr-10): Clopidogrel and proton pump inhibitors: interaction—updated advice</p>	    	<p>For ACS patients; stroke patients intolerant of aspirin; high-risk patients who've stroked on aspirin</p>
<p><b>Ticagrelor</b></p> <p>Green</p> <p>tablets; orodispersible tablets</p>	   	<p>In combination with aspirin for primary PCI in ACS patients &amp; in line with NICE TA420</p>
<p><b>Prasugrel</b></p> <p>Green</p> <p>tablets</p> <p>MHRA Drug Safety Update (Jan-14): Prasugrel (Efient): increased risk of bleeding                      MHRA Drug Safety Update (May-11): Prasugrel (Efient ▼): rare but serious hypersensitivity reactions</p>	    	<p><b>RESTRICTED</b> adults. Cardiac Catheter Lab as per NICE</p>
<p><b>Dipyridamole</b></p> <p>M/R capsules; oral suspension; tablets; injection</p>	   	<p>2<sup>RY</sup> prevention of stroke in patients already on aspirin</p>
<p><b>Tirofiban</b></p> <p>infusion</p>	   	<p><b>RESTRICTED</b> adults. Cardiac Catheter Lab only (1<sup>st</sup> line)</p>
<p><b>Eptifibatide</b></p> <p>injection; infusion</p>	   	<p><b>RESTRICTED</b> adult patients admitted on this or tirofiban</p>

<b>2.10 Stable angina, ACS &amp; fibrinolysis</b>		
• Stable angina (BNF treatment summary)		
• Acute coronary syndromes (BNF treatment summary)		
• Fibrinolytic Drugs (BNF treatment summary)		<b>NICE CG126</b>
<b>2.10.2 Fibrinolytic Drugs</b>		<b>NICE NG128</b>
<b>Tenecteplase</b>  injection	   	
<b>Streptokinase</b>  infusion	  	
<b>Urokinase</b>  injection	 	
<b>Alteplase</b>  injection; infusion	   	<b>RESTRICTED</b>

2.11 Antifibrinolytic drugs & haemostatics		GMMMG
2.11 Antifibrinolytic Drugs & Haemostatics		
<b>Etamsylate</b>		
tablets	 	
<b>Tranexamic acid</b>		
injection; tablets	 	
<b>Aprotinin</b>		<b>RESTRICTED</b>
infusion	 	
<b>Aminocaproic acid</b>		<b>RESTRICTED</b>
sachets	  	
<b>Emicizumab</b>		<b>RESTRICTED</b> Haematology as per NHSE
 <b>Hemlibra</b> ® injection	   	 
<b>Vonicog alfa</b>		<b>RESTRICTED</b> Haematology as per NHSE
Veyvondi® injection	  	



2.12 Lipid-regulating drugs		GMMMG
<b>Statins</b>		
<b>Simvastatin</b>		
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
<b>Atorvastatin</b>		<b>1<sup>st</sup> line use</b>
DNP		
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
<b>Rosuvastatin</b>		<b>RESTRICTED</b> <b>Not stocked</b>
tablets	PbR X NICE MMC BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
<b>Pravastatin Sodium</b>		<b>RESTRICTED MCSH</b> for cases with potential drug interactions
tablets	PbR X NICE BNF emc	
MHRA Drug Safety Update (Sep-23): Statins: very infrequent reports of myasthenia gravis		
<b>Bile Acid Sequestrants</b>		
<b>Colestyramine</b>		
Green		
sachets (see also section 1.9.2)	BNF emc	
<b>Colesevelam Hydrochloride</b>		<b>RESTRICTED</b> adults. Gastro & Lipid Clinic Consultants only
Green		
tablets (see also section 1.9.2)	MMC BNF emc	
<b>Fibrates</b>		
<b>Bezafibrate</b>		
M/R tablets; tablets	BNF emc	<b>1<sup>st</sup> line use</b>
<b>Fenofibrate</b>		
67mg / 200mg / 267mg capsules; 160mg tablets	MMC BNF emc	<b>2<sup>nd</sup> line use</b>
<b>Omega-3 fatty acid compounds</b>		
<b>Omega-3-acid ethyl esters</b>		
Green		<b>2<sup>RY</sup> prevention post MI / Prevention of preterm birth</b>
capsules	PbR X MMC BNF emc	
MHRA Drug Safety Update (Jan-24): Omega-3-acid ethyl ester (1000mg caps): dose-dependent increased risk of AF in patients with established CV diseases or CV risk factors		
<b>Ezetimibe</b>		
<b>Ezetimibe</b>		
10mg tablets	NICE MMC BNF emc	<b>RESTRICTED</b> adults. Lipid Clinic Consultants only
<b>Lipid-regulating drugs</b>		
<b>Alirocumab</b>		
Red		<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with TA393
Praluent® injection	PbR X NICE MMC BNF emc	
<b>Bempedoic acid (see also Nustendi®)</b>		
Green		<b>RESTRICTED</b> adults. Consultants in line with TA694
Nilemdo® tablets	PbR X NICE MMC BNF emc	
<b>Bempedoic acid (see also Nilemdo®)</b>		
Green		<b>RESTRICTED</b> adults. Consultants in line with TA694
Nustendi® tablets	PbR X NICE MMC BNF emc	
<b>Evolocumab</b>		
Red		<b>RESTRICTED.</b> Lipid Clinic Consultants for HoFH / & NICE TA394
Repatha® injection	PbR X NICE MMC BNF emc	
<b>Icosapent Ethyl</b>		
Green		<b>RESTRICTED</b> adults in line with NICE TA805
Vazkepa® capsules	PbR X NICE MMC BNF emc	
<b>Inclisiran</b>		
Green		<b>RESTRICTED</b> adults. Consultants in line with TA733 for Primary Care Referral
Leqvio® injection	PbR X NICE MMC BNF emc	
<b>Lomitapide</b>		
Red	££	<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with NHSE 170059P
Lojuxta® capsules	PbR X MMC BNF emc	
<b>Volanesorsen</b>		
Red	££	<b>RESTRICTED</b> adults. Lipid Clinic Consultants in line with HST13
Waylivra® injection	PbR X NICE MMC BNF emc	

**2.13 Local sclerosants****Local Sclerosants****Ethanolamine Oleate**

injection

**Sodium Tetradecyl Sulfate**

injection



## 2.14 Miscellaneous preparations



### Ajmaline



Gilurytmal® 50mg/10mL injection



**RESTRICTED** adults.  
Cardiology Consultant only

### Dapagliflozin

Green

tablets



**RESTRICTED**  
in line with NICE TA679 / TA902

MHRA Drug Safety Update (Dec-21): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus

### Empagliflozin

Green

tablets



**RESTRICTED**  
in line with NICE TA929

### Mavacamten

Red



Camzyos® capsules



**RESTRICTED specialist use**  
in line with NICE TA913

### Regadenoson



Rapiscan® 400micrograms/5mL injection



**RESTRICTED** adults.  
Myocardial perfusion scans

Non-Formulary Items		
<p><b>Cilostazol</b></p> <p>DNP</p> <p><i>Pletal® 50mg; 100mg tablets</i></p>	<p>NICE MMC BNF emc</p>	<p><b>REJECTED in line with NICE TA223</b></p>
<p><b>Doxazosin</b></p> <p>DNP</p> <p><i>MR tablets / 8mg immediate release tablets</i></p>	<p>NICE MMC BNF emc</p>	
<p><b>Inositol nicotinate</b></p> <p>DNP</p> <p><i>Hexopal® tablets</i></p>	<p>NICE MMC BNF emc</p>	<p><b>REJECTED in line with NICE TA223</b></p>
<p><b>Pentoxifylline</b></p> <p>DNP</p> <p><i>Trental® tablets</i></p>	<p>NICE MMC BNF emc</p>	<p><b>REJECTED in line with NICE TA223</b></p>
<p><b>Simvastatin / ezetimibe</b></p> <p>DNP</p> <p><i>Inegy® 10mg/20mg; 10mg/40mg &amp; 10mg/80mg tablets</i></p>	<p>NICE MMC BNF emc</p>	

## Section 3: Respiratory System

Supported by the  
formulary (click here)



### 3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers
  - Inhaler Devices
  - Nebuliser Diluent

### 3.2 Corticosteroids

- Compound preparations

### 3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

### 3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

### 3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants

### 3.6 Oxygen (refer to oxygen guidelines)

### 3.7 Mucolytics

### 3.8 Aromatic inhalations

### 3.9 Cough preparations

- 3.9.1 Cough Suppressants
  - Cough Suppressants (Palliative Care ONLY)
- 3.9.2 Demulcent & expectorant cough preparations

### 3.10 Systemic Nasal Decongestants

### 3.11 Antifibrotics

### Non-Formulary Items

## Trust Guidelines


















ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)
























## NICE Guidance

Idiopathic pulmonary fibrosis (CG163)  
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)  
Inhaler devices for children under 5 (TA10)  
Asthma (older children) - inhaler devices (TA38)  
Asthma (in children) - corticosteroids (TA131)  
Asthma (in adults) - corticosteroids (TA138)  
Venom anaphylaxis - immunotherapy pharmlagen (TA246)  
Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)  
Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)  
Omalizumab for previously treated chronic spontaneous urticaria (TA339)  
Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)  
Reslizumab for treating severe eosinophilic asthma (TA479)  
Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)  
Benralizumab for treating severe eosinophilic asthma (TA565)  
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)  
Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)  
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)  
Dupilumab for treating severe asthma with type 2 inflammation (TA751)  
Palforzia for treating peanut allergy in children and young people (TA769)  
Tezepelumab for treating severe asthma (TA880)

## GMMMG Formulary












Formulary Homepage  
Chapter 3: Respiratory system (Complete)  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#) Drug List





























































3.1 Bronchodilators		GMMMG
<b>Asthma</b>		
<b>Methacholine Chloride</b>  Provocholine® nebuliser solution	MMC emc	<b>RESTRICTED detection test for bronchial airway hyperreactivity</b>
<b>3.1.1 Adrenoceptor agonists</b>		GMMMG GMMMG GMMMG
<b>3.1.1.1 Selective beta<sub>2</sub> agonists</b>		
<b>Salbutamol</b>  injection	MMC  emc	
<b>Terbutaline Sulfate</b>  injection	 emc	
<b>Salmeterol</b>	 emc	
<b>Formoterol Fumarate</b>	MMC  emc	<b>Asthma BTS step 3 add-on therapy</b>
<b>3.1.1.2 Other Adrenoceptor Agonists</b>		
<b>Ephedrine Hydrochloride</b>	 emc	
<b>3.1.2 Antimuscarinic Bronchodilators</b>		GMMMG GMMMG GMMMG
<b>Ipratropium Bromide</b>	 emc	<b>1<sup>st</sup> line use</b>
<b>Tiotropium</b>	MMC  emc	<b>2<sup>nd</sup> line use COPD maintenance</b>
MHRA Drug Safety Update (Feb-15): Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial		
<b>Acclidinium Bromide</b> Eklira Genuair®	MMC  emc	<b>2<sup>nd</sup> line use COPD maintenance</b>
<b>Glycopyrronium Bromide</b> Seebri Breezhaler®	MMC  emc	<b>2<sup>nd</sup> line use COPD maintenance</b>
<b>Umeclidinium Bromide</b> Incruse Ellipta®	MMC  emc	<b>2<sup>nd</sup> line use COPD maintenance</b>
<b>Compound Preparations</b>		
<b>Acclidinium Bromide / Formoterol Fumarate Dihydrate</b> Duaklir Genuair®	MMC  emc	<b>3<sup>rd</sup> line use COPD maintenance</b>
<b>3.1.3 Theophylline</b>		
<b>Theophylline</b> M/R tablets; M/R capsules	 emc	<b>1<sup>st</sup> line use PRESCRIBE BY BRAND NAME</b>
<b>Aminophylline</b>  injection M/R tablets; injection	 emc	<b>PRESCRIBE BY BRAND NAME</b>























































































3.1.4 Compound Bronchodilator Preparations		GMMMG		
<b>Ipratropium Bromide / Salbutamol</b>				
<i>Combivent®</i>	 			
<b>Glycopyrronium Bromide / Formoterol Fumarate</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance		
<i>Bevespi Aerosphere®</i>	  			
<b>Glycopyrronium Bromide / Indacaterol Maleate</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance		
<i>Ultibro®</i>	  			
<b>Tiotropium Bromide Monohydrate / Olodaterol Hydrochloride</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance		
<i>Spolto Respimat®</i>	  			
<b>Umeclidinium Bromide / Vilanterol Trifenatate</b>		<b>3<sup>rd</sup> line use</b> COPD maintenance		
<i>Anoro Ellipta®</i>	  			
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers		GMMMG GMMMG GMMMG		
Inhaler Devices				
<b>Volumatic® (spacer inhaler)</b>				
	 			
<b>Aerochamber® Plus (spacer device)</b>				
	 			
<b>Able Spacer® (spacer device)</b>				
	  			
Nebuliser Diluent				
<b>Sodium Chloride</b>				
0.9% nebuliser diluent	 			











3.2 Corticosteroids		GMMMG
Corticosteroids		GMMMG GMMMG GMMMG
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
<b>Beclometasone Dipropionate</b>		
MDI (Clenil Modulite® 50, 100, 200, 250)	NICE MMC BNF emc	
<b>Beclometasone Dipropionate CFC-free</b>		
MDI (Qvar Easi-Breathe® or Qvar Autohaler® 50, 100)	NICE MMC BNF emc	<b>PRESCRIBE BY BRAND NAME</b>
<b>Budesonide</b>		
DPI (Easyhaler®; Pulmicort® Turbohaler® 100, 200, 400) 500micrograms/2mL & 1mg/2mL nebuliser liquid	NICE MMC BNF emc	
<b>Fluticasone Propionate</b>		
MDI (FlixotideEvohaler®) 50, 125, 250; DPI (FlixotideAccuhaler® 50,100, 250, 500)	BNF emc	
<b>Compound preparations</b>		
<b>Budesonide / Formoterol fumarate</b>		
DPI (Fobumix Easyhaler® 80/4.5, 160/4.5, 320/9); DPI (Symbicort Turbohaler® 100/6, 200/6, 400/12); DPI (Duoresp Spiromax® 160/4.5, 320/9)	NICE MMC BNF emc	Asthma BTS step 3 management GMMMG GMMMG
<b>Beclometasone Dipropionate / Formoterol fumarate</b>		
MDI (Luforbec®; Fostair®; 100/6, 200/6); DPI (Fostair NEXThaler® 100/6, 200/6)	MMC BNF emc	Asthma BTS step 3 management
<b>Fluticasone Furoate / Vilanterol Trifenatate</b>		
DPI (Relvar Ellipta® 92/22 asthma or COPD; 184/22 asthma)	MMC BNF emc	Asthma BTS step 3 management
<b>Fluticasone Propionate / Salmeterol</b>		
MDI (Sirdupla® 125, 250)	MMC BNF emc	Asthma BTS step 3 management
<b>Fluticasone Propionate / Salmeterol</b>		
MDI (SeretideEvohaler® 50, 125, 250)	NICE MMC BNF emc	Asthma BTS step 3 management
<b>Fluticasone Propionate / Formoterol Fumarate</b>		
MDI (Flutiform® 50/5, 125/5, 250/10)	MMC BNF emc	Asthma BTS step 3 management
<b>Beclometasone dipropionate / Formoterol fumarate / Glycopyrronium bromide</b>		
MDI (Trimbow 87/5/9® & 172/5/9®) DPI (Trimbow NEXThaler 88/5/9®)	MMC BNF emc	<b>RESTRICTED - COPD patients who require triple therapy</b> GMMMG COPD GMMMG Asthma
<b>Fluticasone Furoate / Vilanterol Trifenatate / Umeclidinium Bromide</b>		
DPI (Trelegy Ellipta® 92/55/22 micrograms)	MMC BNF emc	<b>RESTRICTED - COPD patients who require triple therapy</b>
<b>Formoterol fumarate / Glycopyrronium Bromide / Budesonide</b>		
DPI (Trixeo Aerosphere® 5/7.2/160 micrograms)	MMC BNF emc	<b>RESTRICTED - COPD patients who require triple therapy</b>
<b>Indacaterol / Mometasone Furoate</b>		
DPI (Ateectura® Breezhaler®)	MMC BNF emc	GMMMG Asthma Guideline 2022
<b>Mometasone Furoate / Glycopyrronium Bromide / Indacaterol</b>		
DPI (Enerzair® Breezhaler®)	MMC BNF emc	GMMMG Asthma Guideline 2022
MHRA Drug Safety Update (Jul-18): Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		

<b>3.3 Cromoglicate &amp; related therapy &amp; leukotriene receptor antagonists</b>		
<b>3.3.1 Cromoglicate &amp; Related Therapy</b>		
<b>Sodium Cromoglicate</b>		
	 	
<b>3.3.2 Leukotriene Receptor Antagonists</b>		
<b>Montelukast</b>		<b>BTS step 2 or 3 in paediatrics</b>
tablets; chewable tablets; sachets	  	
MHRA Drug Safety Update (Apr-24): Montelukast: reminder of the risk of neuropsychiatric reactions		
MHRA Drug Safety Update (Sep-19): Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions		
<b>3.3.3 Phosphodiesterase type-4 inhibitors</b>		
<b>Roflumilast</b>		<b>RESTRICTED</b> <b>as per NICE TA461</b>
	   	
tablets		
























































3.4 Antihistamines, hyposensitisation & allergic emergencies		GMMMG
<b>3.4.1 Antihistamines</b>		
<b>Non-sedating antihistamines</b>		
<b>Cetirizine Hydrochloride</b>		
tablets; oral solution	 	
<b>Loratadine</b>		
tablets; oral solution	 	
<b>Desloratadine</b>		<b>RESTRICTED</b> children 1-2 years old
tablets; oral solution	  	
<b>Fexofenadine Hydrochloride</b>		
tablets	  	
<b>Sedating antihistamines</b>		
<b>Chlorphenamine Maleate</b>		
tablets; oral solution; injection	  	
<b>Hydroxyzine Hydrochloride</b>		
tablets; oral solution	 	
MHRA Drug Safety Update (Apr-15): Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes		
<b>Promethazine Hydrochloride</b>		
tablets; oral solution	  	
<b>Alimemazine Tartrate</b>		
DNP tablets; oral solution	 	
<b>3.4.2 Allergen Immunotherapy</b>		
<b>Allergoid immunotherapy tablets</b>		<b>RESTRICTED</b> Immunology Consultants only
 Lofarma Lais®	  	
<b>Bee venom extract</b>		<b>RESTRICTED</b> Immunology Consultants only
Red injection	  	
<b>Wasp venom extract</b>		<b>RESTRICTED</b> Immunology Consultants only
Red injection	   	
<b>Grass &amp; Rye or tree pollen extract</b>		<b>RESTRICTED</b> Immunology Consultants only
Red Pollinex®	  	
<b>Grass Pollen extract</b>		<b>RESTRICTED</b> Immunology Consultants only
DNP Grazax® oral lyophilisates	   	
<b>House Dust Mite extract</b>		<b>RESTRICTED</b> Immunology Consultants only
Red Acarizax 12-SQ HDM oral lyophilisates®	   	
<b>Peanut Protein powder</b>		<b>RESTRICTED</b> Immunology Consultants only
Red  Palforzia® oral powder in capsules; sachet	   	
<b>Wasp venom extract</b>		<b>RESTRICTED</b> Immunology Consultants only
Red injection	   	
<b>White birch (<i>Betula verrucosa</i>) Pollen extract</b>		<b>RESTRICTED</b> Immunology Consultants only
Red Itulazax 12-SQ Bet oral lyophilisates®	 	
<b>Omalizumab</b>		
<b>Omalizumab</b>		<b>RESTRICTED</b> as per NICE
Red DNP  injection	     	

<b>Anti-interleukin-5 (IL-5) antibody</b>		
<b>Benralizumab</b>   <i>Fasenra</i> ® injection      		<b>RESTRICTED</b> as per NICE TA565
<b>Dupilumab</b>    <i>Dupilixent</i> ® injection (see also section 13.5.3)      		<b>RESTRICTED</b> as per NICE TA751
MHRA Drug Safety Update (Nov-22): Dupilumab (Dupixent ▼): risk of ocular adverse reactions and need for prompt management		
<b>Mepolizumab</b>   <i>Nucala</i> ® injection      		<b>RESTRICTED</b> as per NICE
<b>Reslizumab</b>   <i>Cinqaero</i> ® infusion      		<b>RESTRICTED</b> as per NICE TA479 <b>NOT STOCKED</b>
<b>Tezepelumab</b>   <i>Tezspire</i> ® injection      		<b>RESTRICTED</b> as per NICE TA880
<b>3.4.3 Allergic Emergencies</b>		
<b>Adrenaline / Epinephrine</b>  injection  		<b>PRESCRIBE BY BRAND NAME</b>
MHRA Drug Safety Update (Jun-23): Adrenaline auto-injectors (AAIs): new guidance and resources for safe use		
MHRA Drug Safety Update (Nov-21): Adrenaline auto-injectors: reminder for prescribers to support safe and effective use		
MHRA Drug Safety Update (Aug-17): Adrenaline auto-injectors: updated advice after European review		
<b>Berotrastat</b>   <i>Orladeyo</i> ® capsules     		<b>RESTRICTED</b> <b>specialist use only</b> as per NICE TA738
<b>C1 esterase inhibitor</b>   <i>Berinerit</i> ®; <i>Cinryze</i> ® injection      		<b>RESTRICTED</b> acute attacks of HAE 
<b>Conestat Alfa</b>   <i>Ruconest</i> ® injection     		<b>RESTRICTED</b> adults acute attacks of HAE
<b>Icatibant</b>   <i>Firazyr</i> ® injection      		<b>RESTRICTED</b> adults acute attacks of HAE
<b>Lanadelumab</b>   <i>Takhzyro</i> ® injection      		<b>RESTRICTED</b> in line with NICE TA606
<b>Oxandrolone</b>  tablets   		<b>RESTRICTED</b> adults acute attacks of HAE

3.5 Respiratory stimulants & pulmonary surfactants		GMMMG
<b>3.5.1 Respiratory Stimulants</b>		
<b>Doxapram Hydrochloride</b>		
injection	 	
<b>Caffeine Citrate</b>		
injection	MMC  	<b>RESTRICTED</b> apnoea in premature babies
<b>3.5.2 Pulmonary Surfactants</b>		
<b>Poractant Alfa</b>		
 Curosurf® liquid	  	

### 3.6 Oxygen ([refer to oxygen guidelines](#))



3.7 Mucolytics		GMMMG
<b>Mucolytics</b>		
<b>Sodium Chloride (hypertonic)</b>		
<i>Nebusal</i> ® 7% nebulas		
	 	
<b>Mannitol inhalation powder</b>		<b>RESTRICTED</b> Respiratory only in line with NICE
		
<i>Bronchitol</i> ® capsules		
	    	
<b>Mannitol diagnostic kit</b>		<b>RESTRICTED</b> Respiratory only
		
<i>Osmohale</i> ® capsules		
	   	
<b>Acetylcysteine</b>		
		
effervescent tablets; injection; sachets		
	  	
<b>Carbocisteine</b>		<b>RESTRICTED</b> COPD Consultant / referral only
		
capsules; oral solution; sachets		
	  	
<b>Dornase Alfa</b>		<b>RESTRICTED</b> Respiratory only
 		
<i>Pulmozyme</i> ® nebulas		
	   	
<b>Elxacaftor with Tezacaftor and Ivacaftor</b>		<b>RESTRICTED</b> Specialist use only
 		
<i>Kafrio</i> ® tablets		
	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elxacaftor (Kafrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
<b>Ivacaftor</b>		<b>RESTRICTED</b> Paediatric Consultants only
 		
<i>Kalydeco</i> ® tablets; granules		
	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elxacaftor (Kafrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
<b>Lumacaftor with Ivacaftor</b>		<b>RESTRICTED</b> Specialist use only
 		
<i>Orkambi</i> ® tablets; granules		
	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elxacaftor (Kafrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		
<b>Tezacaftor with Ivacaftor</b>		<b>RESTRICTED</b> Specialist use only
 		
<i>Symkevi</i> ® tablets		
	   	
MHRA Drug Safety Update (Feb-22): Ivacaftor, tezacaftor, elxacaftor (Kafrio▼) in combination with ivacaftor (Kalydeco): risk of serious liver injury; updated advice on LFT		

### 3.8 Aromatic inhalations



#### Aromatic Inhalations

##### Benzoin Tincture, Compound, BP

*Friars' Balsam liquid*














##### Menthol and Eucalyptus Inhalation, BP 1980

inhalation vapour





3.9 Cough preparations		GMMMG
<b>3.9.1 Cough Suppressants</b>		
<b>Codeine Phosphate</b>		
oral solution	 	
MHRA Drug Safety Update (Feb-24): Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine MHRA Drug Safety Update (Jul-23): Codeine linctus: public consultation on the proposal to reclassify to a prescription-only medicine		
<b>Dextromethorphan hydrobromide</b>		<b>RESTRICTED</b> non-ketotic hyperglycinaemia
oral solution	  	
<b>Cough Suppressants (Palliative Care ONLY)</b>		
<b>Methadone Hydrochloride</b>		
liquid	 	
<b>Morphine Hydrochloride</b>		
oral solution	 	
<b>3.9.2 Demulcent &amp; expectorant cough preparations</b>		
<b>Simple Linctus</b>		
liquid	 	

## 3.10 Systemic nasal decongestants



### Systemic Nasal Decongestants

**NO DRUGS ARE RECOMMENDED FROM THIS GROUP**

PbR X

NICE

BNF

**NHSE: OTC prescribing reduction**

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)

### 3.11 Antifibrotics



#### Antifibrotics

#### Pirfenidone







capsules; tablets



**RESTRICTED**  
Respiratory Consultants only  
**NOT STOCKED**

MHRA Drug Safety Update (Nov-20): Pirfenidone (Esbriet): risk of serious liver injury; updated advice on liver function testing

Non-Formulary Items	
<b>Levocetirizine</b> DNP Xyzal® tablets	  <b>in line with GMMG</b>
<b>Pholcodine</b> oral solution	  <b>Withdrawn from UK market as per MHRA alert March 2023</b>
MHRA Drug Safety Update (Mar-23): Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure	

# Chapter 4: Central Nervous System

Supported by the  
formulary ([click here](#))



## 4.1 Hypnotics & anxiolytics

- 4.1.1 Hypnotics
- 4.1.2 Anxiolytics
- 4.1.3 Barbiturates
- 4.1.4 Other hypnotics and anxiolytics

## 4.2 Drugs used in psychoses & related disorders

- 4.2.1 Antipsychotic Drugs
- 4.2.2 Antipsychotic Depot Injections
- 4.2.3 Drugs used for mania and hypomania

## 4.3 Antidepressant drugs

- 4.3.1 Tricyclic & Related Antidepressant Drugs
- 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
- 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
- 4.3.4 Other Antidepressant Drugs

## 4.4 CNS stimulants & drugs used for ADHD

## 4.5 Drugs used in the treatment of obesity

## 4.6 Drugs used in nausea & vertigo

## 4.7 Analgesics

- 4.7.1 Non-Opioid Analgesics
- 4.7.2 Opioid Analgesics
- 4.7.3 Neuropathic Pain
- 4.7.4 Antimigraine Drugs

## 4.8 Antiepileptic drugs

- 4.8.1 Control of the Epilepsies
- 4.8.2 Drugs Used in Status Epilepticus

## 4.9 Drugs used in Parkinsonism & related disorders

- 4.9.1 Dopaminergic Drugs Used in Parkinsonism
- 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
- 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders

## 4.10 Drugs used in substance dependence

## 4.11 Drugs for dementia

## Non-Formulary Items

## Trust Guidelines














































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Obsessive compulsive disorder (OCD) & body dysmorphic disorder (BDD) (CG31)  
 Management of Obesity (CG43) (replaces TA22, TA31 & TA46)  
 Drug misuse: opioid detoxification (CG52)  
 Depression with a chronic physical health problem (CG91)  
 Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)  
 Anxiety (CG113) (replaces CG22)  
 Neuropathic pain - pharmacological management (CG173)  
 Psychosis and schizophrenia in adults (CG178)  
 Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)  
 Eating Disorders: recognition and treatment (NG69)  
 Parkinson's disease in adults (NG71)  
 Attention deficit hyperactivity disorder: diagnosis and management (NG87)  
 Stop smoking interventions and services (NG92)  
 Dementia: supporting people with dementia and their carers in health and social care (NG97)  
 Post-traumatic stress disorder (NG116)  
 Depression in children and young people: identification and management (NG134)  
 Epilepsies in children, young people and adults (NG217)  
 Depression in adults: treatment and management (NG222)  
 Motor Neurone Disease: Riluzole (TA20)  
 Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)  
 Drug Misuse: Methadone & Buprenorphine (TA114)  
 Drug Misuse: Naltrexone (TA115)  
 Smoking Cessation: Varenicline (TA123)  
 Schizophrenia - aripiprazole (TA213)  
 Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)  
 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)  
 Bipolar disorder (children) - aripiprazole (TA292)  
 Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)  
 Vortioxetine for treating major depressive episodes (TA367)  
 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)  
 Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)  
 Cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome (TA615)  
 Galcanezumab for preventing migraine (TA659)  
 Cenobamate for treating focal onset seizures in epilepsy (TA753)  
 Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)  
 Fremanezumab for preventing migraine (replacing TA631) (TA764)  
 Fenfluramine for treating seizures associated with Dravet syndrome (TA808)  
 Eptinezumab for preventing migraine (TA871)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Rimegepant for preventing migraine (TA906)  
 Rimegepant for treating migraine (TA919)  
 Daridorexant for treating long-term insomnia (TA922)  
 Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)  
 Atogepant for preventing migraine (TA973)

## GMMM Formulary

Formulary Homepage  
 Chapter 4: Central Nervous system (Complete)  
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red/Amber/Green](#) Drug List

4.1 Hypnotics & anxiolytics		GMMMG
4.1.1 Hypnotics		NICE CG112
<b>Benzodiazepines</b>		
<b>Temazepam</b>		
 tablets; oral solution	 	
<b>Nitrazepam</b>		
tablets; oral suspension	 	
<b>Zaleplon, Zolpidem &amp; Zopiclone</b>		
<b>Zopiclone</b>		
tablets	  	
<b>Chloral &amp; Derivatives</b>		
<b>Chloral Hydrate</b>		
oral solution; suppositories	 	
MHRA Drug Safety Update (Oct-21): Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication		
<b>Clomethiazole</b>		
192mg capsules	 	
<b>Sodium Oxybate</b>		
<b>Sodium Oxybate</b>		
   oral solution	    	<b>RESTRICTED</b> 2 <sup>nd</sup> line narcolepsy with cataplexy
<b>Melatonin</b>		
<b>Melatonin</b>		
capsules; tablets; oral solution	  	<b>RESTRICTED</b> GMMMG
Melatonin (licensed product 1 <sup>st</sup> line) - Paediatric patients, e.g. sleep disorders, ADHD		Amber
Melatonin (licensed product only) - Adult patients over 55yrs of age		Green
Melatonin - management of jet lag		DNP
4.1.2 Anxiolytics		NICE CG113
<b>Benzodiazepines</b>		
MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression		
<b>Chlordiazepoxide hydrochloride</b>		
 capsules	 	<b>Symptomatic relief of acute alcohol withdrawal</b>
<b>Diazepam</b>		
tablets; liquid; injection; rectal tube	 	
<b>Lorazepam</b>		
tablets; injection	 	
<b>Oxazepam</b>		
tablets	 	
<b>Busiprone</b>		
<b>Busiprone Hydrochloride</b>		
tablets	 	
<b>Others</b>		
<b>Pregabalin</b>		
  capsules; oral solution	  	<b>RESTRICTED</b> generalised anxiety disorder after standard treatment following NICE has failed.
4.1.3 Barbiturates		
<b>NO DRUGS ARE RECOMMENDED FROM THIS GROUP</b>		
4.1.4 Other hypnotics and anxiolytics		
<b>Daridorexant</b>		
 Quviviq® tablets	   	<b>RESTRICTED</b> in line with NICE TA922 <b>NOT STOCKED</b>

4.2 Drugs used in psychoses & related disorders		GMMMG
4.2.1 Antipsychotic Drugs		NICE CG178
MHRA Drug Safety Update (May-12): Antipsychotics: initiative to reduce prescribing to older people with dementia		
<b>Chlorpromazine Hydrochloride</b> Green tablets; oral solution; injection	  MMC BNF emc	
<b>Haloperidol</b> Green tablets; capsules; oral solution (500microgram tablets see DNP)	  BNF emc	
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
<b>Levomepromazine</b> Green 6.25mg, 25mg tablets; oral solution; injection	  MMC BNF emc	
<b>Promazine Hydrochloride</b> tablets; oral solution	  BNF emc	
<b>Sulpiride</b> tablets; oral solution	  BNF emc	
<b>Trifluoperazine</b> tablets; oral solution	  BNF emc	
<b>Zuclopenthixol</b> tablets	  BNF emc	
<b>Atypical Antipsychotic Drugs</b>		
<b>Amisulpride</b> Amber Red tablets; oral solution	  MMC BNF emc	<b>RESTRICTED</b> adults. Consultant Psychiatrist only
<b>Aripiprazole</b> Amber Red tablets; oral solution	   NICE MMC BNF emc	<b>RESTRICTED</b> paediatrics. Consultant Psychiatrist only
MHRA Drug Safety Update (Dec-23): Aripiprazole (Abilify and generic brands): risk of pathological gambling		
<b>Clozapine</b> Red tablets	  BNF emc	
MHRA Drug Safety Update (Aug-20): Clozapine and other antipsychotics: monitoring blood concentrations for toxicity		
MHRA Drug Safety Update (Oct-17): Clozapine: reminder of potentially fatal risk of intestinal obstruction, faecal impaction, and paralytic ileus		
<b>Olanzapine</b> Amber Red tablets; orodispersible tablets; oral solution	  BNF emc	
<b>Quetiapine</b> Amber Red tablets; M/R tablets	  MMC BNF emc	<b>RESTRICTED</b> - Consultant initiation - schizophrenia patients
<b>Risperidone</b> Amber Red tablets; orodispersible tablets; oral solution	  BNF emc	
<b>4.2.2 Antipsychotic Depot Injections</b>		
<b>Flupentixol Decanoate</b> Amber injection	  BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
<b>Fluphenazine Decanoate</b> Amber injection	  BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
<b>Haloperidol Decanoate</b> Amber injection	  BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium		
<b>Risperidone</b> Amber injection	  BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only
<b>Zuclopenthixol Decanoate</b> Amber injection	  BNF emc	<b>RESTRICTED</b> Consultant Psychiatrist only



**4.2.3 Drugs used for mania and hypomania****Lithium Carbonate**

Amber

tablets; M/R tablets

**PRESCRIBE BY BRAND NAME****Lithium Citrate**

Amber

oral solution

**PRESCRIBE BY BRAND NAME****Valproic Acid**





































Green
































Gastro-resistant tablets



MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance

MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended

4.3 Antidepressant drugs		GMMMG
		NICE CG31
		NICE CG91
<b>4.3.1 Tricyclic &amp; Related Antidepressant Drugs</b>		NICE NG134
<b>Tricyclic antidepressants</b>		NICE NG222
<b>Amitriptyline Hydrochloride (standard release preparations only)</b>		
tablets; oral solution	 	
<b>Clomipramine Hydrochloride (standard release preparations only)</b>		
capsules	 	
<b>Doxepin Hydrochloride</b>		
capsules	 	
<b>Imipramine Hydrochloride</b>		
tablets	 	
<b>Lofepramine</b>		
tablets; oral suspension	 	1 <sup>st</sup> line use
<b>Nortriptyline</b>		
tablets	 	
<b>Trimipramine</b>		
DNP tablets; capsules	 	
<b>Tricyclic-related antidepressants</b>		
<b>Mianserin Hydrochloride</b>		
tablets	 	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Trazodone Hydrochloride</b>		
capsules; tablets; oral solution	 	<b>RESTRICTED</b> initiation by Psychiatrist
<b>4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)</b>		
<b>Isocarboxazid</b>		
Red tablets	 	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Phenelzine</b>		
Red 15mg tablets	 	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Tranlycypromine</b>		
Red 10mg tablets	 	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Reversible Monoamine-Oxidase Inhibitors (MAOIs)</b>		
<b>Moclobemide</b>		
Green 150mg; 300mg tablets	 	<b>RESTRICTED 2<sup>nd</sup> line</b> initiation by Psychiatrist
<b>4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)</b>		
MHRA Drug Safety Update (Jan-21): SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery		
<b>Fluoxetine</b>		
capsules; tablets; dispersible tablets; oral solution	 	
<b>Citalopram</b>		
tablets; oral drops	 	
MHRA Drug Safety Update (Jul-16): Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
<b>Sertraline</b>		
tablets; oral suspension	 	
<b>Fluvoxamine maleate</b>		
tablets	 	
<b>Paroxetine</b>		
tablets; oral suspension	 	

<b>Escitalopram</b> tablets	  	<b>RESTRICTED</b> Mental Health Trust initiation only
MHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT interval prolongation		
<b>4.3.4 Other Antidepressant Drugs</b>		
<b>Venlafaxine</b>  M/R capsules; tablets; M/R tablets	  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Mirtazapine</b> tablets; orodispersible tablets; oral solution	   	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Duloxetine</b>  gastro-resistant tablets	  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Flupentixol</b> tablets	  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Reboxetine</b> tablets	   	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Tryptophan</b> capsules	  	<b>RESTRICTED</b> initiation by Psychiatrist
<b>Vortioxetine</b>  tablets	    	<b>RESTRICTED</b> initiation by Psychiatrist

4.4 CNS stimulants & drugs used for ADHD		GMMMG
4.4 CNS stimulants & drugs used for ADHD <span style="float: right;">GMMMG</span>		NICE NG87
<b>Atomoxetine</b> <span style="background-color: orange; padding: 2px;">Amber</span> capsules NICE MMC BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Jan-12): Atomoxetine (Strattera ▼): increases in blood pressure and heart rate MHRA Drug Safety Update (Mar-09): Atomoxetine: risk of psychotic or manic symptoms in children and adolescents		
<b>Dexamfetamine</b> <span style="background-color: orange; padding: 2px;">Amber</span> <span style="background-color: red; padding: 2px;">Red</span> tablets NICE BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
<b>Guanfacine</b> <span style="background-color: orange; padding: 2px;">Amber</span> Prolonged release tablets NICE MMC BNF emc		<b>RESTRICTED</b> 2 <sup>nd</sup> line use for ADHD
<b>Lisdexamfetamine</b> <span style="background-color: orange; padding: 2px;">Amber</span> <span style="background-color: yellow; padding: 2px;">CT</span> capsules NICE MMC BNF emc GMMMG		<b>RESTRICTED</b> 2 <sup>nd</sup> line use for ADHD
<b>Methylphenidate</b> <span style="background-color: orange; padding: 2px;">Amber</span> <span style="background-color: yellow; padding: 2px;">CT</span> tablets; M/R tablets; capsules; M/R capsules NICE MMC BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice <b>PRESCRIBE BY BRAND NAME</b>
MHRA Drug Safety Update (Sep-22): Methylphenidate long-acting (MR) preparations: caution if switching between products due to differences in formulations MHRA Drug Safety Update (Mar-09): Methylphenidate: safe and effective use to treat ADHD		
<b>Modafinil</b> <span style="background-color: green; padding: 2px;">Green</span> <span style="border: 1px solid black; padding: 2px;">DNP</span> <span style="background-color: red; padding: 2px;">Red</span> tablets BNF emc		<b>RESTRICTED</b> on Paediatric / Psychiatric advice
MHRA Drug Safety Update (Nov-20): Modafinil (Provigil): increased risk of congenital malformations if used during pregnancy MHRA Drug Safety Update (Mar-11): Modafinil (Provigil): now restricted to narcolepsy		
<b>Solriamfetol hydrochloride</b> <span style="background-color: red; padding: 2px;">Red</span> <span style="border: 1px solid black; border-radius: 50%; padding: 2px;">££</span> Sunosi® tablets NICE MMC BNF emc		<b>RESTRICTED</b> Sleep Centre only in line with NICE

## 4.5 Drugs used in the treatment of obesity

GMMMG

### 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract

NICE CG43

#### Orlistat
































**RESTRICTED**

Consultant initiation - Paeds. only




























































capsules



MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines
































































4.6 Drugs used in nausea & vertigo		GMMMG
<b>Antihistamines</b>		
<b>Cyclizine</b>		<b>1<sup>st</sup> line use</b>
tablets; injection	 	
<b>Promethazine Hydrochloride</b>		
tablets; oral solution (see also section 3.4.1)	 	
<b>Promethazine Teoclate</b>		
tablets	 	
<b>Phenothiazines &amp; Related Drugs</b>		
<b>Prochlorperazine</b>		
tablets; buccal tablet; injection	 	
<b>Droperidol</b>		<b>RESTRICTED</b> Consultant initiation only for PONV
injection	  	
<b>Domperidone &amp; Metoclopramide</b>		
<b>Domperidone</b>		
tablets; oral suspension (see also section 1.2)	 	
MHRA Drug Safety Update (Dec-19): Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents		
MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects		
MHRA Drug Safety Update (May-14): Domperidone: risks of cardiac side effects		
<b>Metoclopramide Hydrochloride</b>		
tablets; oral suspension; injection (see also section 1.2)	 	
MHRA Drug Safety Update (Aug-13): Metoclopramide: risk of neurological adverse effects		
<b>5HT<sub>3</sub>-receptor antagonists</b>		
<b>Ondansetron</b>		<b>RESTRICTED - Chemotherapy induced &amp; post-op vomiting</b>
 	 	
tablets; orodispersible tablets; injection; oral solution; orodispersible film		
MHRA Drug Safety Update (Jul-13): Ondansetron for intravenous use: dose-dependent QT interval prolongation		
MHRA Drug Safety Update (Aug-12): Ondansetron (Zofran): important new intravenous dose restriction		
<b>Neurokinin 1-receptor antagonist</b>		
<b>Aprepitant</b>		<b>RESTRICTED</b> highly / moderately emetogenic CINV
80mg; 125mg capsules; 25mg/mL oral suspension	  	
<b>Cannabinoids</b>		
<b>Nabilone</b>		<b>RESTRICTED</b> highly emetogenic CINV
	  	
0.25mg; 1mg capsules		
<b>Hyoscine</b>		
<b>Hyoscine Hydrobromide</b>		
patches; tablets (for Hyoscine Butylbromide see section 1.2)	  	
MHRA Drug Safety Update (Jul-23): Hyoscine hydrobromide patches: risk of anticholinergic side effects, including hyperthermia		
<b>Other Drugs for Ménière's Disease</b>		
<b>Betahistine Dihydrochloride</b>		
tablets	 	

4.7 Analgesics		GMMMG
<b>4.7.1 Non-Opioid Analgesics</b>		(see also Chapter 10 for NSAIDs)
<b>Paracetamol</b>		<b>1<sup>st</sup> line use</b>
tablets; soluble tablets; infusion; injection; oral suspension; suppositories	MMC BNF emc	
<b>Sucrose 24% solution</b>		<b>RESTRICTED</b> Pain relief in neonates
Sweet-Ease® oral solution	MMC BNF emc	
<b>Compound Analgesic Preparations</b>		
<b>Paracetamol and codeine (Co-codamol®)</b>		
tablets; effervescent tablets	BNF emc	
<b>Paracetamol and dihydrocodeine (Co-dydramol®)</b>		
tablets	BNF emc	
<b>4.7.2 Opioid Analgesics</b>		
MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction		
<b>Buprenorphine</b>		<b>RESTRICTED</b>
<b>NOT patch</b>	NICE BNF emc	
<b>Codeine Phosphate</b>		
tablets; syrup; injection	BNF emc	
MHRA Drug Safety Update (Jul-13): Codeine for analgesia: restricted use in children because of reports of morphine toxicity		
MHRA Drug Safety Update (Jun-13): Codeine: restricted use as analgesic in children and adolescents after European safety review		
<b>Diamorphine Hydrochloride</b>		
injection	BNF emc	
<b>Difelikefalin</b>		<b>RESTRICTED</b> Renal Consultants in line with NICE
<b>Kapivia® injection</b>	PBR X NICE MMC BNF bluefeg emc	
<b>Dihydrocodeine Tartrate standard release preparations only</b>		
tablets	BNF emc	
<b>Fentanyl</b>		<b>Spray RESTRICTED</b> palliative care & haematology initiation (Wd44)
<b>NOT lozenge</b>	MMC BNF emc	
MHRA Drug Safety Update (Oct-18): Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children		
MHRA Drug Safety Update (Sep-08): Serious and fatal overdose of fentanyl patches		
<b>Methadone Hydrochloride</b>		<b>RESTRICTED</b> palliative care & substance misuse
oral solution	NICE BNF emc	
<b>Morphine Sulphate</b>		
tablets; M/R tablets; capsules; M/R capsules; oral solution; injection	BNF emc	
<b>Morphine Sulphate</b>		<b>RESTRICTED</b> palliative care / GMMMG
<b>Actimorph® orodispersible tablets</b>	MMC BNF emc	
<b>Oxycodone Hydrochloride</b>		<b>RESTRICTED</b> 2 <sup>nd</sup> line for morphine intolerance
capsules; liquid; tablets; M/R tablets; injection	MMC BNF emc	
<b>Pethidine Hydrochloride</b>		
injection; tablets	BNF emc	
<b>Tapentadol Hydrochloride MR</b>		<b>RESTRICTED</b> 3 <sup>rd</sup> line - Pain Team Consultants only
tablets	MMC BNF emc	
MHRA Drug Safety Update (Jan-19): Tapentadol (Palexia): risk of seizures and reports of serotonin syndrome when co-administered with other medicines		
<b>Tramadol Hydrochloride</b>		
capsules; M/R capsules; tablets; M/R tablets; soluble tablets; injection	BNF emc	























<b>4.7.3 Neuropathic Pain</b>		
<b>Amitriptyline</b>		
tablets; oral solution	 	
<b>Carbamazepine</b>		
Green	 	
tablets; M/R tablets; oral solution; suppositories		
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
<b>Gabapentin</b>		
Green 	 	
capsules; oral suspension		
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April		
MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression		
Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
<b>Pregabalin</b>		<b>3<sup>rd</sup> / 4<sup>th</sup> line use if gabapentin contraindicated or not tolerated</b>
Green 	  	
capsules; oral solution		
MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression		
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April		
Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
<b>4.7.4 Antimigraine Drugs</b>		
<b>4.7.4.1 Treatment Of Acute Migraine</b>		
<b>Analgesics</b>		
<b>Aspirin</b>		
tablets; dispersible tablets; E/C tablets; suppositories	 	
<b>Paracetamol</b>		
tablets; soluble tablets; oral suspension; infusion; suppositories	 	
<b>Ibuprofen</b>		
tablets; M/R tablets; oral suspension; sachets	 	
<b>5HT<sub>1</sub> receptor agonists</b>		
<b>Sumatriptan</b>		
tablets; nasal spray; injection	 	
<b>4.7.4.2 Prophylaxis of Migraine</b>		
<b>Botulinum Toxin Type A</b>		<b>RESTRICTED Specialist use only in line with NICE</b>
Red 	    	
Botox® injection		
<b>Clonidine Hydrochloride</b>		
tablets	 	
<b>Erenumab</b>		<b>RESTRICTED Specialist use only NOT STOCKED</b>
Red  	   	
injection		
<b>Eptinezumab</b>		<b>RESTRICTED Specialist use only NOT STOCKED</b>
Red  	   	
injection		
<b>Fremanezumab</b>		<b>RESTRICTED Specialist use only NOT STOCKED</b>
Red  	    	
injection		
<b>Galcanezumab</b>		<b>RESTRICTED Specialist use only NOT STOCKED</b>
Red  	   	
injection		
<b>Pizotifen</b>		
tablets	 	
<b>Rimegepant</b>		<b>RESTRICTED Specialist use only in line with NICE</b>
Green 	   	
oral lyophilisate		















































4.8 Antiepileptic drugs <span style="float: right;">Green</span>		GMMMG
4.8.1 Control of the Epilepsies		NICE NG217
<b>Carbamazepine</b> <span style="color: green;">Green</span>	tablets; M/R tablets; oral solution; suppositories NICE BNF emc	
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
<b>Phenobarbital</b> <span style="color: green;">Green</span> <span style="color: orange;">⚠</span>	tablets; oral solution; injection NICE BNF emc	
<b>Phenytoin Sodium</b> <span style="color: green;">Green</span>	capsules; oral suspension; injection NICE BNF emc	
<b>Sodium Valproate</b> <span style="color: green;">Green</span>	tablets; M/R tablets; oral solution; M/R granules; injection NICE BNF emc	
MHRA Drug Safety Update (Jan-24): Valproate: new safety and educational materials to support regulatory measures in men and women under 55 years of age MHRA Drug Safety Update (Oct-23): Valproate: dispense full packs of valproate-containing medicines MHRA Drug Safety Update (Aug-23): Valproate: re-analysis of study on risks in children of men taking valproate MHRA Drug Safety Update (Dec-22): Valproate: reminder of current Pregnancy Prevention Programme requirements... MHRA Drug Safety Update (Jan-20): Valproate (Epilim ▼, Depakote ▼) pregnancy prevention programme: updated educational materials MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance... MHRA Drug Safety Update (Apr-18): Valproate medicines (Epilim ▼, Depakote ▼): contraindicated in women & girls of childbearing potential unless conditions of PPP met MHRA Drug Safety Update (May-10): Carbapenems: concomitant use with valproic acid not recommended		
<b>cenobamate</b> <span style="color: green;">Green</span>	Ontozry® tablets NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Clobazam</b> <span style="color: green;">Green</span>	tablets; oral suspension NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Clonazepam</b> <span style="color: green;">Green</span>	tablets; oral solution; injection NICE BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Eslicarbazepine</b> <span style="color: green;">Green</span>	tablets; oral suspension NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only in line with NICE
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
<b>Ethosuximide</b> <span style="color: green;">Green</span>	capsules; oral solution NICE BNF emc	<b>RESTRICTED</b> Paediatrics only
<b>Fenfluramine Hydrochloride</b> <span style="color: red;">Red</span>	Fintepla® oral solution NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Gabapentin</b> <span style="color: green;">Green</span> <span style="color: orange;">⚠</span>	capsules; oral suspension NICE BNF emc	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April MHRA Drug Safety Update (Oct-17): Gabapentin (Neurontin): risk of severe respiratory depression Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin		
<b>Lacosamide</b> <span style="color: green;">Green</span>	tablets; oral solution; infusion NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Lamotrigine</b> <span style="color: green;">Green</span>	tablets; dispersible tablets NICE BNF emc	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review		
<b>Levetiracetam</b> <span style="color: green;">Green</span>	tablets; oral solution; infusion; granules NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Jan-21): Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review		
<b>Oxcarbazepine</b> <span style="color: green;">Green</span>	tablets; oral suspension NICE BNF emc	<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Dec-12): Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions		
<b>Perampanel</b> <span style="color: green;">Green</span>	tablets; oral suspension MMC BNF emc	<b>RESTRICTED</b> Specialist use only

<p><b>Pregabalin</b>                         capsules; oral solution     </p> <p>MHRA Drug Safety Update (Feb-21): Pregabalin (Lyrica): reports of severe respiratory depression                      MHRA Drug Safety Update (Apr-19): Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April                      Public Health England briefing (Dec-14): risk of misuse of gabapentin and pregabalin</p>	<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Primidone</b>                        tablets   </p>	<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Rufinamide</b>                        tablets     </p>	<p><b>RESTRICTED</b> Specialist use only                      Lennox-Gastaut Syndrome</p>
<p><b>Stiripentol</b>                        capsules; sachets     </p>	<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Tiagabine</b>                        tablets     </p>	<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Topiramate</b>                        tablets; capsules     </p>	<p><b>RESTRICTED</b>                      Specialist use only</p>
<p>MHRA Drug Safety Update (Jun-24): Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme</p>	
<p><b>Vigabatrin</b>                        tablets; sachets    </p>	<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Zonisamide</b>                        capsules     </p>	<p><b>RESTRICTED</b>                      Specialist use only</p>
<p><b>Cannabidiol (CBD)</b>                         Epidyolex®     </p>	<p><b>RESTRICTED</b> Specialist use only                      in line with NICE TA614 / 615</p>
<p><b>4.8.2 Drugs Used in Status Epilepticus</b></p>	
<p><b>Lorazepam</b>                      tablets; injection   </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p><b>Diazepam</b>                      tablets; liquid; injection; rectal tube   </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p><b>Clonazepam</b>                        tablets; oral solution; injection   </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p><b>Midazolam</b>                         oromucosal solution; injection; infusion   </p>	
<p>MHRA Drug Safety Update (Mar-20): Benzodiazepines and opioids: reminder of risk of potentially fatal respiratory depression</p>	
<p><b>Paraldehyde</b>                      injection; rectal solution   </p>	
<p><b>Phenytoin Sodium</b>                        capsules; oral suspension; injection   </p>	
<p><b>Sulthiame</b>                        Ospolot® 50mg tablets    </p>	<p><b>RESTRICTED</b>                      Consultant Neurologist use only</p>

4.9 Drugs used in Parkinsonism & related disorders		GMMMG
4.9.1 Dopaminergic Drugs Used in Parkinsonism		NICE NG71
<b>Amantadine Hydrochloride</b> Green capsules; oral solution NICE BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>Apomorphine Hydrochloride</b> Amber injection; infusion NICE MMC BNF emc MHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: minimising risk of cardiac side effects	<b>RESTRICTED</b> Specialist use only	
<b>Cabergoline</b> Green tablets NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>Co-beneldopa</b> Green capsules; M/R capsules; dispersible tablets NICE BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>Co-careldopa</b> Green tablets; M/R tablets PbR X NICE BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>Entacapone</b> Green tablets MMC BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>Foscarbidopa / Foslevodopa</b> Red Produodopa® infusion NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use in line with NICE	
<b>Opicapone</b> Green capsules MMC BNF emc	<b>RESTRICTED 2<sup>nd</sup> line</b> Specialist use only	
<b>Pramipexole</b> Green tablets; M/R tablets MMC BNF emc	<b>RESTRICTED 3<sup>rd</sup> line add-on use</b> Specialist use only	
<b>Rasagiline</b> Green tablets MMC BNF emc	<b>RESTRICTED</b> patients with end of dose fluctuations	
<b>Ropinirole</b> Green tablets; M/R tablets BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>Rotigotine</b> Green transdermal patches NICE MMC BNF emc	<b>RESTRICTED</b> Specialist use only. NBM patients	
<b>Safinamide</b> Green tablets MMC BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>Selegiline</b> Green tablets BNF emc	<b>RESTRICTED</b> Specialist use only	
<b>4.9.2 Antimuscarinic Drugs Used in Parkinsonism</b>		
<b>Orphenadrine Hydrochloride</b> oral solution BNF emc		
<b>Procyclidine (Oral &amp; IM)</b> tablets; oral solution; injection BNF emc		
<b>Trihexyphenidyl Hydrochloride (Benzhexol Hydrochloride)</b> tablet; syrup MMC BNF emc		

4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders		
<b>Propranolol</b> tablets; M/R capsules; oral solution; injection  		
<b>Haloperidol</b> Green tablets; capsules; oral solution (500microgram tablets see DNP) MHRA Drug Safety Update (Dec-21): Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium  		<b>RESTRICTED</b> Specialist use only
<b>Piracetam</b> tablets; oral solution  		<b>RESTRICTED</b> Specialist use only
<b>Tetrabenazine</b> tablets  		<b>RESTRICTED</b> Specialist use only
Torsion Dystonias & Other Involuntary Movements		
The dose of botulinum toxin is specific to each individual preparation and is <b>NOT</b> interchangeable. The doses for different indications vary - consult product literature & specialist guidance		
<b>Botulinum Toxin Type A</b> Red Botox® injection     		<b>RESTRICTED</b> Specialist use only see decision tables
<b>Botulinum Toxin Type A</b> Red Dysport® injection    		<b>RESTRICTED</b> Specialist use only
<b>Botulinum Toxin Type A</b> Red Xeomin® injection     		<b>RESTRICTED</b> Specialist use only see decision tables

4.10 Drugs used in substance dependence		GMMMG
<b>4.10.1 Alcohol dependence</b>		
<b>Nalmefene</b> Green    		<b>RESTRICTED</b> - Specialist use only in line with NICE TA325 <b>NOT STOCKED</b>
<b>4.10.2 Nicotine dependence</b>		
<b>Nicotine Replacement Therapy</b> patches, lozenges, inhalator, microtabs  		<b>NICE NG92</b> <b>1<sup>st</sup> line use</b>
<b>Cytisine</b> Green Cytisine 1.5mg tablets   		<b>1<sup>st</sup> line use</b>
<b>Bupropion Hydrochloride</b> tablets   		
MHRA Drug Safety Update (Nov-20): Bupropion (Zyban): risk of serotonin syndrome with use with other serotonergic drugs		
<b>Varenicline</b> tablets    		
<b>4.10.3 Opioid Dependence</b>		
MHRA Drug Safety Update (Sep-20): Opioids: risk of dependence and addiction		
<b>Buprenorphine</b> Green  sublingual tablets   		<b>RESTRICTED</b> Initiation by substance misuse specialist
<b>Methadone Hydrochloride</b>  oral solution   		<b>RESTRICTED</b> Initiation by substance misuse specialist
<b>Naltrexone Hydrochloride</b> Red  tablets    		<b>RESTRICTED</b> Gastro Consultant - cholestatic itch

4.11 Drugs for dementia		GMMMG
4.11 Drugs for Dementia		NICE NG97
<p><b>Donepezil Hydrochloride</b></p> <p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>tablets; orodispersible tablets</p>	   	<p><b>RESTRICTED</b></p> <p>Specialist use only</p>
<p><b>Galantamine</b></p> <p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>M/R capsules; tablets</p> <p style="background-color: yellow;">MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals</p>	  	<p><b>RESTRICTED</b></p> <p>Specialist use only</p>
<p><b>Memantine Hydrochloride</b></p> <p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>tablets; oral solution</p>	   	<p><b>RESTRICTED</b></p> <p>Specialist use only</p>
<p><b>Rivastigmine</b></p> <p><span style="background-color: green; color: white; padding: 2px;">Green</span></p> <p>capsules; oral solution; transdermal patches</p>	   	<p><b>RESTRICTED</b></p> <p>Specialist use only</p>
<p><b>Dementia - as per NICE TA217 &amp; NG97 Green (following specialist initiation)</b></p>		<p><span style="background-color: green; color: white; padding: 2px;">Green</span></p>

## Non-Formulary Items

**Haloperidol**

DNP

500microgram tablets

MMC BNF emc

**in line with GMMG**

## Section 5: Infections

Supported by the  
formulary ([click here](#))



### 5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulphonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antileprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

### 5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

### 5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

### 5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

### 5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, Enterobius vermicularis)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

### Non-Formulary Items



## Trust Guidelines

MFT Adult Antimicrobial guidelines  
 MFT Paediatric Antimicrobial guidelines  
 ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Prophylaxis against infective endocarditis (CG64)  
 Bacterial meningitis and meningococcal septicaemia (CG102)  
 Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)  
 Hepatitis B (Chronic) (CG165)  
 Tuberculosis (NG33)  
 Sinusitis (acute): antimicrobial prescribing (NG79)  
 Sore throat (acute): antimicrobial prescribing (NG84)  
 Otitis media (acute): antimicrobial prescribing (NG91)  
 Cough (acute): antimicrobial prescribing (NG120)  
 Surgical site infections: prevention and treatment (NG125)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Hepatitis B: Entecavir (TA153)  
 Hepatitis B: Telbivudine (TA154)  
 Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)  
 Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)  
 Hepatitis B: Tenofovir disoproxil (TA173)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Sofosbuvir for treating chronic hepatitis C (TA330)  
 Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)  
 Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)  
 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)  
 Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)  
 Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)  
 Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)  
 Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)  
 Letemovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)  
 Cabotegravir with rilpivirine for treating HIV-1 (TA757)  
 Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)  
 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)  
 Bulevirtide for treating chronic hepatitis D (TA896)  
 Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

## GMMM Formulary

Formulary Homepage  
 Chapter 5: Infections (Complete)  
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red/Amber/Green](#) Drug List

**RESTRICTED USE ANTIBIOTICS**

1. Must be recommended / approved for use by consultant medical microbiologist
2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
3. Only available from Pharmacy

**RESERVED USE ANTIBIOTICS**

1. Can be used only in accordance with the restrictions outlined below.
2. Indication must be clearly documented on the prescription chart.
3. If being used outside of guidelines Microbiology approval must be sought as above.

**UNRESTRICTED USE ANTIBIOTICS**

1. Can be used according to CMFT Trust guidelines, (those drugs not marked Restricted or Reserved)

**5.1 Antibacterial drugs****5.1.1 Penicillins****5.1.1.1 Benzylpenicillin & Phenoxymethylpenicillin****Benzylpenicillin Sodium (Penicillin G)**

600mg injection

**Phenoxymethylpenicillin (Penicillin V)**

tablets

**Benzathine Benzylpenicillin**

injection

**RESTRICTED**  
unlicensed treatment for syphilis**5.1.1.2 Penicillinase-Resistant Penicillins****Flucloxacillin**

capsules; injection; oral solution

**Temocillin**

1g injection

**RESTRICTED** infection caused by  
multi-resistant coliforms.  
**Micro only****5.1.1.3 Broad Spectrum Penicillins****Amoxicillin**

capsules; oral suspension; injection

**Co-amoxiclav**

tablets; oral suspension; injection

**5.1.1.4 Antipseudomonal Penicillins****Piperacillin with Tazobactam**

injection

**RESERVED**  
serious / resistant infections**Ticarcillin with Clavulanic Acid**

Timentin® 3.2g injection

**RESERVED**  
serious / resistant infections**5.1.1.5 Mecillinams****Pivmecillinam Hydrochloride**

200mg tablets

**RESTRICTED** UTIs caused by resistant  
coliforms**5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams****5.1.2.1 Cephalosporins****Cefalexin**

capsules; tablets; oral suspension

**Cefazolin**

injection

**RESTRICTED**  
on Micro. advice only**Cefotaxime**

injection












































**RESERVED**  
as per guidelines for children**Ceftriaxone**












































injection















































































**RESERVED**  
as per guidelines for children**Cefuroxime**



















































injection

**RESERVED**  
as per guidelines for children

<b>Cefixime</b>		<b>RESERVED</b> GU infections only
tablets	MMC  	
<b>Ceftazidime</b>		<b>RESERVED</b> pseudomonas infection in CF
injection	MMC  	
<b>Cetazidime / Avibactam</b>		<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
Zavicefta® infusion	MMC  	
<b>Ceftolozane sulfate / Tazobactam sodium</b>		<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
Zerbaxa® infusion	MMC  	
<b>Ceftaroline Fosamil</b>		<b>RESERVED</b> CAP & cSSTI treatment. <b>Micro. Consultant only</b>
Zinforo® infusion	MMC  	
<b>Cefoxitin</b>		<b>RESERVED for treatment of</b> mycobacterium abscessus in CF. <b>Micro. Consultant only</b>
injection	MMC  	
<b>Cefiderocol</b>		<b>RESERVED for</b> gram negative organisms <b>Micro. Consultant only</b>
Fetroja® infusion	MMC  	
<b>5.1.2.2 Carbapenems</b>		
<b>Ertapenem</b>		<b>RESTRICTED</b> Outpatient therapy only
infusion	MMC  	
<b>Imipenem with Cilastatin</b>		<b>RESTRICTED</b> Non-Tuberculous Mycobacteria in CF
infusion	MMC  	
<b>Imipenem / Cilastatin / Relebactam</b>		<b>RESTRICTED</b> <b>Micro. Consultant only</b>
 Recarbrio® infusion	MMC  	
<b>Meropenem</b>		<b>RESERVED</b> as per guidelines
injection	MMC  	
<b>Meropenem with Vaboractam</b>		<b>RESTRICTED</b> <b>Micro. Consultant only</b>
Vaborem® infusion	MMC  	
<b>5.1.2.3 Other Beta-Lactam antibiotics</b>		
<b>Aztreonam</b>		<b>RESTRICTED</b> gram negative organisms
injection	 	
<b>Aztreonam lysine</b>		<b>RESTRICTED 3<sup>rd</sup> line CF patients with</b> chronic pulmonary infection
  Cayston® nebuliser solution	MMC  	
<b>5.1.3 Tetracyclines</b>		
<b>Doxycycline</b>		
capsules; tablets; dispersible tablets	MMC  	
<b>Oxytetracycline</b>		
tablets	 	
<b>Demeclocycline Hydrochloride</b>		<b>RESTRICTED</b> SIADH only
capsules	MMC  	
<b>Lymecycline</b>		<b>RESTRICTED</b> Non-Formulary <b>MMC approved for GP referral</b>
capsules	MMC  	
<b>Minocycline</b>		
capsules; tablets	MMC  	
<b>Tigecycline</b>		<b>RESERVED</b> as per guidelines
infusion	MMC  	

5.1.4 Aminoglycosides		
MHRA Drug Safety Update (Jan-21): Aminoglycosides (gentamicin, amikacin, tobramycin & neomycin): increased risk of deafness in patients with mitochondrial mutations		
<b>Amikacin</b>		<b>RESERVED</b> as per guidelines
injection	 <b>MMC</b>  	
<b>Gentamicin</b>		
injection	 	
<b>Tobramycin</b>		<b>RESERVED</b> as per guidelines
  		
injection; inhalation powder; nebuliser liquid	 <b>MMC</b>  	
<b>Neomycin Sulfate</b>		<b>RESTRICTED</b> Gastro team only - op prep
oral solution	 	
5.1.5 Macrolides		
<b>Clarithromycin</b>		
tablets; oral suspension; infusion	 	
<b>Azithromycin</b>		<b>RESERVED</b> GU only or specialist use
tablets; oral suspension	 	
<b>Erythromycin</b>		<b>RESERVED</b> in pregnancy or neonates
tablets; oral suspension; injection	 	
MHRA Drug Safety Update (Dec-20): Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban		
MHRA Drug Safety Update (Dec-20): Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis		
5.1.6 Clindamycin		
<b>Clindamycin</b>		<b>RESERVED</b> as per guidelines
capsules; oral suspension; injection; 2% vaginal cream	 	
5.1.7 Some other Antibacterials		
<b>Chloramphenicol</b>		<b>RESERVED</b> as per guidelines
capsules; injection	 	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
Dalbavancin		
<b>Dalbavancin</b>		<b>RESTRICTED Consultant only</b>  <b>Micro. approval required</b>
500mg infusion	<b>MMC</b>  	
Fidaxomicin		
<b>Fidaxomicin</b>		<b>RESTRICTED</b> <i>clostridium difficile</i> associated diarrhoea <b>Micro. only</b>
 		
200mg tablets; 40mg/mL granules for oral suspension	<b>MMC</b>  	
Fusidic Acid		
<b>Sodium Fusidate</b>		<b>RESERVED</b> as per guidelines
		
tablets; oral suspension; 2% cream	 	
MHRA Drug Safety Update (Sep-11): Systemic fusidic acid and interaction with statins		
Glycopeptides		
<b>Vancomycin</b>		
		
injection; capsules; oral suspension	<b>MMC</b>  	
<b>Teicoplanin</b>		<b>RESERVED</b> as per guidelines
injection	 	
Daptomycin		
<b>Daptomycin</b>		<b>RESTRICTED</b> as per guidelines
		
infusion	<b>MMC</b>  	
Linezolid		
<b>Linezolid</b>		<b>RESTRICTED</b> as per guidelines
		
tablets; infusion	<b>MMC</b>  	

<b>Polymyxins</b>		
<b>Colistimethate Sodium</b>   injection  		<b>RESTRICTED</b> as per guidelines
<b>Colistimethate Sodium (DPI)</b>   Colobreathe® inhalation powder    		<b>RESTRICTED</b> as per guidelines
MHRA Drug Safety Update (Nov-14): Colobreathe (colistimethate sodium dry powder for inhalation): risk of capsule breakage - new instructions for use		
<b>Pristinamycin</b>		
<b>Pristinamycin</b>   500mg tablets   		<b>RESTRICTED</b> as per BASHH guidelines for <i>Mycoplasma genitalium</i>
<b>Rifaximin</b>		
<b>Rifaximin</b>  550mg tablets (see also section 1)    		<b>RESTRICTED</b> as per guidelines
<b>Spectinomycin</b>		
<b>Spectinomycin</b>  Kirin® injection  		<b>RESTRICTED</b> cephalosporin resistant gonorrhoea
<b>Taurolidine</b>		
<b>Taurolidine citrate 4%</b> TauroLock® 4% ampoules  		<b>RESTRICTED</b> as per CVC guidelines
<b>5.1.8 Sulphonamides &amp; Trimethoprim</b>		
<b>Trimethoprim</b>		
tablets; oral suspension  		
<b>Co-trimoxazole</b>		
 tablets; oral suspension; infusion  		<b>RESERVED</b> as per guidelines
<b>Sulfadiazine</b>		
tablets  		<b>RESTRICTED</b>
<b>5.1.9 Antituberculosis Drugs</b>  until patient stabilised then  		
<b>Bedaquiline</b>		
 tablets     		<b>RESTRICTED</b> MDR TB only
<b>Ethambutol Hydrochloride</b>		
 tablets    		
<b>Isoniazid</b>		
 tablets; oral solution; injection    		
<b>Prothionamide</b>		
 tablets   		<b>RESTRICTED</b> MDR TB only
<b>Pyrazinamide</b>		
 tablets   		
<b>Rifampicin</b>		
 capsules; oral solution; infusion   		
<b>Rifabutin</b>		
 caspules  		<b>2<sup>nd</sup> line</b> where rifampicin not suitable
<b>Rifater®</b>		
 Rifampicin / Isoniazid / Pyrazinamide tablets   		
<b>Rifinah®</b>		
 Rifampicin / Isoniazid tablets   		
<b>Voractiv®</b>		
 Rifampicin / Isoniazid / Pyrazinamide / Ethambutol Hydrochloride tablets   		

<b>Capreomycin</b>		
injection	  	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Cycloserine</b>		
capsules	 	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Delamanid</b>		
 tablets	  	<b>RESTRICTED</b> MDR TB only
<b>Streptomycin</b>		
 injection	  	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Moxifloxacin</b>		
tablets; injection	   	<b>RESTRICTED</b>
<b>Para aminosalicylic acid (PAS)</b>		
granules	   	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>5.1.10 Antileprotic Drugs</b>		
<b>Clofazimine</b>		
 capsules	  	<b>RESTRICTED</b> MDR TB only
<b>Dapsone</b>		
 tablets	  	<b>RESERVED</b>
<b>5.1.11 Metronidazole &amp; Tinidazole</b>		
<b>Metronidazole</b>		
tablets; oral suspension; infusion; suppositories; vaginal gel	  	
<b>Tinidazole</b>		
tablets	 	<b>RESTRICTED</b>
<b>5.1.12 Quinolones</b>		
<b>Ciprofloxacin</b>		
tablets; oral suspension; infusion (see also sections 11.3.1 & 12.1.1)	 	<b>RESERVED</b> as per guidelines
<b>Delafloxacin</b>		
 <i>Quofenix</i> ® tablets; infusion	  	<b>RESTRICTED Micro / Infectious diseases recommendation only</b>
<b>Levofloxacin</b>		
tablets; infusion (see also section 11.3.1)	  	<b>RESTRICTED</b> MDR TB only <b>Not stocked</b>
<b>Moxifloxacin</b>		
tablets; infusion	  	<b>RESTRICTED</b> MDR TB only
<b>Nalidixic acid</b>		
tablets	 	<b>RESTRICTED</b> Urology use in children only
<b>Ofloxacin</b>		
tablets (see also section 11.3.1)	 	<b>RESTRICTED</b> GU infections only
<p>MHRA Drug Safety Update (Jan-24): Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate</p> <p>MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour</p> <p>MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk</p> <p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p> <p>MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling &amp; potentially long-lasting or irreversible side effects</p> <p>MHRA Drug Safety Update (Nov-18): Systemic &amp; inhaled fluoroquinolones: small increased risk of aortic aneurysm &amp; dissection; advice for prescribing in high-risk patients</p>		

**5.1.13 Urinary-tract Infections****Nitrofurantoin**

M/R capsules; capsules; tablets



MHRA Drug Safety Update (Apr-23): Nitrofurantoin: reminder of the risks of pulmonary and hepatic adverse drug reactions

MHRA Drug Safety Update (Sep-14): Nitrofurantoin now contraindicated in most patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min/1.73m<sup>2</sup>**Fosfomycin**

sachets; infusion
















































**RESTRICTED**  
Micro recommendation only**Methenamine Hippurate**

tablets

**RESTRICTED** Urology Consultants**Urease inhibitor****Acetohydroxamic acid**























































































































Lithostat® tablets

**RESTRICTED** Urology Consultants
































































































5.2 Antifungal drugs		GMMMG
<b>5.2.1 Triazole Antifungals</b>		
<b>Fluconazole</b> capsules; infusion; oral suspension.	 	
<b>Isavuconazole</b> capsules; infusion	   	<b>RESTRICTED</b> micro / specialist use only
<b>Itraconazole</b> capsules; oral solution; infusion	 	
<b>Posaconazole</b> G/R tablets; oral suspension; infusion	   	<b>RESTRICTED</b> micro / specialist use only
MHRA Drug Safety Update (Sep-16): Posaconazole (Noxafil): tablets and oral suspension are not directly interchangeable		
<b>Voriconazole</b> tablets; oral suspension; infusion	   	<b>RESTRICTED</b> micro / specialist use only
<b>5.2.3 Polyene Antifungals</b>		
<b>Nystatin</b> 100,000 units/mL oral suspension	 	
<b>Amphotericin (liposomal)</b>  <i>AmBisome</i> ® infusion (systemic use)	   	<b>RESTRICTED</b> micro / specialist use only
<b>Amphotericin</b>  <i>Fungizone</i> ®	   	<b>RESTRICTED</b> micro / specialist use only
<b>5.2.4 Echinocandin Antifungals</b>		
<b>Anidulafungin</b>   <i>Ecalta</i> ® infusion	   	<b>1<sup>st</sup> line RESTRICTED</b> micro / specialist use only
<b>Micafungin</b>   <i>Mycamine</i> ® infusion	   	<b>RESTRICTED</b> micro / specialist use only
<b>5.2.5 Other Antifungals</b>		
<b>Griseofulvin</b> tablets	  	<b>2<sup>nd</sup> line</b> following topical therapy
<b>Terbinafine</b> tablets	 	<b>2<sup>nd</sup> line</b> following topical therapy
<b>Flucytosine</b> infusion	 	<b>RESTRICTED</b> micro / Neonates only
MHRA Drug Safety Update (Oct-20): Flucytosine (Ancotil): new contraindication in patients with DPD deficiency		





































































5.3 Antiviral drugs		GMMMG
<b>Casirivimab with Imdevimab</b> Red Ronapreve® infusion PbR X NICE MMC BNF		<b>RESTRICTED</b> 
<b>Molnupiravir</b> Red Lagevrio® 200mg capsules PbR X MMC BNF		<b>RESTRICTED CMDU</b> see COVID-19 guidance 
<b>Nirmatrelvir with Ritonavir</b> Red Paxlovid® 150mg/100mg tablets PbR X NICE MMC BNF		<b>RESTRICTED</b> see COVID-19 guidance 
MHRA Drug Safety Update (Nov-23): Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir		
<b>Remdesivir</b> Red Veklury® infusion PbR X NICE MMC BNF		<b>RESTRICTED</b> see COVID-19 guidance 
<b>Sotrovimab</b> Red Veklury® infusion PbR X NICE MMC BNF		<b>RESTRICTED</b> see COVID-19 guidance 
<b>Tecovirimat monohydrate</b> Red Tecovirimat SIGA® 200mg capsules PbR X MMC BNF		<b>RESTRICTED</b> patients hospitalised due to monkeypox 
<b>5.3.1 HIV Infection</b> Red		<b>BHIVA treatment guidelines</b>
<b>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</b>		<b>CHIVA PEP 2023</b>
<b>Abacavir</b> Red tablets; oral solution PbR X MMC BNF		
<b>Bictegravir / Emtricitabine / Tenofovir Alafenamide</b> Red Biktarvy® tablets PbR X MMC BNF		
<b>Emtricitabine</b> Red capsules PbR X MMC BNF		
<b>Lamivudine</b> Red tablets; oral solution PbR X BNF		
<b>Tenofovir Disoproxil</b> Red tablets; granules PbR X NICE MMC BNF		
<b>Tenofovir Alafenamide</b> Red Descovy® / Odefsey® / Genvoya® tablets PbR X MMC BNF		<b>RESTRICTED</b> patients requiring new formulation 
<b>Tenofovir Disoproxil / Efavirenz / Emtricitabine</b> Red Atripla® tablets PbR X MMC BNF		
<b>Tenofovir / Cobicistat / Elvitegravir / Emtricitabine</b> Red Stribild® tablets PbR X MMC BNF		
<b>Tenofovir / Emtricitabine</b> Red Truvada® tablets PbR X MMC BNF		
<b>Emtricitabine / Rilpivirine / Tenofovir</b> Red Eviplera® tablets PbR X MMC BNF		
<b>Zidovudine / Lamivudine</b> Red Combivir® tablets PbR X BNF		
<b>Didanosine</b> Red Videx® capsules (to be DISCONTINUED Q1 2020) PbR X MMC BNF		
<b>Stavudine</b> Red Zerit® capsules (to be DISCONTINUED Q1 2020) PbR X BNF		



















Protease Inhibitors		BHIVA treatment guidelines
<b>Atazanavir</b>   capsules    		
<b>Atazanavir / Cobicistat</b>   Evotaz® tablets    		
<b>Darunavir</b>   tablets; oral suspension    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Darunavir / Cobicistat</b>   RezoSta® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Darunavir / Cobicistat / Emtricitabine &amp; Tenofovir</b>   Symtuza® tablets    		
MHRA Drug Safety Update (Jul-18): Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1		
<b>Fosamprenavir</b>   Telzir® tablets    		
<b>Fostemsavir tromethamine</b>   Rukobia® tablets    		
<b>Lopinavir / Ritonavir</b>   Kaletra® tablets; oral solution   		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
<b>Ritonavir</b>   tablets; powder for oral suspension   		
MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels		
<b>Saquinavir</b>   tablets   		
<b>Tipranavir</b>   capsules    		
Non-Nucleoside Reverse Transcriptase Inhibitors (Non-NRTIs)		BHIVA treatment guidelines
<b>Doravirine</b>   Pifeltro® tablets    		
<b>Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate</b>   Delstrigo® tablets    		
<b>Efavirenz</b>   tablets; capsules   		
<b>Etravirine</b>   Intelence® tablets    		
<b>Nevirapine</b>   tablets; oral suspension; M/R tablets    		
<b>Rilpivirine</b>   Edurant® tablets / Rekambys® injection     		
Other Antiretrovirals		BHIVA treatment guidelines
<b>Cabotegravir</b>   Vocabria® injection     		
<b>Dolutegravir</b>   Tivicay® tablets    		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects		
MHRA Drug Safety Update (Jun-18): Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): increased risk of neural tube defects; DNP to women seeking to become pregnant...		

<b>Dolutegravir / Abacavir / Lamivudine</b> 		
Triumeq® tablets		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
<b>Dolutegravir / Lamivudine</b> 		
Dovato® tablets		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
<b>Dolutegravir / Rilpivirine</b> 		
Juluca® tablets		
MHRA Drug Safety Update (Oct-20): Dolutegravir (Tivicay ▼, Triumeq ▼, Juluca ▼): updated advice on increased risk of neural tube defects		
<b>Enfuvirtide</b> 		
Fuzeon® injection		
<b>Maraviroc</b> 		
Celsentri® tablets		
<b>Raltegravir</b> 		
tablets; chewable tablets; granules		
<b>Pharmacokinetic enhancers of antiretrovirals</b>		
<b>Cobicistat</b> 		
Tybost® tablets		
<b>5.3.2 Herpesvirus Infection</b>		
<b>5.3.2.1 Herpes Simplex &amp; Varicella-Zoster Infection</b>		
<b>Aciclovir</b> tablets; oral suspension; infusion (see also section 13.10.3)		
<b>Valaciclovir</b> tablets		<b>RESTRICTED</b> Specialist use only Haematology / Renal
<b>5.3.2.2 Cytomegalovirus (CMV) Infection</b>		
<b>Cidofovir</b> 		<b>RESERVED</b> Specialist use only
infusion		
<b>Foscarnet Sodium</b> 		<b>RESERVED</b> Specialist use only; also for aggressive CMV retinitis
infusion		
<b>Ganciclovir</b> 		<b>RESERVED</b> Specialist use only
infusion (see also eye gel section 11.3.3)		
<b>Letermovir</b> 		<b>RESERVED</b> Specialist use only
Prevymis® tablets		
<b>Maribavir</b> 		<b>RESERVED</b> Specialist use only in line with NICE
Livtency® tablets		
<b>Valganciclovir</b> 		<b>RESERVED</b> Specialist use only
tablets; oral solution		
<b>5.3.3 Viral Hepatitis</b>		
<b>5.3.3.1 Chronic hepatitis B</b>		
<b>Adefovir Dipivoxil</b> 		<b>NICE CG165</b>
Hepsera® tablets		
<b>Entecavir</b> 		
Baraclude® tablets		<b>NHSE Hepatitis C</b>
<b>5.3.3.2 Chronic hepatitis C</b>		
MHRA Drug Safety Update (Jan-17): Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation MHRA Drug Safety Update (Jan-17): Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR		
<b>Dasabuvir</b> 		<b>RESTRICTED</b> Specialist use only in line with NHSE Commissioning
Exviera® tablets		

<p><b>Elbasvir / Grazoprevir</b>                         Zepatier® tablets       </p>	<p><b>RESTRICTED Specialist use only</b> in line with NICE TA413</p>
<p><b>Glecaprevir / Pibrentasvir</b>                         Maviret® tablets       </p>	<p><b>RESTRICTED Specialist use only</b> in line with NHSE and NICE TA499</p>
<p><b>Ombitasvir / Paritaprevir / Ritonavir</b>                         Viekirax® tablets       </p>	<p><b>RESTRICTED Specialist use only</b> in line NICE / NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (Oct-18): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels</p>	
<p><b>Sofosbuvir</b>                         Sovaldi® tablets       </p>	<p><b>RESTRICTED Specialist use only</b> in line with NICE TA330</p> 
<p>MHRA Drug Safety Update (Aug-15): Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone</p>	
<p><b>Sofosbuvir / Ledipasvir</b>                         Harvoni® tablets       </p>	<p><b>RESTRICTED Specialist use only</b> in line NHSE Commissioning</p> 
<p>MHRA Drug Safety Update (May-15): Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone</p>	
<p><b>Sofosbuvir / Velpatasvir</b>                         Epclusa® tablets       </p>	<p><b>RESTRICTED Specialist use only</b> in line with NICE TA430</p>
<p><b>Sofosbuvir / Velpatasvir / Voxilaprevir</b>                         Vosevi® tablets       </p>	<p><b>RESTRICTED Specialist use only</b> in line with NICE TA507</p>
<p><b>5.3.3.3 Hepatitis D</b></p>	
<p><b>Bulevirtide</b>                         Hepcludex® injection       </p>	<p><b>RESTRICTED Specialist use only</b> in line with NICE TA896</p>
<p><b>5.3.4 Influenza</b></p>	
<p><b>Oseltamivir</b>                      Tamiflu® capsules; oral suspension      </p>	
<p>MHRA Drug Safety Update (Sep-12): Oseltamivir (Tamiflu): changed concentration and dosing dispenser of oral suspension</p>	
<p><b>Zanamivir</b>                      Relenza® inhalation powder      </p>	
<p><b>Zanamivir</b>                        Dectova® 10mg/mL infusion      </p>	<p><b>RESTRICTED</b> Virology approval only</p>
<p><b>5.3.5 Respiratory Syncytial Virus (RSV)</b></p>	
<p><b>Palivizumab</b>                         Synagis® 100mg/mL injection      </p>	<p><b>RESTRICTED Specialist use only</b></p> 
<p><b>Ribavirin</b>                         capsules; tablets       </p>	<p><b>RESTRICTED Specialist use only</b></p>

5.4 Antiprotozoal drugs		GMMMG
<b>Nitazoxanide</b>    500mg tablets; 100mg/5mL oral suspension  <b>MMC</b> 		<b>RESTRICTED</b> Specialist use only
<b>5.4.1 Antimalarials</b>		
<b>Artesunate</b>  injection  		<b>RESTRICTED</b> Specialist use only
<b>Artemether with Lumefantrine</b>  tablets <b>MMC</b>  		<b>RESTRICTED</b> Specialist use only
<b>Chloroquine</b>  tablets  		<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
<b>Mefloquine</b>  tablets  		<b>RESTRICTED</b> Specialist use only
<b>Primaquine</b>  tablets  		<b>RESTRICTED</b> Specialist use only
<b>Proguanil Hydrochloride</b>  tablets  		<b>RESTRICTED</b> Specialist use only
<b>Proguanil Hydrochloride / Atovaquone</b>  Malarone® tablets  		<b>RESTRICTED</b> Specialist use only
<b>Pyrimethamine</b>  tablets <b>MMC</b>  		<b>RESTRICTED</b> Specialist use only
<b>Pyrimethamine with Sulfadoxine</b>  tablets  		<b>RESTRICTED</b> Specialist use only
<b>Quinine Dihydrochloride</b>   injection  		<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
<b>Quinine Sulfate</b>  tablets  		<b>RESTRICTED</b> Specialist use only
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
<b>5.4.2 Amoebicides</b>		
<b>Metronidazole</b> (see also section 5.1.11)  		
<b>Tinidazole</b> Fasigyn® tablets  		<b>RESERVED</b> Specialist use only
<b>Diloxanide Furoate</b> tablets  		<b>RESTRICTED</b> Non-formulary <b>micro. recommendation only</b>
<b>5.4.3 Trichomonacides</b>		
<b>Metronidazole</b> (see also section 5.1.11)  		
<b>5.4.4 Antigiardial drugs</b>		
<b>Metronidazole</b> (see also section 5.1.11)  		

<b>5.4.5 Leishmaniicides</b>		
<b>Paromomycin</b>  tablets	  	<b>RESTRICTED</b> treatment of Cryptosporidiosis
<b>Sodium Stibogluconate</b>  injection	  	<b>RESTRICTED</b> treatment of Leishmaniicides
<b>5.4.7 Drugs for toxoplasmosis</b>		
<b>Sulfadiazine</b>  tablets	 	<b>RESTRICTED</b> treatment of toxoplasmosis <b>micro. recommendation only</b>
<b>5.4.8 Drugs for pneumocystis pneumonia</b>		
<b>Atovaquone</b>  oral suspension	 	<b>RESTRICTED</b> Specialist use only
<b>Pentamidine Isethionate</b>  injection	 	<b>RESTRICTED</b> Specialist use only

5.5 Anthelmintic		GMMMG
<b>5.5.1 Drugs for Threadworms (pinworms, <i>Enterobius vermicularis</i>)</b>		
<b>Albendazole</b>  tablets   		<b>RESTRICTED</b> Specialist use only
<b>Mebendazole</b> chewable tablets; oral suspension  		
<b>5.5.2 Ascaricides</b>		
<b>Levamisole</b>  tablets   		<b>RESTRICTED</b> Specialist use only
<b>5.5.5 Schistosomicides (bilharziasis)</b>		
<b>Praziquantel</b>  tablets   		<b>RESTRICTED</b> Schistosomicides / tapeworm
<b>5.5.6 Filaricides</b>		
<b>Diethylcarbamazine</b>  tablets   		<b>RESTRICTED</b> Specialist use only

## Section 6: Endocrine System

Supported by the  
formulary (click here)



### 6.1 Drugs used in diabetes

#### 6.1.1 Insulins

##### 6.1.1.1 Short-acting insulins

##### 6.1.1.2 Intermediate & long-acting insulins

##### Biphasic insulins

#### 6.1.2 Antidiabetic drugs

##### 6.1.2.1 Sulphonylureas

##### 6.1.2.2 Biguanides

##### 6.1.2.3 Other antidiabetic drugs

##### Alpha glucosidase inhibitors

##### Dipeptidyl peptidase-4 (DPP-4) inhibitors

##### Rapid acting insulin secretagogues (meglitinides)

##### Glucagon-like peptide-1 (GLP-1) receptor agonists

##### Sodium-glucose co-transporter 2 (SGLT2) inhibitors

##### Thiazolidinediones

#### 6.1.4 Treatment of hypoglycaemia

#### 6.1.5 Treatment of diabetic nephropathy and neuropathy

#### 6.1.6 Diagnostic and monitoring agents for diabetes mellitus

### 6.2 Thyroid & antithyroid drugs

#### 6.2.1 Thyroid hormones

#### 6.2.2 Antithyroid drugs

### 6.3 Corticosteroids

#### 6.3.1 Replacement therapy

#### 6.3.2 Glucocorticoid therapy

### 6.4 Sex hormones

#### 6.4.1 Female sex hormones and their modulators

##### 6.4.1.1 Oestrogens & HRT

##### 6.4.1.2 Progestogens and progesterone receptor modulators

#### 6.4.2 Male sex hormones & antagonists

### 6.5 Hypothalamic and pituitary hormones & anti-oestrogens

#### 6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

#### 6.5.2 Posterior pituitary hormones & antagonists

### 6.6 Drugs affecting bone metabolism

#### 6.6.1 Calcitonin & parathyroid hormone

#### 6.6.2 Bisphosphonates & other drugs affecting bone metabolism

### 6.7 Other endocrine drugs

#### 6.7.1 Bromocriptine & other dopaminergic drugs

#### 6.7.2 Drugs affecting gonadotrophins

#### 6.7.3 Metyrapone

#### 6.7.4 Somatomedins

### Non-Formulary Items



## Trust Guidelines










































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

















## NICE Guidance



Safer insulin prescribing (KTT20)  
 Diabetes in pregnancy: management from preconception to the postnatal period (NG3)  
 Type 1 diabetes in adults: diagnosis and management (NG17)  
 Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)  
 Diabetic foot problems: prevention and management (NG19)  
 Type 2 diabetes in adults: management (NG28)  
 Heavy menstrual bleeding: assessment and management (NG88)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Human growth hormone - adults (TA64)  
 Diabetes (type 1) - insulin pump therapy (TA151)  
 Osteoporosis - Primary Prevention (TA160)  
 Osteoporosis - Secondary Prevention (TA161)  
 Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)  
 Osteoporotic Fractures - denosumab (TA204)  
 Bone metastases from solid tumours - denosumab (TA265)  
 Type 2 diabetes - Dapagliflozin combination therapy (TA288)  
 Diabetes (type 2) - canagliflozin (TA315)  
 Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)  
 Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)  
 Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)  
 Bisphosphonates for treating osteoporosis (TA464)  
 Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)  
 Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)  
 Dapagliflozin with insulin for treating type 1 diabetes (TA597)  
 Sotagliflozin with insulin for treating type 1 diabetes (TA622)  
 Liraglutide for managing overweight and obesity (TA664)  
 Dapagliflozin for treating chronic kidney disease (TA775)  
 Romosozumab for treating severe osteoporosis (TA791)  
 Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)  
 Somatrogen for treating growth disturbance in people 3 years and over (TA863)  
 Tirzepatide for treating type 2 diabetes (TA924)  
 Empagliflozin for treating chronic kidney disease (TA942)  
 Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

## GMMMG Formulary














Formulary Homepage  
 Chapter 6: Endocrine system (Complete)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List




















6.1 Drugs used in diabetes		GMMMG
<b>6.1.1 Insulins</b>		
<b>Insulins must ONLY be initiated by practitioners experienced in their use</b> <b>Insulins must be prescribed by BRAND NAME</b>		
MHRA Drug Safety Update (Apr-15): High strength, fixed combination & biosimilar insulin products: minimising the risk of medication error		
		NICE NG3
		NICE NG17
		NICE NG18
		NICE NG19
		NICE NG28
<b>6.1.1.1 Short-acting insulins</b>		
<b>Human</b>		
<b>Actrapid®</b>		
Human Insulin	 	
<b>Apidra®</b>		
Insulin Glulisine	 	
<b>Fiasp®</b>		
Insulin Aspart	  	
<b>Humalog®</b>		
Insulin Lispro	 	
<b>Humulin R®</b>		
 Human Insulin	  	
<b>Humulin S®</b>		
Human Insulin	 	
<b>Insulin Lispro Sanofi®</b>		
Insulin Lispro	  	
<b>Lyumjev®</b>		
 Insulin Lispro	  	
<b>NovoRapid®</b>		
Insulin Aspart	  	
<b>Trurapi®</b>		
 Insulin Aspart	  	
<b>Animal</b>		
<b>Hypurin® Bovine Neutral</b>		
Insulin Bovine	 	
<b>Hypurin® Porcine Neutral</b>		
Insulin Porcine	 	
<b>6.1.1.2 Intermediate &amp; long-acting insulins</b>		
<b>Human</b>		
<b>Humulin I® Insulin</b>		
Isophane Insulin	 	
<b>Insulatard®</b>		
Isophane Insulin	 	
<b>Animal</b>		
<b>Hypurin® Bovine Isophane</b>		
Isophane Insulin	 	
<b>Hypurin® Porcine Isophane</b>		
Isophane Insulin	 	

<b>Long-acting insulins</b>		
<b>Human</b>		
<b>Levemir®</b>		
Insulin Detemir	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Lantus®</b>		
Insulin Glargine	 <b>MMC</b> <b>BNF</b> <b>emc</b>	<b>2<sup>nd</sup> line use</b> in patients where normal basal insulins cause nocturnal hypoglycaemia
<b>Abasaglar®</b>		
Insulin Glargine biosimilar	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Toujeo®</b>		
Insulin Glargine HIGH STRENGTH	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Tresiba®</b>		
Insulin Degludec	 <b>MMC</b> <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>3<sup>rd</sup> line after Levemir &amp; Lantus</b> <b>Diabetes Consultant only</b>
MHRA Drug Safety Update (Apr-13): Insulin degludec (Tresiba ▼): available in additional higher strength		
<b>Animal</b>		
<b>Hypurin® Bovine Lente</b>		
Insulin Zinc suspension	 <b>BNF</b> <b>emc</b>	
<b>Biphasic insulins</b>		
<b>Human</b>		
<b>Humalog® Mix 25</b>		
Biphasic Insulin Lispro	 <b>BNF</b> <b>emc</b>	
<b>Humalog® Mix 50</b>		
Biphasic Insulin Lispro	 <b>BNF</b> <b>emc</b>	
<b>Humulin M3®</b>		
Biphasic Isophane Insulin	 <b>BNF</b> <b>emc</b>	
<b>Insuman® Comb 25</b>		
Biphasic Isophane Insulin	 <b>BNF</b> <b>emc</b>	
<b>NovoMix® 30</b>		
Biphasic Insulin Aspart	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
<b>Animal</b>		
<b>Hypurin® Porcine 30/70 Mix Insulin</b>		
Biphasic Isophane Insulin	 <b>BNF</b> <b>emc</b>	
<b>6.1.2 Antidiabetic drugs</b>		
<b>6.1.2.1 Sulfonylureas</b>		
<b>Gliclazide</b>		
tablets	 <b>BNF</b> <b>emc</b>	
<b>Glipizide</b>		
tablets	 <b>BNF</b> <b>emc</b>	<b>RESTRICTED</b> <b>Not for initiation</b>
<b>6.1.2.2 Biguanides</b>		
<b>Metformin Hydrochloride</b>		
 Green oral solution; tablets	 <b>MMC</b> <b>BNF</b> <b>emc</b>	
MHRA Drug Safety Update (Jun-22): Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk MHRA Drug Safety Update (Mar-22): Metformin in pregnancy: study shows no safety concerns		

6.1.2.3 Other antidiabetic drugs		NICE NG28
<b>Alpha glucosidase inhibitors</b>		
<b>Acarbose</b>		
tablets	 	
<b>Dipeptidyl peptidase 4 (DPP 4) inhibitors</b>		
MHRA Drug Safety Update (Sep-12): Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis		
<b>Alogliptin</b>		
		
tablets	  	
<b>Linagliptin</b>		
		
tablets	  	
<b>Saxagliptin</b>		
		<b>2<sup>nd</sup> line</b> to improve glycaemic control in adults with metformin
tablets	  	
<b>Sitagliptin</b>		
		
tablets	  	
<b>Rapid acting insulin secretagogues (meglitinides)</b>		
<b>Nateglinide</b>		
tablets	  	<b>2<sup>nd</sup> line</b>
<b>Repaglinide</b>		
tablets	  	<b>2<sup>nd</sup> line</b>
<b>Glucagon-like peptide-1 (GLP-1) receptor agonists</b>		
MHRA Drug Safety Update (Jun-19): GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued		
<b>Dulaglutide</b>		
		<b>RESTRICTED</b> <b>1<sup>st</sup> line weekly preparation</b> <b>Diabetes Consultants only</b>
injection	  	
<b>Exenatide</b>		
		<b>2<sup>nd</sup> line</b> patients with poor glycaemic control
injection	   	
<b>Bydureon®</b>		
		<b>3<sup>rd</sup> line</b> after failure / inadequate response to oral therapy
Exenatide prolonged release (once weekly injection)	  	
<b>Liraglutide (Victoza®)</b>		
		<b>2<sup>nd</sup> line</b> to achieve glycaemic control with metformin or a sulphonylurea
6mg/mL pre-filled pen	   	<b>PRESCRIBE BY BRAND NAME</b>
<b>Liraglutide (Saxenda®)</b>		
		<b>RESTRICTED</b> <b>in line with NICE TA664</b> <b>PRESCRIBE BY BRAND NAME</b>
6mg/mL pre-filled pen	   	
MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
<b>GLP-1 receptor agonists (continued)</b>		
<b>Lixisenatide</b>		
		<b>RESTRICTED</b> <b>3<sup>rd</sup> line</b> as per by GMMMG & NICE <b>Diabetes Consultants only</b>
injection	  	
<b>Semaglutide</b>		
		<b>1<sup>st</sup> line</b> weekly preparation
Ozempic® injection	  	
MHRA Drug Safety Update (Nov-23): Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products		
<b>Semaglutide</b>		
		<b>RESTRICTED</b> <b>as per by GMMMG</b>
Rybelsus® tablets	   	
<b>Tirzepatide</b>		
		<b>RESTRICTED</b> <b>as per NICE / GMMMG T2DM pathway</b>
Mounjaro® injection	   	













<b>Sodium-glucose co-transporter 2 (SGLT2) inhibitors</b>		
MHRA Drug Safety Update (Mar-20): SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness		
MHRA Drug Safety Update (Feb-19): SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum)		
MHRA Drug Safety Update (Mar-17): SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)		
MHRA Drug Safety Update (Apr-16): SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis		
<b>Canagliflozin</b>		<b>RESTRICTED</b> in line with NICE <b>Diabetes Consultants only</b>
tablets		
MHRA Drug Safety Update (Jun-16): Canagliflozin (Invokana▼, Vokanamet▼): signal of increased risk of lower extremity amputations in trial in high CV risk patients		
<b>Dapagliflozin</b>		<b>RESTRICTED</b> in line with NICE
tablets		
MHRA Drug Safety Update (Apr-16): Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus		
<b>Empagliflozin</b>		<b>RESTRICTED</b> in line with NICE
tablets		
<b>Ertugliflozin</b>		<b>RESTRICTED</b> in line with NICE <b>Diabetes Consultants only</b>
tablets		
<b>Sotagliflozin</b>		<b>RESTRICTED</b> in line with NICE <b>Diabetes Consultants only</b>
Zynquista® 200mg tablets		
<b>Thiazolidinediones</b>		
<b>Pioglitazone</b>		<b>2<sup>nd</sup> line</b> add-on with metformin or a sulphonylurea
tablets		
MHRA Drug Safety Update (Aug-11): Pioglitazone: risk of bladder cancer		
<b>6.1.4 Treatment of hypoglycaemia</b>		
<b>Glucagon</b>		
1mg injection		
<b>Glucose gel</b>		
40% oral gel		
<b>Diazoxide</b>		<b>Hyperinsulinaemic Hypoglycaemia</b>
tablets		
<b>6.1.5 Treatment of diabetic nephropathy and neuropathy</b>		
<b>Diabetic nephropathy</b>		<b>NICE NG3</b>
<b>Diabetic neuropathy</b>	<a href="#">(see also section 4.7.3 Neuropathic pain)</a>	<b>NICE NG17</b>
		<b>NICE NG18</b>
		<b>NICE NG19</b>
		<b>NICE NG28</b>
<b>6.1.6 Diagnostic and monitoring agents for diabetes mellitus</b>		



6.2 Thyroid & antithyroid drugs		GMMMG
<b>6.2.1 Thyroid hormones</b>		
<b>Levothyroxine Sodium</b>		
oral solution; tablets	 	
MHRA Drug Safety Update (May-21): Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products		
<b>Liothyronine Sodium</b>		
<span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: green; color: white; padding: 2px;">Green</span>	 	<b>2<sup>nd</sup> line use (I.V. RESTRICTED to hypothyroid coma)</b>
injection; tablets		
<b>6.2.2 Antithyroid drugs</b>		
<b>Carbimazole</b>		
5mg; 20mg tablets (see also DNP below)	 	
MHRA Drug Safety Update (Feb-19): Carbimazole: increased risk of congenital malformations; strengthened advice on contraception MHRA Drug Safety Update (Feb-19): Carbimazole: risk of acute pancreatitis		
<b>Iodine (Aqueous Iodine Oral Solution)</b>		
 Lugol's Iodine	 	
<b>Potassium Iodide</b>		
tablets	 	
<b>Propylthiouracil</b>		
<span style="background-color: green; color: white; padding: 2px;">Green</span>	 	
tablets		












6.3 Corticosteroids		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
<b>6.3.1 Replacement therapy</b>		
<b>Fludrocortisone</b>		
tablets	 	
<b>6.3.2 Glucocorticoid therapy</b>		
<b>Prednisolone</b>		<b>1<sup>st</sup> line:</b> standard tablets <b>If 1<sup>st</sup> line not tolerated</b> <b>2<sup>nd</sup> line:</b> dissolve standard tablets <b>3<sup>rd</sup> line:</b> oral liquid <b>4<sup>th</sup> line:</b> soluble tablets (££)
	 	
<b>Dexamethasone</b>		
	 	
<b>Hydrocortisone</b>		
	 	
MHRA Drug Safety Update (Dec-18): Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks		
<b>Hydrocortisone M/R</b>		<b>RESTRICTED</b> <b>2<sup>nd</sup> line use in adrenal insufficiency</b>
5mg tablets	<b>MMC</b>  	
<b>Hydrocortisone</b>		<b>RESTRICTED</b> <b>2<sup>nd</sup> line use in adrenal insufficiency</b>
<span style="background-color: #008000; color: white; padding: 2px;">Green</span>	 	
Alkindi® granules in capsules		
MHRA Drug Safety Update (Feb-21): Alkindi (granules): risk of acute adrenal insufficiency in children when switching from hydrocortisone tablet formulations to granules		
<b>Betamethasone</b>		<b>RESTRICTED</b> <b>Specialist use only</b>
	 	
<b>Methylprednisolone</b>		
	 	
MHRA Drug Safety Update (Oct-17): Methylprednisolone injectable medicine containing lactose (Solu-Medrone 40 mg): do not use in patients with cows' milk allergy		
<b>Triamcinolone</b>		<b>RESTRICTED</b> <b>Specialist use only</b>
(see also section 10.1.2.2)	 	

6.4 Sex hormones		GMMMG
<b>6.4.1 Female sex hormones and their modulators</b>		
<b>6.4.1.1 Oestrogens &amp; HRT</b>		
<b>Conjugated oestrogens with progestogen</b>		
<b>Premique®</b>		<b>2<sup>nd</sup> line use oral</b> (continuous combined HRT)
tablets	BNF emc	
<b>Estradiol with Progestogen</b>		
<b>Elleste-Duet®</b>		<b>1<sup>st</sup> line use oral</b> (sequential HRT)
tablets	BNF emc	
<b>Femoston®</b>		<b>2<sup>nd</sup> line use oral</b> (sequential HRT)
tablets	BNF emc	
<b>Kliovance®</b>		<b>1<sup>st</sup> line use oral</b> (continuous combined HRT)
tablets	MMC BNF emc	
<b>Evorel Conti®</b>		<b>RESTRICTED</b> (Continuous combined HRT) when oral contraindicated
patch	BNF emc	
<b>Estradiol only</b>		
<b>Elleste Solo®</b>		<b>1<sup>st</sup> line use oral</b> (oestrogen only HRT)
tablets	BNF emc	
<b>Estradot®</b>		<b>RESTRICTED</b> (Oestrogen only HRT) when oral contraindicated.
patch	BNF emc	
<b>Evorel®</b>		<b>RESTRICTED</b> Paed. Endocrine Consultants
patch	MMC BNF emc	
<b>Ethinylestradiol, raloxifene &amp; tibolone</b>		
<b>Ethinylestradiol</b>		2 microgram tablets (unlicensed) for amenorrhoea
tablets	MMC BNF emc	
<b>Raloxifene Hydrochloride</b>		<b>RESTRICTED</b> Specialist Med. Consultant only
tablets	NICE MMC BNF emc	
<b>Tibolone</b>		<b>3<sup>rd</sup> line use oral</b> (continuous combined HRT)
tablets	BNF emc	
<b>6.4.1.2 Progestogens and progesterone receptor modulators</b>		
<b>Dydrogesterone</b>		
tablets	BNF emc	
<b>Medroxyprogesterone Acetate</b>		
<i>Depo-Provera®</i> 150mg/mL injection	BNF emc	
<b>Medroxyprogesterone Acetate</b>		
<i>Sayana Press®</i> 104mg/0.65 mL injection	MMC BNF emc	
<b>Norethisterone</b>		
tablets	BNF emc	
<b>Progesterone</b>		
<b>Red</b> (suppositories in IVF)		
pessaries; vaginal capsules; injection	MMC BNF emc	
<b>Ulipristal Acetate</b>		
<b>Red</b>		<b>RESTRICTED</b> Specialist use only uterine fibroids
<i>Esmya®</i> 5mg tablets	MMC BNF emc	
MHRA Drug Safety Update (Feb-21): Ulipristal acetate 5mg (Esmya): further restrictions due to risk of serious liver injury		
MHRA Drug Safety Update (Aug-18): Esmya - risk of serious liver injury: new restrictions to use, requirements for LFT monitoring before, during & after treatment		
MHRA Drug Safety Update (Mar-18): Esmya (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor LFT in current and recent users		



6.4.2 Male sex hormones & antagonists		
<b>Testosterone &amp; Esters</b>		
<b>Oral</b>		
<b>Testosterone</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> <span style="background-color: orange; color: white; padding: 2px;">Amber</span>	 	<b>RESTRICTED</b> Specialist use only
injection & implants only		
<b>Transdermal preparations</b>		
<b>Androstanolone (aka Dihydrotestosterone (DHT))</b>	  	<b>RESTRICTED</b> Specialist use only - 3 <sup>rd</sup> line
Andractim® 2.5% gel		
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure		
<b>Testosterone</b>	  	<b>RESTRICTED</b> Specialist use only
Tostran® 2% gel		
MHRA Drug Safety Update (Jan-23): Topical testosterone (Testogel): risk of harm to children following accidental exposure		
<b>Anti-androgens</b>		
<b>Cyproterone Acetate</b> <span style="background-color: green; color: white; padding: 2px;">Green</span>	 	<b>RESTRICTED</b> Specialist use only
tablets (see also section 8.3.4.2)		
<b>Finasteride</b> <span style="background-color: orange; color: white; padding: 2px;">Amber</span>	 	<b>RESTRICTED</b> Specialist use only
tablets		
MHRA Drug Safety Update (Apr-24): Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation..)		
MHRA Drug Safety Update (May-17): Finasteride: rare reports of depression and suicidal thoughts		

6.5 Hypothalamic & pituitary hormones & anti-oestrogens		GMMMG
<b>6.5.1 Hypothalamic &amp; anterior pituitary hormones &amp; anti-oestrogens</b>		
<b>Anti-oestrogens</b>		
<b>Clomifene Citrate</b> <span>Red</span>		
tablets	BNF emc	
<b>Anterior pituitary hormones (Corticotrophins)</b>		
<b>Tetracosactide</b> <span>Red</span>		<b>RESTRICTED</b> test for adrenocortical insufficiency
injection	BNF emc	
<b>Corticotropin releasing hormone</b> <span>Red</span>		<b>RESTRICTED</b> Specialist use only
injection	BNF emc	
<b>Anterior pituitary hormones (Gonadotrophins)</b>		
<b>Human Chorionic Gonadotrophin (hCG)</b> <span>Red</span>		<b>RESTRICTED</b> Specialist use only
Zivafert® injection	MMC BNF emc	
<b>Recombinant human follicle stimulating hormone (r-hFSH)</b> <span>Red</span>		<b>RESTRICTED</b> Specialist use only
Ovaleap® injection	MMC BNF emc	
<b>Anterior pituitary hormones (Growth Hormone)</b>		
<b>Somatropin</b> <span>Red</span> <span>Amber</span> <span>££</span>		<b>RESTRICTED</b> as per NICE
injection	PbR X NICE MMC BNF emc	
<b>Somatogon</b> <span>Red</span> <span>££</span>		<b>RESTRICTED</b> as per NICE
Ngenla® injection	PbR X NICE MMC BNF emc	
Growth hormone for children		Amber
Growth hormone for primary and secondary hypopituitarism		Green
Growth hormone for adults except in proven primary and secondary hypopituitarism		Red
<b>Anterior pituitary hormones (Growth Hormone receptor antagonists)</b>		
<b>Pegvisomant</b> <span>Red</span> <span>££</span>		<b>RESTRICTED</b> acromegaly on named patient basis <b>NOT STOCKED</b>
injection	PbR X MMC BNF blueTEQ emc	
<b>Hypothalamic hormones</b>		
<b>Gonadorelin (GnRH; LHRH)</b> <span>Red</span>		<b>RESTRICTED</b> Specialist use only
injection	BNF emc	
<b>Protirelin (TRH)</b> <span>Red</span>		<b>RESTRICTED</b> Specialist use only
injection	BNF emc	
<b>6.5.2 Posterior pituitary hormones &amp; antagonists</b>		
<b>Desmopressin</b>		<b>RESTRICTED</b> Haematology Consultants only
injection; oral lyophilisates; nasal spray; solution; tablets (see also section 7.4.2)	MMC BNF emc	
<b>Terlipressin Acetate</b>		<b>RESTRICTED</b> oesophageal varices / HRS-AKI
injection	MMC BNF emc	
MHRA Drug Safety Update (Mar-23): Terlipressin: new recommendations to reduce risks of respiratory failure & septic shock in patients with type 1 hepatorenal syndrome		
<b>Tolvaptan</b> <span>Red</span> <span>££</span>		<b>RESTRICTED</b> Adult. Endocrine / Renal Consultant only
tablets	PbR X NICE MMC BNF emc	
<b>Vasopressin</b>		<b>RESTRICTED</b> pituitary diabetes insipidus
injection	BNF emc	
<b>Antidiuretic hormone antagonists</b>		
<b>Demeclocycline Hydrochloride</b> <span>Red</span>		<b>RESTRICTED</b> SIADH only
capsules (see also section 5.1.3)	MMC BNF emc	

6.6 Drugs affecting bone metabolism		GMMMG
<b>6.6.1 Calcitonin &amp; parathyroid hormone</b>		
<b>Calcitonin (salmon) / Salcatonin (Miacalcic®)</b>		<b>RESTRICTED</b> osteoporosis patients with acute fracture pain.
injection	MMC BNF emc	
MHRA Drug Safety Update (Aug-12): Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.		
<b>Parathyroid hormone</b>		<b>RESTRICTED</b> postmenopausal osteoporosis if failure or non-compliance with bisphosphonates
Red 		
injection	PbR X MMC BNF emc	
<b>Teriparatide (Forsteo®)</b>		<b>RESTRICTED</b> as per NICE/NHSE
Red 		
250 micrograms / mL injection	PbR X NICE MMC BNF emc	Paeds. see decision tables
<b>Teriparatide (Movymia®)</b>		<b>RESTRICTED</b> as per forsteo for new patients
Red 		
250 micrograms / mL injection	PbR X NICE MMC BNF emc	
<b>6.6.2 Bisphosphonates &amp; other drugs affecting bone metabolism</b>		
MHRA Guidance (Dec-14): Bisphosphonates: use and safety		
MHRA Drug Safety Update (Dec-15): Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jun-11): Bisphosphonates: atypical femoral fractures		
MHRA Drug Safety Update (Nov-09): Bisphosphonates: osteonecrosis of the jaw		
<b>Alendronic Acid</b>		<b>1<sup>st</sup> line use</b>
tablets	NICE MMC BNF emc	
<b>Risedronate Sodium</b>		<b>2<sup>nd</sup> line</b> Osteoporosis & Paget's disease
tablets	NICE MMC BNF emc	
<b>Strontium Ranelate</b>		<b>3<sup>rd</sup> line</b> osteoporosis patients unable to take bisphosphonates
Red 		
oral suspension	MMC BNF emc	
<b>Ibandronic Acid</b>		<b>RESTRICTED</b> monthly treatment when daily/weekly dosing contraindicated; NICE TA464
Red  injection  tablets		
tablets; injection	NICE MMC BNF emc	
<b>Denosumab</b>		<b>RESTRICTED</b> specialist use / NICE TA204
Amber 		
Prolia® injection	NICE MMC BNF emc	
MHRA Drug Safety Update (May-22): Denosumab 60mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia		
MHRA Drug Safety Update (Aug-20): Denosumab 60mg (Prolia): increased risk of multiple vertebral fractures after stopping or delaying ongoing treatment		
MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk		
<b>Denosumab</b>		<b>RESTRICTED</b> specialist use / NICE TA265
Red 		
Xgeva® injection	NICE MMC BNF emc	
MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for advanced malignancies involving bone: study data show new 1ry malignancies reported more frequently...		
MHRA Drug Safety Update (Jun-18): Denosumab (Xgeva ▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation		
MHRA Drug Safety Update (Jun-17): Denosumab (Xgeva ▼, Prolia): reports of osteonecrosis of the external auditory canal		
MHRA Drug Safety Update (Jul-15): Denosumab (Xgeva ▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk		
<b>Zoledronic Acid</b>		<b>RESTRICTED</b> see decision tables; also NICE TA464
Red 		
infusion	NICE MMC BNF emc	
<b>Burosumab</b>		<b>RESTRICTED</b> specialist use only XLH / TIO
Red 		
infusion	NICE MMC BNF emc	
<b>Romosozumab</b>		<b>RESTRICTED</b> specialist use NICE TA791
Red 		
Evenity® injection	NICE MMC BNF emc	

6.7 Other endocrine drugs		GMMMG
<b>6.7.1 Bromocriptine &amp; other dopaminergic drugs</b>		
<b>Bromocriptine</b>		
1mg; 2.5mg tablets	MMC BNF emc	
<b>Cabergoline</b>		
500 microgram tablets	BNF emc	<b>RESTRICTED</b> Hyperprolactinaemia
<b>6.7.2 Drugs affecting gonadotrophins</b>		
<b>Danazol</b>		
capsules	BNF emc	
<b>Buserelin</b>		
Red		<b>RESTRICTED</b> IVF
injection (see also section 8.3.4.2)	MMC BNF emc	
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Buserelin Acetate</b>		
Red		<b>RESTRICTED</b> adult haem-oncology patients
Suprecur® nasal spray	MMC BNF emc	
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Goserelin</b>		
Amber Red		
implant (also section 8.3.4.2)	BNF emc	
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Leuprorelin Acetate</b>		
Amber Red		
injection (also section 8.3.4.2)	MMC BNF emc	
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Triptorelin</b>		
Amber Red		<b>RESTRICTED</b>
injection (also section 8.3.4.2)	MMC BNF emc	
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Cetrorelix acetate</b>		
Red		<b>RESTRICTED</b> IVF
injection	MMC BNF emc	
<b>Ganirelix</b>		
Red		<b>RESTRICTED</b> IVF
injection	MMC BNF emc	
<b>Relugolix with estradiol &amp; norethisterone acetate</b>		
Green		<b>RESTRICTED</b> specialist use NICE TA832
Ryeqo® 40mg/1mg/0.5mg tablets	NICE MMC BNF emc	
Goserelin/Leuprorelin - Licensed Indications (Pre-op management prior to endometrial ablation/fibroid surgery)		Amber
Goserelin/Leuprorelin/Triptorelin - Licensed Indications (Prostate cancer for all and breast cancer for Goserelin)		Amber
Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)		Red
Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)		Red
<b>6.7.3 Metyrapone</b>		
<b>Metyrapone</b>		
Red		<b>RESTRICTED</b> Specialist use only
250mg capsules	BNF emc	
<b>6.7.4 Somatomedins</b>		
<b>Mecasermin</b>		
££		<b>RESTRICTED</b> Specialist use only
10mg/mL injection	PbR X BNF emc	
MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex▼): risk of benign and malignant neoplasia		

## Non-Formulary Items

**Carbimazole**

DNP

10mg; 15mg tablets

MMC BNF emc

**in line with  
GMMMG**

## Section 7: Obstetrics, gynaecology & urinary tract disorders

Supported by the  
formulary ([click here](#))



### 7.1 Drugs used in Obstetrics

- 7.1.1 Prostaglandins & oxytocics
  - 7.1.1.1 Drugs affecting the ductus arteriosus
- 7.1.2 Mifepristone
- 7.1.3 Myometrial relaxants

### 7.2 Treatment of vaginal & vulval conditions

- 7.2.1 Preparations for vaginal & vulval changes
- 7.2.2 Vaginal & vulval infections

### 7.3 Contraceptives

- 7.3.1 Combined hormonal contraceptives
  - Ethinylestradiol with Desogestrel
  - Ethinylestradiol with Gestodene
  - Ethinylestradiol with Levonorgestrel
  - Ethinylestradiol with Norelgestromin
  - Ethinylestradiol with Norethisterone
  - Ethinylestradiol with Norgestimate
  - Mestranol with Norethisterone
- 7.3.2 Progestogen-only contraceptives
  - 7.3.2.1 Oral progestogen-only contraceptives
  - 7.3.2.2 Parenteral progestogen-only contraceptives
  - 7.3.2.3 Intra-uterine progestogen-only device
- 7.3.5 Emergency contraception

### 7.4 Drugs for genito-urinary disorders

- 7.4.1 Drugs for urinary retention
- 7.4.2 Drugs for urinary, enuresis & incontinence
- 7.4.3 Drugs used in urological pain
- 7.4.4 Bladder instillations & urological surgery
- 7.4.5 Drugs for erectile dysfunction
- 7.4.6 Drugs for premature ejaculation

## Trust Guidelines

















ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Long-acting reversible contraception (CG30)  
Lower urinary tract symptoms (CG97)  
Nocturnal enuresis - the management of bedwetting in children and young people (CG111)  
Antenatal and postnatal mental health: clinical management and service guidance (CG192)  
Heavy menstrual bleeding: assessment and management (NG88)  
Urinary incontinence and pelvic organ prolapse in women: management (NG123)  
Caesarean birth (NG192)  
Antenatal care for uncomplicated pregnancies (NG201)  
Inducing labour (NG207)  
Intrapartum care for healthy women and babies (NG235)  
Overactive bladder - mirabegron (TA290)  
Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)


































## GMMMG Formulary

























Formulary Homepage  
Chapter 7: Obstetrics, gynaecology & urinary tract disorders (Complete)  
GMMMG Adult [Red](#)/[Amber](#)/[Green](#); DNP and [Grey](#) Drug List  
GMMMG Paediatric [Red](#)/[Amber](#)/[Green](#) Drug List

7.1 Drugs used in Obstetrics		GMMMG
<b>7.1.1 Prostaglandins &amp; oxytocics</b>		<b>NICE NG207</b>
<b>Carbetocin</b> 		<b>RESTRICTED</b> Obs & Gynae Consultants only
<i>Pabal</i> ® injection	MMC BNF emc	
<b>Carboprost</b> 		
injection	BNF emc	
<b>Ergometrine Maleate</b> 		
injection	BNF emc	
<b>Gemeprost</b> 		
pessaries	BNF emc	
<b>Oxytocin</b> 		
injection	BNF emc	
<b>Dinoprostone</b> 		<b>RESTRICTED</b> Obs & Gynae Consultants only
injection; pessaries; vaginal gel; vaginal tablet	MMC BNF emc	
<b>7.1.1.1 Drugs affecting the ductus arteriosus</b>		(see also BNFC)
<b>Maintenance of patency</b>		
<b>Alprostadil</b> 		
<i>Prostin VR</i> ® infusion	MMC BNF emc	
<b>Closure of the ductus arteriosus</b>		
<b>Indometacin</b> 		
injection	BNF emc	
<b>7.1.2 Mifepristone</b>		
<b>Mifepristone</b> 		
tablets	BNF emc	
<b>7.1.3 Myometrial relaxants</b>		
<b>Nifedipine</b>  		<b>RESTRICTED (1<sup>st</sup> line)</b> Obs & Gynae Consultants only
capsules; tablets	MMC BNF emc	
<b>Atosiban</b> 		<b>RESTRICTED (2<sup>nd</sup> line)</b> Obs & Gynae Consultants only
infusion; injection	MMC BNF emc	
<b>Indometacin</b>  		<b>RESTRICTED (3<sup>rd</sup> line)</b> Obs & Gynae Consultants only
capsules; suppositories	MMC BNF emc	
<b>Beta<sub>2</sub> agonists</b>		
<b>Salbutamol</b> 		
injection (see also section 3.1.1.1)	BNF emc	
<b>Terbutaline Sulfate</b> 		
injection (see also section 3.1.1.1)	BNF emc	


































7.2 Treatment of vaginal & vulval conditions		GMMMG
<b>7.2.1 Preparations for vaginal &amp; vulval changes</b>		
<b>Oestrogens, topical</b>		
<b>Estradiol</b>		
Vagifem® 10 microgram pessaries	BNF emc	
<b>Estriol</b>		
0.01% cream	BNF emc	
<b>Estradiol vaginal ring</b>		
Estring® 7.5 microgram / 24 hours ring	BNF emc	<b>RESTRICTED</b> Obs & Gynae Consultants only
<b>7.2.2 Vaginal &amp; vulval infections</b>		
<b>Preparations for vaginal &amp; vulval candidiasis</b>		
<b>Clotrimazole</b>		
cream; pessaries	BNF emc	
<b>Miconazole</b>		
vaginal cream	BNF emc	
<b>Preparations for other vaginal infections</b>		
<b>Clindamycin</b>		
2% vaginal cream	BNF emc	
<b>Nystatin</b>		
vaginal cream; pessaries	BNF emc	
<b>Metronidazole</b>		
Zidoval® 0.75% vaginal gel	MMC BNF emc	<b>RESTRICTED</b> Obs & Gynae Consultants only
<b>Boric acid</b>		
Red U vaginal pessary	MMC emc	<b>RESTRICTED</b> specialist use only for vulvovaginal candidiasis

7.3 Contraceptives		GMMMG
MHRA Drug Safety Update (Mar-19): Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?		
<b>7.3.1 Combined hormonal contraceptives</b>		<b>NICE CG30</b>
MHRA Drug Safety Update (Mar-14): Combined hormonal contraceptives: risk of venous thromboembolism		
<b>Ethinylestradiol with Desogestrel</b>		
<b>Munalea</b> ®		<b>2<sup>nd</sup> line</b> due to increased risk of VTE
tablets	 	
<b>Mercilon</b> ®		<b>2<sup>nd</sup> line</b> due to increased risk of VTE
tablets	 	
<b>Ethinylestradiol with Gestodene</b>		
<b>Femodene</b> ®		<b>2<sup>nd</sup> line</b> due to increased risk of VTE
tablets	 	
<b>Aidulan</b> ®		<b>2<sup>nd</sup> line</b> due to increased risk of VTE
20microgram / 75 microgram tablets	 	
<b>Ethinylestradiol with Levonorgestrel</b>		<b>NICE NG88</b>
<b>TriRegol</b> ®		
tablets	 	
<b>Microgynon 30</b> ®		
tablets	 	
<b>Ovranette</b> ®		
tablets	 	
<b>Ethinylestradiol with Norelgestromin</b>		
<b>Evra</b> ®		<b>RESTRICTED</b> in line with GMMMG and SmPC
patch	  	
<b>Ethinylestradiol with Norethisterone</b>		
<b>Loestrin 20</b> ®		
tablets	 	
<b>Loestrin 30</b> ®		
tablets	 	
<b>Norimin</b> ®		
tablets	 	
<b>Ethinylestradiol with Norgestimate</b>		
<b>Cilest</b> ®		
tablets	 	
<b>Mestranol with Norethisterone</b>		
<b>Norinyl-1</b> ®		<b>2<sup>nd</sup> line</b> due to increased risk of VTE
tablets	 	
<b>7.3.2 Progestogen-only contraceptives</b>		
<b>7.3.2.1 Oral progestogen-only contraceptives</b>		
<b>Desogestrel</b>		
Cerazette® 75 microgram tablets	 	
<b>Levonorgestrel</b>		
Norgeston® 35 microgram tablets	 	
<b>Norethisterone</b>		
Noriday® 350 microgram tablets	 	

<b>7.3.2.2 Parenteral progestogen-only contraceptives</b>	
<b>Injectable preparations</b>	
<b>Medroxyprogesterone Acetate</b>	
<i>Depo-Provera</i> ® 150mg/mL intramuscular injection	 
<b>Medroxyprogesterone Acetate</b>	
<i>Sayana Press</i> ® 160mg/mL subcutaneous injection	  
<b>Implants</b>	
<b>Etonogestrel</b>	<b>2<sup>nd</sup> line as per MMC</b>
<i>Nexplanon</i> ® 68mg subdermal implant	  
MHRA Drug Safety Update (Feb-20): Nexplanon (etonogestrel) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury & implant migration	
MHRA Drug Safety Update (Jun-16): Nexplanon (etonogestrel) contraceptive implants: reports of device in vasculature and lung	
<b>7.3.2.3 Intra-uterine progestogen-only device</b>	
<b>Levonorgestrel</b>	
<i>Mirena</i> ® 20micrograms/24 hours IUD	 
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
<b>Levonorgestrel</b>	<b>RESTRICTED</b> <b>Specialist use Tertiary Services only</b>
<i>Jaydess</i> ® 13.5mg IUD	  
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
<b>Levonorgestrel</b>	<b>RESTRICTED</b> <b>Specialist use Tertiary Services only</b>
<i>Kyleena</i> ® 19.5mg IUD	  
MHRA Drug Safety Update (Jan-16): Levonorgestrel-releasing intrauterine systems: prescribe by brand name	
<b>7.3.5 Emergency contraception</b>	
<b>Levonorgestrel</b>	
<i>Levonelle</i> ® 1500 microgram tablets	 
MHRA Drug Safety Update (Sep-16): Levonorgestrel-containing emergency hormonal contraception: advice on interactions with hepatic enzyme inducers...	
MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women	
<b>Ulipristal Acetate</b>	<b>RESTRICTED</b> <b>emergency contraception (SARC)</b>
<i>ellaOne</i> ® 30mg tablets	  
MHRA Drug Safety Update (Aug-14): Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women	
<b>Assisted Reproductive Technology (ART) cycles</b>	
<b>Progesterone</b>	<b>RESTRICTED</b> <b>ART cycles</b> <b>2<sup>nd</sup> line</b>
<i>Utrogestan</i> ® 100mg; 200mg vaginal capsules	  

7.4 Drugs for genito-urinary disorders		GMMMG
7.4.1 Drugs for urinary retention		NICE CG97
Alpha blockers		NICE CG111
		NICE NG123
<b>Alfuzosin Hydrochloride</b>		
tablets	BNF emc	
<b>Tamsulosin Hydrochloride</b>		
capsules, tablets	MMC BNF emc	1 <sup>st</sup> line
7.4.2 Drugs for urinary, enuresis & incontinence		
Urinary incontinence		NICE NG123
<b>Oxybutynin Hydrochloride</b>		
oral solution; patch; tablets	NICE MMC BNF emc	1 <sup>st</sup> line in OAB
<b>Darifenacin Hydrobromide</b>		
tablets	NICE MMC BNF emc	1 <sup>st</sup> line in OAB
<b>Tolterodine Tartrate</b>		
capsules, tablets	NICE MMC BNF emc	1 <sup>st</sup> line in OAB
<b>Solifenacin Succinate</b>		
tablets	MMC BNF emc	2 <sup>nd</sup> line in OAB patients failed / intolerant to oxybutynin
<b>Duloxetine</b>		
capsules	MMC BNF emc	
<b>Tropium Chloride</b>		
capsules; tablets	MMC BNF emc	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
<b>Mirabegron</b>		
tablets	NICE MMC BNF emc	<b>RESTRICTED</b> in line with TA290 / Paeds 3 <sup>rd</sup> line
MHRA Drug Safety Update (Oct-15): Mirabegron (Betmiga ▼): risk of severe hypertension and associated cerebrovascular and cardiac events		
Nocturnal enuresis		
<b>Amitriptyline</b>		
oral solution; tablets (see also section 4.3.1)	BNF emc	
<b>Desmopressin</b>		
injection; nasal spray; tablets (see also section 6.5.2)	MMC BNF emc	<b>RESTRICTED</b> Haematology Consultants only
7.4.3 Drugs used in urological pain		
<b>Methionine</b>		
tablets	BNF emc	<b>RESTRICTED</b> resistant calcium phosphate lithiasis eau European Association of Urology
<b>Pentosan polysulfate sodium</b>		
capsules	NICE MMC BNF emc	<b>RESTRICTED</b> Urology Cons. in line with NICE
MHRA Drug Safety Update (Sep-19): Elmiron (pentosan polysulfate sodium): rare risk of pigmentary maculopathy		
<b>Potassium Citrate</b>		
tablets	BNF emc	

7.4.4 Bladder instillations & urological surgery		
<b>Chlorhexidine</b> 0.02% irrigation solution	 	
<b>Dimethyl Sulfoxide</b>  50% solution	 	
<b>Glycine</b> 1.5% irrigation solution	 	
<b>Sodium Chloride</b> 0.9% irrigation solution	 	
<b>Sodium Citrate</b> 3% irrigation solution	 	
<b>Sodium Hyaluronate</b>  Cystistat® 40mg/50mL bladder instillation	 	<b>RESTRICTED</b> Urology Consultants only
<b>Sodium Hyaluronate with sodium chondroitin sulfate</b>  iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation	 	<b>RESTRICTED</b> Urology Consultants only

7.4.5 Drugs for erectile dysfunction		
<b>Alprostadil</b> <span style="background-color: green; color: white; padding: 2px;">Green</span>	   	<b>RESTRICTED</b> Urology Consultants only
cream; injection; urethral sticks		
<b>Aviptadil with Phentolamine</b> <span style="background-color: green; color: white; padding: 2px;">Green</span>	   	<b>RESTRICTED</b> Urology Consultants only
<i>Invicorp</i> ® injection		
<b>Sildenafil</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> or <span style="background-color: red; color: white; padding: 2px;">Red</span> PAH	   	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
injection; oral suspension; tablets ( <a href="#">see also section 2.5.1</a> )		
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero exposure in a clinical trial on intrauterine growth restriction		
<b>Tadalafil</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> or <span style="background-color: red; color: white; padding: 2px;">Red</span> PAH	   	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
tablets ( <a href="#">see also section 2.5.1</a> )		
<b>Vardenafil</b>	   	<b>RESTRICTED</b> 1 <sup>RY</sup> Care referral only
tablets		
7.4.6 Drugs for premature ejaculation		
<b>NOT STOCKED</b>		<b>NOT STOCKED</b>

## Section 8: Malignant disease & immunosuppression

Supported by the  
formulary ([click here](#))



### 8.1 Cytotoxic drugs

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

### 8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

### 8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
  - 8.3.4.1 Breast Cancer
  - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
  - 8.3.4.3 Somatostatin analogues

### 8.4 Miscellaneous preparations

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Advanced breast cancer (CG81)  
 Familial breast cancer (CG164)  
 Hepatitis B (chronic) (CG165)  
 Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)  
 Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)  
 Early and locally advanced breast cancer: diagnosis and management (NG101)  
 Lung cancer: diagnosis and management (NG122)  
 Prostate cancer: diagnosis and management (NG131)  
 Colorectal cancer (NG151)  
 Temozolomide for malignant glioma (TA23)  
 Leukaemia (lymphocytic) - fludarabine (TA29)  
 Trastuzumab for advanced breast cancer (TA34)  
 Paclitaxel for ovarian cancer (TA55)  
 Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)  
 Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)  
 Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)  
 Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)  
 Hepatitis B: Chronic (TA96) (partially updated by CG165)  
 Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)  
 Docetaxel for prostate cancer (hormone-refractory) (TA101)  
 Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)  
 Paclitaxel for early breast cancer (TA108)  
 Docetaxel for early breast cancer (TA109)  
 Gemcitabine for Breast Cancer (TA116)  
 Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)  
 Leukaemia (lymphocytic) - fludarabine (TA119)  
 Carmustine implants and temozolomide for glioma (newly diagnosed & high grade) (TA121)  
 Pemetrexed for lung cancer (non small cell) (TA124)  
 Multiple sclerosis - natalizumab (TA127)  
 Bortezomib for relapsed multiple myeloma (TA129)  
 Pemetrexed for mesothelioma (TA135)  
 Rituximab for follicular non-Hodgkin's lymphoma (TA137)  
 Head and neck cancer - cetuximab (TA145)  
 Renal cell carcinoma - sunitinib (TA169)  
 Lenalidomide - multiple myeloma (TA171)  
 Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)  
 Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)  
 Renal Cell Carcinoma (TA178)  
 Sunitinib for gastrointestinal stromal tumours (TA179)  
 Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)  
 Cervical cancer (recurrent) - topotecan (TA183)  
 Lung cancer (small cell) - topotecan (TA184)  
 Soft tissue sarcoma - trabectedin (TA185)  
 Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)  
 Gastric cancer (advanced) - capecitabine (TA191)  
 Lung cancer (non-small-cell, first line) - gefitinib (TA192)  
 Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)  
 Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)  
 Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)  
 Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)  
 Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)  
 Colorectal cancer (metastatic) - bevacizumab (TA212)  
 Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)  
 Renal cell carcinoma (1<sup>st</sup> line metastatic) - pazopanib (TA215)  
 Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)  
 Myelodysplastic syndrome - azacitidine (TA218)  
 Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)  
 Multiple myeloma (1<sup>st</sup> line) - bortezomib and thalidomide (TA228)  
 Osteosarcoma - mifamurtide (TA235)  
 Follicular lymphoma - rituximab (review TA110) (TA243)  
 Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)  
 Bevacizumab in combination with paclitaxel & carboplatin for 1<sup>st</sup> line treatment of advanced ovarian cancer (TA284)  
 Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)  
 Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)  
 Multiple sclerosis (relapsing) - teriflunomide (TA303)  
 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Multiple myeloma - bortezomib (induction therapy) (TA311)



Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312)  
 Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)  
 Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320)  
 Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321)  
 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)  
 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326)  
 Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)  
 Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)  
 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347)  
 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)  
 Idelalisib for treating chronic lymphocytic leukaemia (TA359)  
 Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)  
 Bortezomib for previously untreated mantle cell lymphoma (TA370)  
 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)  
 Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)  
 Nintedanib for treating idiopathic pulmonary fibrosis (TA379)  
 Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380)  
 Olaparib for ovarian, fallopian tube and peritoneal cancer (TA381)  
 Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)  
 Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)  
 Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)  
 Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389)  
 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)  
 Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395)  
 Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)  
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)  
 Bosutinib for previously treated chronic myeloid leukaemia (TA401)  
 Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)  
 Degarelix for treating advanced hormone-dependent prostate cancer (TA404)  
 Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)  
 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)  
 Pegaspargase for treating acute lymphoblastic leukaemia (TA408)  
 Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)  
 Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)  
 Nivolumab for previously treated advanced renal cell carcinoma (TA417)  
 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)  
 Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)  
 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)  
 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)  
 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)  
 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)  
 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)  
 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)  
 Everolimus for advanced renal cell carcinoma after previous treatment (TA432)  
 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)  
 Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449)  
 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)  
 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)  
 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)  
 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)  
 Cabozantinib for previously treated advanced renal cell carcinoma (TA463)  
 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)  
 Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)  
 Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)  
 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)  
 Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)  
 Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)  
 Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)  
 Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)  
 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)  
 Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)  
 Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)  
 Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)  
 Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)  
 Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)  
 Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)  
 Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)  
 Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)  
 Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)  
 Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)  
 Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)  
 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)  
 Tivozanib for treating advanced renal cell carcinoma (TA512)  
 Obinutuzumab for untreated advanced follicular lymphoma (TA513)  
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)  
 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)  
 Cabozantinib for treating medullary thyroid cancer (TA516)  
 Avelumab for treating metastatic Merkel cell carcinoma (TA517)  
 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)  
 Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)  
 Midostaurin for untreated acute myeloid leukaemia (TA523)  
 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)  
 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)  
 Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)  
 Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)  
 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)  
 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)  
 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)  
 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)  
 Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)  
 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)  
 Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)  
 Dinutuximab beta for treating neuroblastoma (TA538)  
 Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)  
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)  
 Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)  
 Cabozantinib for untreated advanced renal cell carcinoma (TA542)  
 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)  
 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)  
 Padeliporfin for untreated localised prostate cancer (TA546)  
 Vandetanib for treating medullary thyroid cancer (TA550)  
 Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)  
 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)  
 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)  
 Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)  
 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)  
 Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)  
 Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)  
 Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)  
 Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)  
 Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)  
 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)  
 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)  
 Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)  
 Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)  
 Ocrelizumab for treating primary progressive multiple sclerosis (TA585)  
 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)  
 Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)  
 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)  
 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)  
 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)  
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)  
 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)  
 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)  
 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)  
 Cladribine for treating relapsing–remitting multiple sclerosis (TA616)  
 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)  
 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)  
 Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)  
 Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)  
 Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)  
 Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)  
 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)  
 Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)  
 Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)  
 Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)  
 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)  
 Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)  
 Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)  
 Entrectinib for treating NTRK fusion-positive solid tumours (TA644)  
 Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)  
 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)  
 Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)  
 Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)  
 Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)  
 Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)  
 Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)  
 Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)  
 Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)  
 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)  
 Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)  
 Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)  
 Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)  
 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)  
 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)  
 Pembrolizumab with pemetrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)  
 Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684)

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687)

Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

Ofatumumab for treating relapsing multiple sclerosis (TA699)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)

Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)

Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)

Midostaurin for treating advanced systemic mastocytosis (TA728)

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)

Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)

Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)

Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA761)

Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)

Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer.... (TA786)

Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)

Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

Diroximel fumarate for treating relapsing–remitting multiple sclerosis (TA794)

Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)

Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)

Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)

Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802)

Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)

Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)

Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)

Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)

Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852)

Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)

Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)

Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)

Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

Regorafenib for previously treated metastatic colorectal cancer (TA866)

Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)

Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)  
 Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)  
 Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)  
 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)  
 Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)  
 Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia... (TA893)  
 Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)  
 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)  
 Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)  
 Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)  
 Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)  
 Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)  
 Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)  
 Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)  
 Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)  
 Ruxolitinib for treating polycythaemia vera (TA921)  
 Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)  
 Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)  
 Targeted-release budesonide for treating primary IgA nephropathy (TA937)  
 Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)  
 Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)  
 Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)  
 Loncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)  
 Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)  
 Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)  
 Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)  
 Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952)  
 Eporitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)  
 Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)  
 Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)  
 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA962)  
 Dostarlimab with platinum-based chemo for advanced / recurrent endometrial cancer with MSI-H or MMR deficiency (TA963)  
 Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)  
 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)  
 Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)  
 Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)  
 Tisagenlecleucel for treating relapsed or refractory B-cell ALL in people 25 years and under (updates & replaces TA554) (TA975)  
 Dabrafenib for treating BRAF V600E mutation-positive glioma in children & young people aged 1 year & over (TA977)  
 Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)  
 Pembrolizumab for untreated locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma (TA983)


























































## GMMM Formulary











































































































Formulary Homepage

































































































































































Chapter 8: Malignant disease & immunosuppression (Complete)

GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List

GMMM Paediatric **Red/Amber/Green** Drug List

































8.1 Cytotoxic drugs		GMMMG
<b>8.1 Cytotoxic drugs</b>		
<b>Dexrazoxane</b> Red 		<b>RESTRICTED</b> Haematology Consultants only 
infusion	 <b>MMC</b>  	
<b>Folinic Acid</b> (as calcium folinate) Red		<b>RESTRICTED</b> Haematology Consultants only
tablets; injection	 	
<b>Mesna</b> Red		<b>RESTRICTED</b> Haematology Consultants only
tablets; injection	 	
<b>Palifermin</b> Red		<b>RESTRICTED</b> Haematology Consultants only
injection	<b>MMC</b>  	
<b>8.1.1 Alkylating drugs</b>		
<b>Busulfan</b> Red		<b>RESTRICTED</b> Haematology Consultants only
infusion	<b>MMC</b>  	
<b>Bendamustine</b> Red 		<b>RESTRICTED</b> Haematology Consultants only
infusion	  <b>MMC</b>   	
MHRA Drug Safety Update (Mar-21): Bendamustine (Levact): increased risk of non-melanoma skin cancer and progressive multifocal encephalopathy (PML) MHRA Drug Safety Update (Jul-17): Bendamustine: increased mortality in recent clinical studies in off-label use; monitor for opportunistic infections, HBV reactivation		
<b>Carmustine</b> Red		<b>RESTRICTED</b> Haematology Consultants only
infusion	  	
<b>Chlorambucil</b> Red		<b>RESTRICTED</b> Haematology Consultants only
tablets	  	
<b>Cyclophosphamide</b> Red		<b>RESTRICTED</b> Haematology Consultants only
injection; tablets; oral suspension	<b>MMC</b>  	
<b>Ifosfamide</b> Red		<b>RESTRICTED</b> Haematology Consultants only
injection	 	
<b>Lomustine</b> Red		<b>RESTRICTED</b> Haematology Consultants only
capsules	 	
<b>Melphalan</b> Red		<b>RESTRICTED</b> Haematology Consultants only
injection; tablets	 	
<b>Treosulfan</b> Red		<b>RESTRICTED</b> Adult Haematology / Paediatric Haematology / Oncology
injection	 <b>MMC</b>  	
<b>8.1.2 Anthracyclines &amp; other cytotoxic antibiotics</b>		
<b>Bleomycin</b> Red		<b>RESTRICTED</b> Haematology Consultants only
injection	 	
<b>Daunorubicin</b> Red		<b>RESTRICTED</b> Haematology Consultants only
injection	 	
<b>Doxorubicin Hydrochloride</b> Red 		<b>RESTRICTED</b> Haematology Consultants only
infusion; injection	  <b>MMC</b>   	
<b>Idarubicin</b> Red		<b>RESTRICTED</b> Haematology Consultants only
capsules; injection	 	
<b>Mitomycin</b> Red		<b>RESTRICTED</b> Consultants only
injection	<b>MMC</b>  	
<b>Mitoxantrone</b> Red		<b>RESTRICTED</b> Haematology Consultants only
infusion	 	
<b>Pixantrone</b> Red 		<b>RESTRICTED</b> Haematology Consultants only
infusion	  <b>MMC</b>  	











































8.1.3 Antimetabolites		NICE CG81
		NICE NG151
<b>Azacitidine</b>   injection     		<b>RESTRICTED</b> Haematology Consultants only
<b>Capecitabine</b>  tablets    		
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity		
MHRA Drug Safety Update (Dec-14): Capecitabine: risk of severe skin reactions - discontinue treatment		
<b>Cladribine</b>   infusion; injection      		<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Mar-22): Cladribine (Mavenclad): new advice to minimise risk of serious liver injury		
MHRA Drug Safety Update (Dec-17): Cladribine (Litak, Leustat) for leukaemia: reports of PML; stop treatment if PML is suspected		
<b>Clofarabine</b>   infusion    		<b>RESTRICTED</b> Haematology Consultants only
<b>Cytarabine</b>  injection   		<b>RESTRICTED</b> Haematology Consultants only
<b>Cytarabine / Daunorubicin</b>   Vyxeos® 100mg/44mg infusion      		<b>RESTRICTED</b> Haematology Consultants only
<b>Fludarabine</b>  injection; tablets   		<b>RESTRICTED</b> Haematology Consultants only
<b>Fluorouracil</b>  injection    		<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity		
<b>Gemcitabine</b>  infusion    		<b>RESTRICTED</b> Haematology Consultants only 
<b>Mercaptopurine</b>  oral suspension; tablets (see also section 1.5.3)  		
<b>Methotrexate</b>  infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3)   		
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions		
<b>Pemetrexed</b>   injection      		<b>RESTRICTED</b> Respiratory Consultants only in line with TA402
<b>8.1.4 Vinca alkaloids &amp; etoposide</b>		
<b>Etoposide</b>  capsules; infusion  		<b>RESTRICTED</b> Haematology Consultants only
<b>Vinblastine Sulfate</b>  injection  		<b>RESTRICTED</b> Haematology Consultants only
<b>Vincristine Sulfate</b>  injection  		<b>RESTRICTED</b> Haematology Consultants only
<b>8.1.5 Other antineoplastic drugs</b>		
<b>Acalabrutinib</b>   infusion      		<b>RESTRICTED</b> Haematology Consultants only
<b>Arsenic Trioxide</b>   infusion      		<b>RESTRICTED</b> Haem. Consultants only / also in line with NICE TA526
<b>Asciminib</b>   Scemblis® 20mg/40mg tablets      		<b>RESTRICTED</b> Haem. Consultants in line with NICE TA813
<b>Asparaginase e-coli</b>  infusion   		<b>RESTRICTED</b> Haematology Consultants only




















































<b>Autologous anti-CD19-transduced CD3+ cells</b>   Tecartus® infusion      	<b>RESTRICTED</b> Haem. Consultants in line with NICE TA677
<b>Axicabtagene ciloleucel</b>   Yescarta® infusion      	<b>RESTRICTED</b> in line with NICE TA872
<b>Bevacizumab</b>   Avastin® 100mg in 4mL vial     	<b>RESTRICTED</b> Haematology Consultants only
<b>Bortezomib</b>   injection      	<b>RESTRICTED</b> Haematology Consultants only
<b>Brentuximab Vedotin</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Brexucabtagene autoleucel</b>   Tecartus® infusion     	<b>RESTRICTED</b> Haem. Consultants only in line with CDF
<b>Cabozantinib</b>   tablets; capsules      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Carfilzomib</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ceritinib</b>   capsules      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Cetuximab</b>   infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Crisantaspase</b>   injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Dacarbazine</b>  injection  	<b>RESTRICTED</b> Haematology Consultants only
<b>Durvalumab</b>   infusion      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Entrectinib</b>   injection      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE
<b>Eribulin</b>   injection      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Erlotinib</b>   tablets      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Everolimus</b>   tablets      	<b>RESTRICTED</b> Specialist Consultant use only in line with NICE <b>NOT STOCKED</b>
<b>Hydroxycarbamide</b>  capsules; tablets (see below)  	<b>RESTRICTED</b> Haematology Consultants only
<b>Ipilimumab</b>   infusion      	<b>RESTRICTED</b> Dermatology Consultants only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation	
<b>Ivosidenib</b>   Tibsovo® 250mg tablets      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ixazomib</b>   capsules      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Lorlatinib</b>   Lorviqua® tablets      	<b>RESTRICTED</b> Respiratory Consultants only in line with NICE

<p><b>Midostaurin</b>  </p> <p>Rydapt® capsules</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line with NICE</p>
<p><b>Nintedanib esilate</b>  </p> <p>Ofev® capsules</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Respiratory                      Consultants only in line with NICE</p>
<p><b>Nintedanib esilate</b>  </p> <p>Vargatef® capsules</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Respiratory                      Consultants only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Niraparib</b>  </p> <p>Zejula® capsules</p> <p>PbR X NICE MMC BNF  </p> <p>MHRA Drug Safety Update (Oct-20): Niraparib (Zejula ▼): reports of severe hypertension &amp; PRES, particularly in early treatment</p>	<p><b>RESTRICTED</b> Gynaecology                      Consultants only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Panitumumab</b>  </p> <p>infusion</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Panobinostat</b>  </p> <p>capsules</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line with TA380</p>
<p><b>Pegaspargase</b>  </p> <p>Oncaspar® injection</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b>                      Haematology Consultants only</p>
<p><b>Pembrolizumab</b>  </p> <p>infusion</p> <p>PbR X NICE MMC BNF  </p> <p>MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection</p>	<p><b>RESTRICTED</b> Specialist use only in                      line with NICE / NHSE</p>
<p><b>Pentostatin</b>  </p> <p>infusion</p> <p>BNF </p>	<p><b>RESTRICTED</b>                      Haematology Consultants only</p>
<p><b>Pertuzumab</b>  </p> <p>infusion</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Specialist Consultant                      use only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Procarbazine</b>  </p> <p>capsules</p> <p>BNF </p>	<p><b>RESTRICTED</b>                      Haematology Consultants only</p>
<p><b>Sacituzumab govitecan</b>  </p> <p>Trodelvy® infusion</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Specialist Consultant                      use only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Selinexor</b>  </p> <p>Nexpvio® tablets</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Specialist Consultant                      use only in line with NICE</p>
<p><b>Sorafenib</b>  </p> <p>tablets</p> <p>PbR X NICE MMC BNF  </p> <p>MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection</p>	<p><b>RESTRICTED</b> Haematology                      Consultants only in line NICE / NHSE</p>
<p><b>Sotorasib</b>  </p> <p>Lumykras® tablets</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b>                      PulmonaryOnc Consultants only                      in line with NICE TA781</p>
<p><b>Talimogene Laherparepvec</b>  </p> <p>injection</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Dermatology                      Consultants only in line with TA410</p>
<p><b>Tisagenlecleucel</b>  </p> <p>Kymriah® infusion</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> in line with CDF criteria                      and NICE TA975</p>
<p><b>Trastuzumab</b>  </p> <p>infusion; injection</p> <p>PbR X NICE MMC BNF  </p>	<p><b>RESTRICTED</b> Specialist use only in                      line with NICE</p>
<p><b>Venetoclax</b>  </p> <p>Venclyxto® tablets</p> <p>PbR X NICE MMC BNF  </p> <p>MHRA Drug Safety Update (Dec-21): Venetoclax (Venclyxto ▼): updated recommendations on tumour lysis syndrome (TLS)</p>	<p><b>RESTRICTED</b> Specialist use only in                      line with NICE / NHSE</p>
<p>Hydroxycarbamide - Essential thrombocythaemia or polycythaemia with high risk of complications</p>	<p></p>
<p>Hydroxycarbamide - Sickle Cell Disease</p>	<p></p>
<p>Hydroxycarbamide - Chemotherapy</p>	<p></p>














































































































































































































































<b>Platinum compounds</b>		
<b>Cisplatin</b> Red injection	 	<b>RESTRICTED</b> Haematology Consultants only
<b>Protein kinase inhibitors</b>		
<b>Abemaciclib</b> Red  Verzenios® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases		
<b>Alectinib</b> Red  Alecensa® capsules	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE TA536 <b>NOT STOCKED</b>
<b>Alpelisib</b> Red  Piqray® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE TA816 <b>NOT STOCKED</b>
<b>Axitinib</b> Red  Inlyta® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Haematology Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Bosutinib</b> Red  Bosulif® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Haematology Consultants only in line with TA401
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
<b>Brigatinib</b> Red  Alunbrig® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Crizotinib</b> Red  Xalkori® capsules	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Dabrafenib</b> Red  Tafinlar® capsules	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Dabrafenib</b> Red  Finlee® dispersible tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Dacomitinib</b> Red  Vizimpro® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Dasatinib</b> Red  Sprycel® tablets; powder for oral suspension	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation		
<b>Encorafenib</b> Red  Braftovi® capsules	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Fedratinib</b> Red  Inrebic® capsules	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Haematology Consultants only
<b>Gefitinib</b> Red  tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
<b>Gemtuzumab ozogamicin</b> Red  Mylotarg® injection	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Haematology Consultants only
<b>Gilteritinib fumarate</b> Red  Xospata® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Haematology Consultants only
<b>Ibrutinib</b> Red  Imbruvica® capsules; tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Haem. Consultants only / also in line with NICE
MHRA Drug Safety Update (Nov-22): Imbruvica (ibrutinib): New risk minimisation measures, including dose modification recommendations		
MHRA Drug Safety Update (Aug-17): Ibrutinib (Imbruvica ▼): reports of ventricular tachyarrhythmia; risk of HBV B reactivation & opportunistic infections		
<b>Idelalisib</b> Red  Zydelig® tablets	PbR X  <b>MMC</b>   	<b>RESTRICTED</b> Specialist use only in line with NICE TA359
MHRA Drug Safety Update (Sep-16): Idelalisib (Zydelig ▼): updated indications and advice on minimising the risk of infection		
















<b>Imatinib</b>   tablets     	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
<b>Inotuzumab ozogamicin</b>   Besponsa® 1mg solution for infusion      	<b>RESTRICTED</b> Haematology Consultants only
<b>Larotrectinib sulfate</b>   Vitrakvi® 20mg/mL oral solution      	<b>RESTRICTED</b> Consultants only in line with NICE
<b>Lenvatinib</b>   Kisplyx® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE TA498 / 858 <b>NOT STOCKED</b>
<b>Lenvatinib</b>   Lenvima® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE TA535 / 551 <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Loncastuximab tesirine</b>   Zynlonta® infusion      	<b>RESTRICTED</b> Specialist use only in line with NICE TA947
<b>Mobocertinib</b>   Exkivity® capsules      	<b>RESTRICTED</b> Specialist use only
<b>Momelotinib</b>   Omjijara® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA957
<b>Neratinib</b>   Nerlynx® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA612 <b>NOT STOCKED</b>
<b>Nilotinib</b>   Tasisign® capsules      	<b>RESTRICTED</b> Haematology Consultants only
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
<b>Osimertinib</b>   Tagrisso® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Palbociclib</b>   Ibrance® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
<b>Ponatinib</b>   Iclusig® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA451
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome	
MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation	
MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events	
<b>Regorafenib</b>   Stivarga® 40mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE TA488 / TA555 <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	
<b>Ribociclib</b>   Kisqali® 200mg tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases	
<b>Ruxolitinib</b>   Jakavi® tablets     	<b>RESTRICTED</b> Specialist use only in line with NICE / NHSE
<b>Selpercatinib</b>   Retsevmo® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Selumetinib</b>   Koselugo® capsules     	<b>RESTRICTED</b> Specialist use only for NF1 in line with NICE HST20
<b>Sunitinib</b>   Sutent® capsules      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>
MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection	

<p><b>Tepotinib</b>     <i>Tepmetko</i>® 225mg tablets       </p>	<p><b>RESTRICTED</b> Specialist use in line with NICE / NHSE</p>
<p><b>Tivozanib</b>     <i>Fotivda</i>® capsules       </p>	<p><b>RESTRICTED</b>  Specialist use only in line with NICE  <b>NOT STOCKED</b></p>
<p><b>Trametinib</b>     <i>Mekinist</i>® tablets       </p>	<p><b>RESTRICTED</b> Specialist use only in line with NICE TA396  <b>NOT STOCKED</b></p>
<p><b>Zanubrutinib</b>     <i>Brukisna</i>® 80mg hard capsules       </p>	<p><b>RESTRICTED</b> Specialist use in line with NICE / NHSE</p>
<b>Topoisomerase I inhibitors</b>	
<p><b>Tretinoin</b>    capsules    </p>	<p><b>RESTRICTED</b>  Haematology Consultants only</p>
<b>Taxanes</b>	
<p><b>Paclitaxel</b>    Infusion       </p>	<p><b>RESTRICTED</b>  Haematology Consultants only</p>
MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error	
<p><b>Cabazitaxel</b>     <i>Jevtana</i>® Infusion       </p>	<p><b>RESTRICTED</b>  Haematology Consultants only</p>

8.2 Drugs affecting the immune response		GMMMG
<b>8.2.1 Antiproliferative immunosuppressants</b>		
<b>Azathioprine</b> Amber tablets; oral solution; injection (see also sections 1.5.3; 10.1.3 & 13.5.3)	PbR X NICE MMC BNF emc	
<b>Mycophenolate Mofetil</b> Amber capsules; tablets; oral suspension; infusion MHRA Drug Safety Update (Feb-18): Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients MHRA Drug Safety Update (Dec-15): Mycophenolate mofetil, mycophenolic acid: new pregnancy-prevention advice for women and men MHRA Drug Safety Update (Jan-15): Mycophenolate mofetil (CellCept) and mycophenolic acid: risk of hypogammaglobulinaemia and risk of bronchiectasis	PbR X NICE MMC BNF emc	
<b>Belatacept</b> U ££ Nulojix® 25mg/mL injection	PbR X NICE MMC BNF emc	<b>RESTRICTED</b> Renal Transplant Consultants only <b>NOT STOCKED</b>
<b>8.2.2 Corticosteroids &amp; other immunosuppressants</b>		
<b>Antithymocyte immunoglobulin (Rabbit)</b> ££ injection	PbR X NICE BNF emc	
<b>Basiliximab</b> Red ££ Simlect® injection	PbR X NICE MMC BNF emc	<b>RESTRICTED</b> Renal Consultants only
<b>Ciclosporin (Dexamune®) &amp; I.V. (Sandimmun®)</b> Amber ££ capsules; oral solution; injection	PbR X NICE MMC BNF emc	
<b>Sirolimus</b> Amber ££ oral solution; tablets	PbR X NICE MMC BNF emc	<b>RESTRICTED</b> Renal Consultants only
<b>Tacrolimus</b> Amber capsules; tablets; ointment; oral suspension; infusion; sachets	PbR X NICE MMC BNF emc	
<b>Voclosporin</b> Red ££ capsules	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Specialist use only in line with NICE
Immunosuppressants - e.g. ciclosporin, tacrolimus, sirolimus Amber Red if no SCP		
<b>8.2.3 Anti-lymphocyte monoclonal antibodies</b>		
<b>Alemtuzumab</b> Red ££ Lemtrada® infusion MHRA Drug Safety Update (Feb-20): Alemtuzumab: updated restrictions & monitoring requirements following review of serious CV & immune-mediated reactions MHRA Drug Safety Update (May-19): Alemtuzumab and serious CV & immune-mediated adverse reactions: new restrictions to use & strengthened monitoring requirements	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Renal Consultants only under Patient Access Scheme
<b>Atezolizumab</b> Red ££ Tecentriq® infusion; solution for injection MHRA Drug Safety Update (Jun-21): Atezolizumab (Tecentriq ▼) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs)	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Specialist Consultants in line with NICE / NHSE
<b>Avacopan</b> Red ££ Tavneos® capsules	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Specialist Consultants in line with NICE
<b>Avelumab</b> Red ££ Bavencio® infusion	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Specialist Consultants in line with NICE
<b>Blinatumomab</b> Red ££ Blinicyto® infusion	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Burosumab</b> Red ££ Crysvida® injection	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> X-linked hypophosphatemia
<b>Daratumumab</b> Red ££ Darzalex® infusion MHRA Drug Safety Update (Aug-19): Daratumumab (Darzalex ▼): risk of reactivation of hepatitis B virus	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Haematology Consultants only in line with NICE / NHSE
<b>Glofitamab</b> Red ££ Columvi® infusion	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Isatuximab</b> Red ££ infusion	PbR X NICE MMC BNF emc blueiq	<b>RESTRICTED</b> Haematology Consultants only in line with EAMS

















































<b>Mogamulizumab</b>   Poteligeo® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE <b>NOT STOCKED</b>
<b>Obinutuzumab</b>   Gazyvaro® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Ofatumumab</b>   Kesimpta® injection      	<b>RESTRICTED</b> Consultants only in line with NICE
MHRA Drug Safety Update (Aug-14): Ofatumumab ▼: reminder of risk of serious and fatal infusion reactions MHRA Drug Safety Update (Jan-14): Ofatumumab: screen for hepatitis B virus before treatment	
<b>Pertuzumab</b>   Perjeta® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Polatuzumab vedotin</b>   Polivy® infusion      	<b>RESTRICTED</b> Haematology Consultants only in line with NICE
<b>Rituximab</b>   injection; infusion (see also section 10.1.3)       	<b>RESTRICTED</b> Consultants only in line with NICE / NHSE
MHRA Drug Safety Update (Dec-13): Rituximab: screen for hepatitis B virus before treatment	
<b>8.2.4 Other immunomodulating drugs</b>	
<b>Interferon alfa</b>	
<b>Interferon alfa-2a</b>   Roferon-A® injection   	
<b>Interferon alfa-2b</b>   IntronA®   	
<b>Peginterferon alfa-2a</b>   Pegasys®      	<b>RESTRICTED</b> Gastro Consultants only
<b>Peginterferon alfa-2b</b>   ViraferonPeg®    	<b>RESTRICTED</b> Gastro Consultants only
<b>Interferon beta</b>	
MHRA Drug Safety Update (Oct-14): Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome	
<b>Interferon beta-1a</b>   injection      	<b>RESTRICTED</b> Specialist use only in line with NICE TA527 <b>NOT STOCKED</b>
<b>Interferon beta-1b</b>   injection      	<b>RESTRICTED</b> Specialist use only in line with NICE TA527 <b>NOT STOCKED</b>
<b>BCG bladder instillation</b>	
<b>Bacillus Calmette–Guérin</b>  OncoTICE® bladder instillation  	<b>RESTRICTED</b> Specialist use only
<b>Bacillus Calmette–Guérin</b>  BCG-medac® intravesical suspension   	<b>RESTRICTED</b> Specialist use only

















Other Agents		
<b>Belumosudil</b>   Rezurock® 200mg tablets      		<b>RESTRICTED Specialist use in line with NICE</b>
<b>Canakinumab</b>   Ilaris® 150mg/mL injection      		<b>RESTRICTED Specialist use in line with NHSE</b> 
<b>Cemiplimab</b>   Libtayo® 50mg/mL injection      		<b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>
<b>Dimethyl Fumarate</b>   Tecfidera® capsules      		<b>RESTRICTED Specialist use only in line with NICE TA320</b>
MHRA Drug Safety Update (Jan-21): Dimethyl fumarate (Tecfidera): updated advice on the risk of PML associated with mild lymphopenia MHRA Drug Safety Update (Apr-16): Dimethyl fumarate (Tecfidera): updated advice on risk of progressive multifocal leukoencephalopathy MHRA Drug Safety Update (Mar-15): Dimethyl fumarate (Tecfidera): fatal PML in an MS patient with severe, prolonged lymphopenia		
<b>Dinutuximab beta</b>   Qarziba® 4.5mg/mL injection      		<b>RESTRICTED Specialist use in line with CDF &amp; NICE</b>
<b>Diroximel Fumarate</b>   Vumerity® 231mg capsules      		<b>RESTRICTED Specialist use in line with NICE TA794</b> <b>NOT STOCKED</b>
<b>Fingolimod Hydrochloride</b>   Gilenya® capsules      		<b>RESTRICTED Specialist use only in line with NICE TA254</b>
MHRA Drug Safety Update (Jan-21): Fingolimod (Gilenya ▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis		
<b>Glatiramer acetate</b>   injection      		<b>RESTRICTED Specialist use only in line with NICE TA527</b> <b>NOT STOCKED</b>
<b>Imlifidase</b>   infusion      		<b>RESTRICTED Specialist use only in line with NICE TA809</b>
<b>Lenalidomide</b>   Revlimid® capsules      		<b>RESTRICTED Haematology Consultants only</b>
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (Jan-13): Lenalidomide (Revlimid): risk of serious hepatic adverse drug reactions		
<b>Mifamurtide</b>   Mepact® Intravenous infusion      		<b>RESTRICTED Specialist use only in line with NICE TA235</b> <b>NOT STOCKED</b>
<b>Natalizumab</b>   Tysabri® infusion      		<b>RESTRICTED Specialist use only in line with NICE TA127</b> <b>NOT STOCKED</b>
MHRA Drug Safety Update (Apr-16): Natalizumab (Tysabri ▼): progressive multifocal leukoencephalopathy—updated advice to support early detection		
<b>Nivolumab</b>   Opdivo® 10mg/mL infusion      		<b>RESTRICTED Specialist use only in line with NICE</b>
MHRA Drug Safety Update (Oct-19): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation MHRA Drug Safety Update (Jul-17): Nivolumab (Opdivo ▼), pembrolizumab (Keytruda ▼): reports of organ transplant rejection		
<b>Ocrelizumab</b>   Ocrevus® 30mg/mL infusion      		<b>RESTRICTED Specialist use only in line with NICE TA533 / TA585</b> <b>NOT STOCKED</b>
<b>Olaparib</b>   Lynparza® tablets      		<b>RESTRICTED Specialist use only in line with NICE</b> <b>NOT STOCKED</b>
<b>Pomalidomide</b>   capsules      		<b>RESTRICTED Haematology only / also in line with NICE</b>
MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19) MHRA Drug Safety Update (May-16): Pomalidomide (Imnovid ▼): risk of hepatitis B reactivation MHRA Drug Safety Update (May-15): Pomalidomide (Imnovid ▼): risks of cardiac failure, interstitial lung disease and hepatotoxicity		
<b>Ponesimod</b>   Ponvory® tablets      		<b>RESTRICTED Specialist use only in line with NICE TA767</b> <b>NOT STOCKED</b>
<b>Rucaparib</b>   tablets      		<b>RESTRICTED Specialist use only in line with NICE TA611</b> <b>NOT STOCKED</b>
MHRA Drug Safety Update (Sep-22): Rucaparib (Rubraca ▼): withdrawal of third-line treatment indication		

<p><b>Teriflunomide</b></p> <p>Red  </p> <p>tablets</p> <p>     </p>	<p><b>RESTRICTED</b> Specialist use only in line with NICE TA303</p> <p><b>NOT STOCKED</b></p>
<p><b>Thalidomide</b></p> <p>Red  </p> <p>capsules</p> <p>    </p>	<p><b>RESTRICTED</b> Haematology Consultants only</p>
<p>MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)</p> <p>MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years</p> <p>MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies</p>	

8.3 Sex hormones & hormone antagonists in malignant disease		GMMMG
<b>8.3.1 Oestrogens</b>		
<b>Diethylstilbestrol</b>		
tablets	BNF emc	<b>RESTRICTED</b> Specialist use only
<b>8.3.2 Progestogens</b>		
<b>Medroxyprogesterone Acetate</b>		
tablets	BNF emc	<b>RESTRICTED</b> Specialist use only
<b>Megestrol Acetate</b>		
tablets	BNF emc	<b>RESTRICTED</b> Specialist use only
<b>8.3.3 Androgens</b>		
<b>Testolactone</b>		
tablets	BNF emc	<b>RESTRICTED</b> Specialist use only
<b>8.3.4 Hormone Antagonists</b>		
<b>8.3.4.1 Breast Cancer</b>		
<b>Aminoglutethimide</b>		
tablets	BNF emc	<b>NICE NG101</b> <b>RESTRICTED</b> Specialist use only
<b>Anastrozole</b>		
Green	tablets	NICE MMC BNF emc
<b>Exemestane</b>		
Green	tablets	NICE MMC BNF emc
<b>Letrozole</b>		
Green	tablets	NICE BNF emc
<b>Tamoxifen</b>		
Green	tablets; oral solution	NICE BNF emc
<b>8.3.4.2 Gonadorelin analogues &amp; gonadotrophin-releasing hormone antagonists</b>		
<b>Gonadorelin analogues</b>		
<b>Buserelin</b>		
Red	injection (see also section 6.7.2)	BNF emc
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Goserelin</b>		
Amber	Red	implant (also section 6.7.2)
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Leuprorelin Acetate</b>		
Amber	Red	injection (also section 6.7.2)
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
<b>Triptorelin</b>		
Amber	Red	injection (also section 6.7.2)
NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)		
Goserelin/Leuprorelin - Licensed Indications (pre-op management prior to endometrial ablation/fibroid surgery)		Amber
Goserelin/Leuprorelin/Triptorelin - Licensed Indications (prostate cancer (all), breast cancer (goserelin))		Amber
Goserelin/Leuprorelin/Triptorelin - Precocious puberty and for testosterone castration in sex offenders (unlicensed in goserelin and leuprorelin)		Red
Goserelin/Leuprorelin/Triptorelin - For all other unlicensed indications (including long term use > 6 months)		Red



<b>Anti-androgens</b>		
<b>Bicalutamide</b> <span style="background-color: green; color: white; padding: 2px;">Green</span> tablets  		<b>RESTRICTED</b> Specialist use only
<b>Cyproterone Acetate</b> <span style="background-color: orange; color: white; padding: 2px;">Amber</span> tablets (see also section 6.4.2) MHRA Drug Safety Update (Jun-20): Cyproterone acetate: new advice to minimise risk of meningioma MHRA Drug Safety Update (Apr-20): Cyproterone acetate: restrictions in use of due to risk of meningioma  		<b>RESTRICTED</b> Specialist use only
<b>Darolutamide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> 300mg tablets      		<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Flutamide</b> tablets  		<b>RESTRICTED</b> Specialist use only
<b>Enzalutamide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> tablets      		<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
<b>Abiraterone</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Zytiga® tablets      		<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
<b>Gonadotrophin-releasing hormone antagonists</b>		
<b>Degarelix</b> <span style="background-color: orange; color: white; padding: 2px;">Amber</span> Firmagon® 80mg; 120mg injection    		<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Other</b>		
<b>Radium-223 dichloride</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Xofigo® 1,100 kBq/mL injection      		<b>RESTRICTED</b> Specialist use only in line with NICE
MHRA Drug Safety Update (Sep-18): Xofigo ▼: new restrictions on use due to increased risk of fracture and trend for increased mortality seen in clinical trial MHRA Drug Safety Update (Dec-17): ▼ Xofigo: Increased risk of death and fractures in RCT with abiraterone acetate & prednisolone/prednisone		
<b>8.3.4.3 Somatostatin analogues</b>		
<b>Lanreotide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection    		<b>RESTRICTED</b> Consultant only - acromegaly
<b>Octreotide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> injection    		<b>RESTRICTED</b> 3 <sup>rd</sup> line use Gastro. Consultant only
<b>Lutetium (<sup>177</sup>Lu) oxodotretotide</b> <span style="background-color: red; color: white; padding: 2px;">Red</span> <span style="background-color: blue; color: white; padding: 2px;">££</span> Lutathera® injection      		<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>

8.4 Miscellaneous preparations		GMMMG
<p><b>Glucarpidase</b></p> <p> </p> <p>Voraxaze® 1,000 unit injection (see also sections 1.10, 10.4 &amp; 13.14)</p>	    	<p><b>RESTRICTED</b></p> <p>2<sup>nd</sup> line rescue therapy</p> 
<p><b>Trifluridine / Tipiracil hydrochloride</b></p> <p> </p> <p>tablets</p>	     	<p><b>RESTRICTED</b> Specialist use only in line with NICE</p> <p><b>NOT STOCKED</b></p>

## Section 9: Nutrition & blood

Supported by the  
formulary ([click here](#))



### 9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells

### 9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance

### 9.3 Intravenous nutrition

### 9.4 Oral nutrition

- 9.4.1 Nutrition in special diets

### 9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

### 9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

### 9.7 Bitters & tonics

### 9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

### Non-Formulary Items

## Trust Guidelines






























































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

























































































































## NICE Guidance


































Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)  
 Nutrition support in adults (CG32)  
 Coeliac disease: recognition, assessment and management (NG20)  
 Chronic kidney disease: assessment and management (NG203)  
 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)  
 Migalastat for treating Fabry disease (HST4)  
 Eliglustat for treating type 1 Gaucher disease (HST5)  
 Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)  
 Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)  
 Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)  
 Lumasiran for treating primary hyperoxaluria type 1 (HST25)  
 Hyperparathyroidism - cinacalcet (TA117)  
 Thrombocytopenic purpura - romiplostim (TA221)  
 Thrombocytopenic purpura - eltrombopag (TA293)  
 Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)  
 Etelcalcetide for treating secondary hyperparathyroidism (TA448)  
 Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)  
 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)  
 Patiromer for treating hyperkalaemia (TA623)  
 Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)  
 Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)  
 Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)  
 Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)  
 Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)  
 Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)  
 Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)  
 Avalglucosidase alfa for treating Pompe disease (TA821)  
 Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)  
 Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)  
 Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)  
 Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)









## GMMMG Formulary

Formulary Homepage  
 Chapter 9: Nutrition & Blood (Complete)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

9.1 Anaemias and some other blood disorders		GMMMG
<b>9.1.1 Iron deficiency anaemias</b>		
<b>9.1.1.1 Oral iron</b>		
<b>Ferrous Sulfate</b>		<b>1<sup>st</sup> line use</b>
tablets	 	<b>STANDARD PREPARATIONS ONLY</b>
<b>Ferrous Fumarate</b>		
tablets; oral solution	 	
<b>Ferric Maltol</b>		
capsules	  	
<b>Sodium Feredetate</b>		<b>LIQUID PREPARATIONS ONLY</b>
oral solution	 	
<b>Iron &amp; folic acid</b>		
<b>Ferrous Sulfate</b>		
M/R tablets	 	
<b>Ferrous Fumarate</b>		
capsules; tablets	 	
<b>9.1.1.2 Parenteral iron</b>		
<b>Ferric Carboxymaltose</b>		<b>RESTRICTED</b>
 Ferinject® injection	  	
MHRA Drug Safety Update (Nov-20): Ferric carboxymaltose (Ferinject▼): risk of symptomatic hypophosphataemia leading to osteomalacia and fractures		
<b>Ferric Derisomaltose</b>		<b>RESTRICTED</b>
 Monofer® injection	  	
MHRA: Monofer and Diafer name change (Nov-20) MHRA Drug Safety Update (Sep-13): Intravenous iron and serious hypersensitivity reactions		
<b>Iron Sucrose</b>		<b>RESTRICTED</b>
 Venofer® injection	  	
<b>9.1.2 Drugs used in megaloblastic anaemias</b>		
MHRA Drug Safety Update (Dec-23): Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions		
<b>Hydroxocobalamin</b>		<b>1<sup>st</sup> line use</b>
Intramuscular injection; sachets	  	
<b>Cyanocobalamin</b>		<b>See BSH guidance</b>
 50microgram; 1mg tablets	  	
<b>9.1.3 Drugs used in hypoplastic, haemolytic &amp; renal anaemias</b>		
<b>Erythropoietins</b>		
MHRA Drug Safety Update (Jan-18): Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)		
<b>Darbepoetin alfa</b>		<b>RESTRICTED</b> Renal Consultants only
 injection	    	
<b>Epoetin Alfa</b>		<b>RESTRICTED</b> Renal Consultants only
 injection	   	
<b>Epoetin Beta</b>		<b>RESTRICTED</b> Renal Consultants only
 injection	   	
MHRA Drug Safety Update (May-15): Epoetin beta (NeoRecormon): increased risk of retinopathy in preterm infants cannot be excluded		
<b>Sickle-cell disease</b>		
<b>Hydroxycarbamide</b>		<b>RESTRICTED</b> Haematology Consultants only
 oral solution; capsules	  	
<b>Voxelotor</b>		<b>RESTRICTED</b> Haematology Consultants only in line with NICE / NHSE IMF
  Oxbryta® 500mg tablets	     	

<b>Iron overload</b>		
<b>Deferasirox</b>   tablets    	<b>RESTRICTED</b> Haematology Consultants only	
<b>Deferiprone</b>   tablets    	<b>RESTRICTED</b> Haematology Consultants only	
<b>Desferrioxamine Mesilate</b>   injection   	<b>RESTRICTED</b> Haematology Consultants only	
<b>Hypoxia-inducible factor, prolyl hydroxylase inhibitor (HIF-PHI)</b>		
<b>Roxadustat</b>   Evrenzo® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>Paroxysmal nocturnal haemoglobinuria &amp; atypical haemolytic uraemic syndrome</b>		
<b>Eculizumab</b>   infusion       	<b>RESTRICTED</b> Haematology Consultants only	
<b>Ravulizumab</b>   infusion      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>9.1.4 Drugs used in autoimmune thrombocytopenic purpura</b>		
<b>Anagrelide</b>   capsules   	<b>RESTRICTED</b> Haematology Consultants only	
<b>Avatrombopag</b>   Doptelet® tablets      	<b>RESTRICTED</b> Specialist use only in line with NICE	
<b>Caplacizumab</b>   Cablivi® injection      	<b>RESTRICTED</b> Specialist use only in line with NICE <b>NOT STOCKED</b>	
<b>Eltrombopag</b>   Revolade® tablets      	<b>RESTRICTED</b> Haematology Consultants only	
MHRA Drug Safety Update (Jul-18): Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results		
<b>Fostamatinib</b>   Tavesse® tablets      	<b>RESTRICTED</b> Specialist use only	
<b>Lusutrombopag</b>   Mulpleo® tablets      	<b>RESTRICTED</b> Specialist use only	
<b>Romiplostim</b>   Nplate® injection      	<b>RESTRICTED</b> Haematology Consultants only	
<b>9.1.6 Drugs used in neutropenia</b>		
<b>Filgrastim</b>   injection    	<b>RESTRICTED</b> Haematology Consultants only	
MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
<b>Lenograstim</b>   injection   	<b>RESTRICTED</b> Haematology Consultants only	
<b>Pegfilgrastim</b>   injection    	<b>RESTRICTED</b> Haematology Consultants only	
MHRA Drug Safety Update (Sep-13): Filgrastim and pegfilgrastim: risk of capillary leak syndrome		
<b>9.1.7 Drugs used to mobilise stem cells</b>		
<b>Plerixafor</b>   injection      	<b>RESTRICTED - initiation on advice of Haematology Consultant only</b>	

9.2 Fluids and electrolytes		GMMMG
<b>9.2.1 Oral preparations for fluid &amp; electrolyte imbalance</b>		
<b>9.2.1.1 Oral potassium</b>		
<b>Potassium Chloride</b>		
Sando-K® effervescent tablets; Kay-Cee-L® syrup	 	
<b>Potassium removal</b>		
<b>Calcium Polystyrene Sulfonate</b>		
Calcium Resonium® powder; enema (unlicensed)	 	
<b>Sodium Zirconium Cyclosilicate</b>		
Red	   	
Lokelma® powder sachets		
<b>9.2.1.2 Oral sodium and water</b>		
<b>Sodium Chloride (Slow Sodium®)</b>		
600mg M/R tablets	 	
<b>Oral Rehydration Therapy (ORT)</b>		
<b>Oral Rehydration Salts (ORS)</b>		
DNP	 	
oral powder		
<b>9.2.1.3 Oral bicarbonate</b>		
<b>Sodium Bicarbonate</b>		
500mg capsules; 8.4% (1mmol/mL) oral solution	 	
<b>Sodium Hydrogen Carbonate</b>		
Nephrotrans® 50mg gastro-resistant capsules	  	<b>RESTRICTED</b> 2 <sup>nd</sup> line patients with severe GI side effects
<b>9.2.2 Parenteral preparations for fluid &amp; electrolyte imbalance</b>		
<b>9.2.2.1 Electrolytes &amp; water</b>		
<b>Intravenous sodium</b>		
<b>Sodium Chloride</b>		
infusion; injection	 	
<b>Sodium chloride with other ingredients</b>		
<b>Sodium Chloride &amp; Glucose</b>		
infusion	 	
<b>Sodium Chloride, Calcium Chloride &amp; Potassium Chloride (Ringer's solution)</b>		
infusion	 	
<b>Sodium Chloride, Calcium Chloride, Potassium Chloride &amp; Sodium Lactate</b>		
infusion	 	
<b>Intravenous glucose</b>		
<b>Glucose</b>		
infusion	 	
MHRA Drug Safety Update (May-23): Glucose solutions: recommendations to minimise the risks associated with the accidental use instead of saline solutions in arterial lines		
MHRA Drug Safety Update (Jul-12): Glucose solutions: false blood glucose readings when used to flush arterial lines		
<b>Intravenous potassium</b>		
<b>Potassium Chloride and Glucose</b>		
infusion	 	
<b>Potassium Chloride and Sodium Chloride</b>		
infusion	 	
<b>Potassium Chloride, Sodium Chloride &amp; Glucose</b>		
infusion	 	

<b>Bicarbonate and lactate</b>	
<b>Sodium Bicarbonate</b>	
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	 
<b>Water</b>	
<b>Water for Injections</b>	
injection	 
<b>9.2.2.2 Plasma &amp; plasma substitutes</b>	
<b>Dextran</b>	
<i>Dextran 40</i> - 10% in sodium chloride 0.9% infusion	
<b>Dextrose Acid Citrate ACDA</b>	
solution	
<b>Gelatin</b>	
<i>Gelofusine</i> ® infusion	 









### 9.3 Intravenous nutrition






























































**Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)**



**NICE CG32**

<b>9.4 Oral nutrition</b>		
<b>Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)</b>		<b>NICE CG32</b>
<b>9.4.1 Nutrition in special diets</b>		
<b>Sapropterin dihydrochloride</b>   <i>Kuvan</i> ® 100mg soluble tablets     	<b>RESTRICTED</b> Tetrahydrobiopterin deficiency 	
<b>LaBiNIC® probiotic drops</b>  <i>LaBiNIC</i> ® probiotic drops   	<b>RESTRICTED</b> prevention of NEC	

9.5 Minerals		GMMMG
<b>9.5.1 Calcium and magnesium</b>		
<b>9.5.1.1 Calcium supplements</b>		
<b>Oral preparations</b>		
<b>Calcium Carbonate</b> Green	<i>Cacit</i> ® effervescent tablets; <i>Calcichew</i> ® chewable tablets	BNF emc
<b>Calcium Carbonate &amp; Calcium Lactate Gluconate</b> Green	<i>Sandocal</i> ® 1000 effervescent tablets	BNF emc
<b>Parenteral preparations</b>		
<b>Calcium Gluconate</b>	10% injection	BNF emc
MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia		
<b>Calcium Chloride</b>	10% injection	BNF emc
MHRA Drug Safety Update (Jun-23): Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia		
<b>with vitamin D</b>		
see section 9.6.4		
<b>with risedronate sodium &amp; colecalciferol</b>		
see section 6.6.2		
BNF emc		
<b>9.5.1.2 Hypercalcaemia &amp; hypercalciuria</b>		
<b>Cinacalcet</b> Red 2 <sup>ty</sup> HPT Amber 1 <sup>ty</sup> HPT ££	tablets	PbR X NICE MMC BNF emc
		RESTRICTED as per NICE TA117
<b>Etelcalcetide</b> Red ££	injection	PbR X NICE MMC BNF emc blueiq
		RESTRICTED as per NICE TA448
<b>9.5.1.3 Magnesium</b>		
<b>Magnesium Aspartate Dihydrate</b>	<i>Magnaspartate</i> ® sachets	MMC BNF emc
		1 <sup>st</sup> line use
<b>Magnesium Glycerophosphate</b>	chewable tablets; capsules; oral solution; tablets	NICE BNF emc
<b>Magnesium Sulfate</b>	injection; infusion	BNF emc
MHRA Drug Safety Update (May-19): Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy		
<b>9.5.2 Phosphorus</b>		
<b>9.5.2.1 Phosphate supplements</b>		
<b>Phosphate supplements (<i>Phosphate-Sandoz</i>®)</b>	effervescent tablets	BNF emc
		Effervescent tabs
<b>Phosphates (<i>Polyfusor</i>®)</b> Red	infusion	BNF emc
		I.V. preparation
<b>9.5.2.2 Phosphate-binding agents</b>		
<b>Aluminium Hydroxide</b> Green	capsules	BNF emc
<b>Calcium Carbonate</b> Green	tablets (see also section 9.5.1.1)	BNF emc
<b>Calcium Acetate</b> Green	tablets	MMC BNF emc
<b>Calcium Acetate / Magnesium Carbonate</b> Green	<i>Osvaren</i> ® 435mg/235mg tablets	MMC BNF emc
		RESTRICTED Renal Consultants only

<p><b>Lanthanum</b>                         chewable tablets; oral powder    </p>	<p><b>RESTRICTED</b>                      Renal Consultants only</p>
<p><b>Patiromer Calcium</b>                         Veltassa® oral powder     </p>	<p><b>RESTRICTED</b> Consultants only                      in line with NICE TA623</p>
<p><b>Sevelamer Carbonate</b>                         tablets      </p>	<p><b>RESTRICTED</b>                      Renal Consultants only</p>
<p><b>Sucroferric Oxyhydroxide</b>                         chewable tablets    </p>	<p><b>RESTRICTED</b>                      Renal Consultants only - 3<sup>rd</sup> line</p>
<p><b>9.5.3 Fluoride</b></p>	
<p><b>Sodium Fluoride</b>                      tablets, paediatric drops, dental rinse   </p>	
<p><b>9.5.4 Zinc</b></p>	
<p><b>Zinc Sulfate</b>                      Solvazinc® 125mg effervescent tabs; Zincomed® 220mg capsules   </p>	

9.6 Vitamins		GMMMG
<b>9.6.1 Vitamin A</b>		
<b>Vitamin A</b>		
150,000units/mL drops	 	
<b>Vitamin A Palmitate</b>		
100,000units/2mL injection	 	
<b>Vitamins A &amp; D</b>		
capsules	 	
<b>9.6.2 Vitamin B group</b>		
<b>Pyridoxine Hydrochloride</b>		
tablets	 	
<b>Thiamine</b>		
tablets	 	
<b>Vitamin B Compound</b>		
	 	
<b>Vitamin B Compound Strong</b>		
tablets	 	
<b>Vitamins B &amp; C</b>		
<i>Pabrinex</i> ® Intramuscular (IM) & Intravenous (IV) injection	 	
<b>9.6.3 Vitamin C (Ascorbic acid)</b>		
<b>Ascorbic acid</b>		
tablets	 	
<b>9.6.4 Vitamin D</b>		
<b>Alfacalcidol</b>		
<span style="background-color: green; color: white; padding: 2px;">Green</span>		
capsules; injection; oral drops	 	
<b>Calcitriol</b>		
capsules; oral solution	 	
<b>Vitamin D and calcium</b>		
<b>Colecalciferol</b>		<b>1<sup>st</sup> line use</b>
Calcichew D3® Forte tablets / Adcal D3® chewable tablets	<b>MMC</b>  	
<b>Calcium &amp; Ergocalciferol</b>		
calcium 97mg/vitamin D 400units	 	
<b>Colecalciferol</b>		
<i>Cacif</i> ® D3 effervescent granules; 800 IU capsules	<b>MMC</b>  	
<b>9.6.5 Vitamin E (Tocopherols)</b>		
<b>Alpha Tocopheryl Acetate (Vitamin E)</b>		
500mg/5mL liquid	 	
<b>Alpha Tocopheryl Acetate (Vitamin E)</b>		
75 unit capsules	 	

9.6.6 Vitamin K		
<b>Phytomenadione</b>		
<i>Konakion® MM &amp; Konakion® MM Paediatric</i> injection	 MMC BNF emc	
<b>Menadiol Sodium Phosphate</b>		
oral solution; tablets	 MMC BNF emc	
9.6.7 Multivitamin preparations		
<b>Vitamins B,C</b>		<b>RESTRICTED</b>
<i>Renavit®</i> tablets	MMC BNF emc	
<b>Vitamins A,D,E,K</b>		<b>RESTRICTED</b> Paediatric CF patients
<i>Paravit-CF®</i> capsules; liquid	MMC BNF emc	

















































































## 9.7 Bitters & tonics



Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use

9.8 Metabolic disorders		GMMMG
<b>9.8.1 Drugs used in metabolic disorders</b>		
<b>Serine deficiency</b>		
<b>L-Serine</b>		<b>RESTRICTED</b> Specialist use only
(Nutricia L-Serine) powder	MMC	
<b>Wilson's Disease</b>		
<b>Penicillamine</b> 		
tablets (see also section 10.1.3)		
<b>Trientine Dihydrochloride</b> 		<b>3<sup>rd</sup> line use</b>
capsules		
<b>Carnitine Deficiency</b>		
<b>Levocarnitine</b> 		<b>RESTRICTED</b> Specialist use only
injection; oral solution		
<b>Fabry's disease</b>		
<b>Agalsidase alfa</b> 		<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
Replagal® infusion		
<b>MigALastat</b> 		<b>RESTRICTED</b> Specialist use only (NICE HST4)
Galafold® capsules		
<b>Mucopolysaccharidosis</b>		
<b>Elosulfase alfa</b> 		<b>RESTRICTED</b> Specialist use only (NICE HST19)
Vimizim® infusion		
<b>Galsulfase</b> 		<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
Naglazyme® infusion		
<b>Idursulfase</b> 		<b>RESTRICTED</b> Specialist use only
Elaprase® infusion		
<b>Laronidase</b> 		<b>RESTRICTED</b> Specialist use only <b>NOT STOCKED</b>
Aldurazyme® infusion		
<b>Vestronidase alfa</b> 		<b>RESTRICTED</b> Specialist use only
Mepsevii® infusion		
<b>Nephropathic cystinosis</b>		
<b>Cystagon® (Mercaptamine)</b> 		<b>RESTRICTED</b> Specialist use only
capsules (NB: prescribe as CYSTAGON®)		
<b>Pompe disease</b>		
<b>Avalglucosidase alfa</b> 		<b>RESTRICTED</b> Specialist use only (NICE TA821)
Nexviadyme® infusion		
<b>Tyrosinemia type I</b>		
<b>Nitisinone</b> 		<b>RESTRICTED</b> Specialist use only
capsules; oral suspension		
<b>Urea cycle disorders</b>		
<b>Arginine</b> 		<b>BIMDG</b> <b>RESTRICTED</b> Specialist use only
infusion; oral solution		
<b>Carglumic acid</b> 		<b>RESTRICTED</b> Specialist use only
dispersible tablets		
<b>Citrulline</b> 		<b>RESTRICTED</b> Specialist use only
powder		
<b>Glycerol Phenylbutyrate</b> 		<b>RESTRICTED</b> Specialist use only
Ravicti® 1.1g/mL oral liquid		



<b>Sodium Phenylbutyrate</b>   tablets; injection; oral liquid; granules (discontinued)	   	<b>RESTRICTED</b> Specialist use only
<b>Homocystinuria</b>		
<b>Betaine</b>   tablets; oral powder	  	 <b>RESTRICTED</b> Specialist use only
<b>Sodium Benzoate</b> injection; oral solution; tablets; powder	  	<b>RESTRICTED</b> Specialist use only
<b>Uridine</b>	  	<b>RESTRICTED</b> Specialist use only
<b>Other metabolic disorders</b>		
<b>Asfotase alfa</b>   <i>Strensiq</i> ® injection	     	<b>RESTRICTED</b> Specialist use only (NICE HST23)
<b>Cerliponase alfa</b>   <i>Brineura</i> ® 150mg solution for infusion	    	<b>RESTRICTED</b> Specialist use only (NICE HST12)
<b>Eliglustat</b>   <i>Cerdelga</i> ® 84mg capsules	     	<b>RESTRICTED</b> Specialist use only (NICE HST5)
<b>Lumasiran</b>   <i>Oxlumo</i> ® injection	     	<b>RESTRICTED</b> Specialist use only (NICE HST25)
<b>MigLUstat</b>   100mg capsules	   	<b>RESTRICTED</b> Specialist use only
<b>Sebelipase alfa</b>   <i>Kanuma</i> ® 2mg/mL solution for infusion	     	<b>RESTRICTED</b> Specialist use only (NICE HST30)
<b>Sodium dichloroacetate</b>    50 mg/mL powder for reconstitution for oral solution (200 mL)	  	<b>RESTRICTED</b> Specialist use only Primary lactic acidosis / PDHC deficiency
<b>Velaglucerase alfa</b>   <i>VPRIV</i> ® 400 units vial	   	<b>RESTRICTED</b> Specialist use only
<b>9.8.2 Acute porphyrias</b>		
<b>Haem Arginate</b>   infusion	  	

# Non-Formulary Items

Cipaglicosidase alfa



Pombiliti® infusion



**Not a commissioned centre**

## Section 10: Musculoskeletal & Joint Diseases

Supported by the  
formulary ([click here](#))



### 10.1 Drugs used in rheumatic diseases & gout

- 10.1.1 Non-steroidal anti-inflammatory drugs
- 10.1.2 Corticosteroids
- 10.1.3 Drugs that suppress the rheumatic disease process
  - Gold
  - Penicillamine
  - Antimalarials
  - Drugs affecting the immune response
  - Cytokine modulators
- 10.1.4 Gout and cytotoxic induced hyperuricaemia
- 10.1.5 Other drugs for rheumatic diseases

### 10.2 Drugs used in neuromuscular disorders

- 10.2.1 Drugs that enhance neuromuscular transmission
- 10.2.2 Skeletal muscle relaxants
  - Nocturnal leg cramps
- 10.2.3 Drugs used in neuromuscular disorders

### 10.3 Drugs for the relief of soft-tissue inflammation

- 10.3.1 Enzymes
- 10.3.2 Rubefacients & other topical antirheumatics

### 10.4 Miscellaneous preparations

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Rheumatoid arthritis in adults: management (NG100)  
 Osteoarthritis in over 16s: diagnosis and management (NG226)  
 Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)  
 Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)  
 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)  
 Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)  
 Hyperuricaemia - febuxostat (TA164)  
 Psoriasis - ustekinumab (TA180)  
 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)  
 Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)  
 Psoriatic arthritis - golimumab (TA220)  
 Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)  
 Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)  
 Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)  
 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)  
 Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)  
 TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)  
 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)  
 Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Baricitinib for moderate to severe rheumatoid arthritis (TA466)  
 Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)  
 Tofacitinib for moderate to severe rheumatoid arthritis (TA480)  
 Sarilumab for moderate to severe rheumatoid arthritis (TA485)  
 Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)  
 Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)  
 Tocilizumab for treating giant cell arteritis (TA518)  
 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)  
 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)  
 Tofacitinib for moderately to severely active ulcerative colitis (TA547)  
 Nusinersen for treating spinal muscular atrophy (TA588)  
 Upadacitinib for treating severe rheumatoid arthritis (TA665)  
 Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)  
 Anakinra for treating Still's disease (TA685)  
 Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)  
 Ixekizumab for treating axial spondyloarthritis in adults (TA718)  
 Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)  
 Tofacitinib for treating juvenile idiopathic arthritis (TA735)  
 Upadacitinib for treating moderate rheumatoid arthritis (TA744)  
 Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)  
 Risdiplam for treating spinal muscular atrophy (TA755)  
 Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)  
 Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)  
 Upadacitinib for treating active ankylosing spondylitis (TA829)  
 Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)  
 Bimekizumab for treating axial spondyloarthritis (TA918)  
 Tofacitinib for treating active ankylosing spondylitis (TA920)

## GMMMG Formulary

Formulary Homepage  
 Chapter 10: Musculoskeletal & Joint Diseases (Complete)  
 GMMMG Adult [Red/Amber/Green](#); DNP and [Grey](#) Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

10.1 Drugs used in rheumatic diseases & gout		GMMMG
10.1 Drugs used in rheumatic diseases & gout		NICE CG177
10.1.1 Non-steroidal anti-inflammatory drugs (NSAIDs)		NICE NG100
MHRA Drug Safety Update (Oct-12): Non-steroidal anti-inflammatory drugs (NSAIDs): cardiovascular risks		
MHRA Drug Safety Update (May-09): Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment		
MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks		
<b>Ibuprofen (oral)</b>		<b>1<sup>st</sup> line use</b>
200mg; 400mg; 600mg tablets; 5% gel	MMC BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk		
<b>Ibuprofen (IV)</b>		<b>short-term symptomatic treatment of acute moderate pain</b>
200mg in 50mL solution for infusion	MMC BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jun-15): High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk		
<b>Naproxen</b>		
250mg; 500mg tablets	BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
<b>Celecoxib</b>		<b>RESTRICTED - osteoarthritis in line with NICE NG226</b>
100mg; 200mg capsules	MMC BNF emc	
MHRA Drug Safety Update (Dec-07): NSAIDs and coxibs: balancing of cardiovascular and gastrointestinal risks		
<b>Diclofenac Sodium</b>		<b>RESTRICTED - acute post-operative pain (injection)</b>
50mg tablets; suppositories; injection (restricted post-op pain)	MMC BNF emc	
MHRA Drug Safety Update (Jun-23): Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy		
MHRA Drug Safety Update (Jan-15): Oral diclofenac no longer available without prescription		
MHRA Drug Safety Update (Dec-14): Diclofenac: new contraindications and warnings		
<b>Flurbiprofen</b>		
50mg tablets	BNF emc	
<b>Indometacin</b>		<b>RESTRICTED 3<sup>rd</sup> line (off-label) for tocolysis</b>
capsules; suppositories	MMC BNF emc	
<b>Mefenamic Acid</b>		
250mg; 500mg tablets	BNF emc	
<b>Meloxicam</b>		
7.5mg; 15mg tablets	BNF emc	
<b>Sulindac</b>		
100mg; 200mg tablets	MMC BNF emc	
<b>Etodolac</b>		<b>RESTRICTED Consultant Anaesthetist use only</b>
600mg tablets	MMC BNF emc	
<b>Phenylbutazone</b>		<b>RESTRICTED Specialist use only, ankylosing spondylitis</b>
100mg; 200mg tablets	BNF emc	
<b>10.1.2 Corticosteroids</b>		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
<b>10.1.2.1 Systemic corticosteroids</b>		<b>NICE NG100</b>
<b>Prednisolone</b>		
	BNF emc	
<b>10.1.2.2 Local corticosteroid injections</b>		<b>NICE NG100</b>
<b>Hydrocortisone Acetate</b>		
25mg/mL injection	BNF emc	
<b>Methylprednisolone Acetate</b>		
40mg/mL injection	BNF emc	
<b>Triamcinolone Acetonide</b>		
10mg/mL; 40mg/mL injection	BNF emc	










































































**Triamcinolone Hexacetonide**

20mg/mL injection






































































**RESTRICTED Paediatric  
Rheumatology Consultants only**









10.1.3 Drugs that suppress the rheumatic disease process		NICE NG100
<b>Gold</b>		
<b>Auranofin</b> Amber tablets	BNF emc	<b>RESTRICTED Rheumatology Consultants only</b>
<b>Sodium Aurothiomalate</b> Amber injection	BNF emc	<b>RESTRICTED Rheumatology Consultants only</b>
<b>Penicillamine</b>		
<b>Penicillamine</b> Amber tablets	BNF emc	<b>RESTRICTED Rheumatology Consultants only</b>
<b>Antimalarials</b>		
<b>Hydroxychloroquine</b> Amber tablets	MMC BNF emc	<b>RESTRICTED Rheumatology Consultants only</b>
MHRA Drug Safety Update (Feb-22): Hydroxychloroquine, chloroquine: increased risk of CV events when used with macrolide antibiotics; reminder of psychiatric reactions MHRA Drug Safety Update (Mar-20): Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID-19) treatment		
<b>Mepacrine hydrochloride</b> Red 100mg tablets	MMC BNF emc	<b>RESTRICTED Rheumatology Consultants only</b>
<b>Drugs affecting the immune response</b>		<b>NICE NG100</b>
<b>Azathioprine</b> Amber tablets; injection; oral solution (see also sections 1.5.3, 8.2.1 & 13.5.3)	PbR X BNF emc	<b>RESTRICTED Rheumatology Consultants only</b>
<b>Ciclosporin</b> Amber capsules; oral solution; injection (see also sections 8.2.2 & 13.5.3)	PbR X MMC BNF emc	<b>RESTRICTED Consultants only</b>
<b>Leflunomide</b> Amber tablets	MMC BNF emc	<b>RESTRICTED Rheumatology Consultants only</b>
<b>Methotrexate</b> Amber oral Red parenteral tablets; injections (see also sections 1.5.3, 8.1.3 & 13.5.3)	MMC BNF emc	<b>RESTRICTED Consultants only</b>
MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose		
<b>Cytokine modulators</b>		
<b>Abatacept</b> Red ££ injection; infusion	PbR X NICE MMC BNF emc blue-teq NHS England	<b>RESTRICTED Rheum. Consultants only in line with NICE / NHSE</b>
<b>Adalimumab</b> Red ££ injection (see also sections 1.5.3, 11.4.2 & 13.5.3)	PbR X NICE MMC BNF emc blue-teq NHS England	<b>RESTRICTED Consultants only in line with NICE</b>
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		
<b>Anakinra</b> Red ££ injection	PbR X NICE MMC BNF emc blue-teq NHS England	<b>RESTRICTED Consultants only in line with NICE / NHSE</b>
<b>Apremilast</b> Red ££ 10mg; 20mg; 30mg tablets	PbR X NICE MMC BNF emc	<b>RESTRICTED 3<sup>rd</sup> / 4<sup>th</sup> line as per NICE/GMMMG</b>
<b>Baricitinib</b> Red ££ 2mg; 4mg tablets	PbR X NICE MMC BNF emc blue-teq NHS England	<b>RESTRICTED Rheumatology Consultants only in line with NICE</b>
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections & increased mortality MHRA Drug Safety Update (Aug-20): Baricitinib (Olmiant▼): increased risk of diverticulitis, particularly in patients with risk factors MHRA Drug Safety Update (Mar-20): Baricitinib (Olmiant▼): risk of venous thromboembolism		
<b>Belimumab</b> Red ££ infusion	PbR X NICE MMC BNF emc blue-teq NHS England	<b>RESTRICTED Consultants only</b>
MHRA Drug Safety Update (Apr-19): Belimumab (Benlysta▼): increased risk of serious psychiatric events seen in clinical trials		
<b>Bimekizumab</b> Red ££ injection (see also section 13.5.3)	PbR X NICE MMC BNF emc blue-teq NHS England	<b>RESTRICTED in line with NICE</b>
<b>Certolizumab</b> Red ££ injection (see also section 13.5.3)	PbR X NICE MMC BNF emc blue-teq NHS England	<b>RESTRICTED Rheumatology Consultants in line with NICE</b>
MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely		

<p><b>Etanercept</b>                         injection       </p>	<p><b>RESTRICTED</b> Consultants only; in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely</p>	
<p><b>Filgotinib</b>                         tablets       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality</p>	
<p><b>Golimumab</b>                         injection      </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely</p>	
<p><b>Guselkumab</b>                         100mg/mL injection      </p>	<p><b>RESTRICTED</b> in line with NICE</p>
<p><b>Infliximab</b>                         Remicade® infusion; Remsima® infusion        </p>	<p><b>RESTRICTED</b> Consultants only  <b>MMC Remsima</b></p>
<p>MHRA Drug Safety Update (Apr-14): TNF alpha inhibitors -risk of TB - screen all patients before starting treatment and monitor them closely</p>	
<p><b>Ixekizumab</b>                         80mg/1mL injection (see also section 13.5.3)      </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p><b>Rituximab</b>                         injection; infusion (see also section 8.2.3)       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE / NHSE</p>
<p><b>Sarilumab</b>                         Kevzara® 150mg/1.14mL injection       </p>	<p><b>RESTRICTED</b> Rheumatology Consultants only in line with NICE</p>
<p><b>Secukinumab</b>                         Cosentyx® 150mg/1mL injection (see also section 13.5.3)       </p>	<p><b>RESTRICTED</b> Rheumatology Consultants only in line with NICE</p>
<p><b>Tocilizumab</b>                         infusion       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Jul-19): Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation</p>	
<p><b>Tofacitinib</b>                         Xeljanz® 5mg; 10mg tablets (see also section 1.5.3)       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality</p>	
<p>MHRA Drug Safety Update (Oct-21): Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies</p>	
<p>MHRA Drug Safety Update (Mar-20): Tofacitinib (Xeljanz▼): new measures to minimise risk of venous thromboembolism and of serious and fatal infections</p>	
<p>MHRA Drug Safety Update (May-19): Tofacitinib (Xeljanz▼): restriction of 10 mg twice-daily dose in patients at high risk of PE while safety review is ongoing</p>	
<p><b>Upadacitinib</b>                         MR tablet (see also sections 1.5.3 &amp; 13.5.3)       </p>	<p><b>RESTRICTED</b> Consultants only in line with NICE</p>
<p>MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections &amp; increased mortality</p>	
<p><b>Ustekinumab</b>                         injection; infusion (see also section 13.5.3)       </p>	<p><b>RESTRICTED</b> Dermatology TA340 / Gastro 3<sup>rd</sup> line Crohn's</p>
<p>MHRA Drug Safety Update (Jan-15): Ustekinumab (Stelara): risk of exfoliative dermatitis</p>	



<b>10.1.4 Gout and cytotoxic induced hyperuricaemia</b>		
<b>Acute attacks of gout</b>		
<b>Colchicine</b>		
tablets	 	
<b>Long-term control of gout</b>		
<b>Allopurinol</b>		<b>1<sup>st</sup> line use</b>
tablets	 	
<b>Febuxostat</b>		<b>RESTRICTED</b> <b>Rheumatology Consultants only</b>
		
tablets	   	
MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease		
MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease		
MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric▼): stop treatment if signs or symptoms of serious hypersensitivity		
<b>Hyperuricaemia associated with cytotoxic drugs</b>		
<b>Rasburicase</b>		<b>RESTRICTED</b> <b>Haematology Consultants only</b>
 		
Fasturtec® infusion	    	
<b>10.1.5 Other drugs for rheumatic diseases</b>		<b>NICE CG177</b>
		<b>NICE TA477</b>
		<b>NICE TA508</b>

10.2 Drugs used in neuromuscular disorders		GMMMG
<b>10.2.1 Drugs that enhance neuromuscular transmission</b>		
<b>Anticholinesterases</b>		
<b>Pyridostigmine Bromide</b>		<b>1<sup>st</sup> line use</b>
tablets	 	
<b>Neostigmine</b>		
tablets; injection	 	
<b>Edrophonium Chloride</b>		<b>RESTRICTED</b> diagnosis of myasthenia gravis <b>Licensed product discontinued</b>
injection	 	
<b>10.2.2 Skeletal muscle relaxants</b>		
<b>Baclofen</b>		<b>1<sup>st</sup> line use</b>
10mg tablets; 5mg/mL oral solution	 	
<b>Dantrolene Sodium</b>		
25mg; 100mg capsules; Ryanodex 250mg/20mL vial	 	
<b>Diazepam</b>		
tablets; liquid; injection; rectal tube (see also sections 4.1.2, 4.8 & 15.1.4.1)	 	
<b>Tizanidine</b>		<b>RESTRICTED</b> Consultant Neurologist only
Amber 2mg; 4mg tablets	 	
<b>Nocturnal leg cramps</b>		
<b>Quinine Sulfate</b>		
tablets (see also section 5.4.1)	 	
MHRA Drug Safety Update (Nov-17): Quinine: reminder of dose-dependent QT-prolonging effects; updated interactions		
MHRA Drug Safety Update (Jun-10): Quinine: not to be used routinely for nocturnal leg cramps		
<b>10.2.3 Drugs used in neuromuscular disorders</b>		
<b>Ataluren</b>		<b>Specialist use only</b> in line with NICE HST22
Red  oral suspension sachets	     	
<b>Atidarsagene autotemcel</b>		<b>Specialist use only</b> in line with NICE HST18
Red  Libmeldy® infusion	     	
<b>Nusinersen</b>		<b>Specialist use only</b> in line with NICE TA588 / NHSE <b>Named patient access</b>
Red  injection	     	
MHRA Drug Safety Update (Sep-18): Nusinersen (Spinraza ▼): reports of communicating hydrocephalus; discuss symptoms with patients & carers - investigate urgently		
<b>Onasemnogene abeparvovec</b>		<b>RESTRICTED</b> Paediatric Neurology Consultants only NICE / NHSE
Red  Zolgensma® infusion	     	
<b>Risdiplam</b>		<b>Specialist use only</b> in line with NICE TA755
Red  oral solution	     	

<b>10.3 Drugs for the relief of soft-tissue inflammation</b>		
<b>10.3.1 Enzymes</b>		
<b>Hyaluronidase</b> <span style="background-color: red; color: white; padding: 2px;">Red</span>	 	<b>RESTRICTED</b> extravasation
injection		
<b>10.3.2 Rubefacients &amp; other topical antirheumatics</b>		
<b>Piroxicam</b>	 	
0.5% gel		
<b>Capsaicin</b> <span style="border: 1px solid black; padding: 2px;">DNP</span>	  	Patch restricted to peripheral neuropathic pain specialists at TGH
cream, patch		

## 10.4 Miscellaneous preparations



### Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 13.14)

PbR X



**RESTRICTED**  
2<sup>nd</sup> line rescue therapy



### Dibotermin alfa



InductOs®

PbR X



**RESTRICTED**  
NHSE CCP 16063/P



## Section 11: Eye

Supported by the  
formulary ([click here](#))



### 11.3 Anti-infective eye preparations

11.3.1 Antibacterials

11.3.3 Antivirals

### 11.4 Corticosteroid & other anti-inflammatory preparations

11.4.1 Corticosteroids

11.4.2 Other anti-inflammatory preparations

### 11.5 Mydriatics & cycloplegics

### 11.6 Treatment of glaucoma

### 11.7 Local anaesthetics

### 11.8 Miscellaneous ophthalmic preparations

11.8.1 Tear deficiency, ocular lubricants & astringents

11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment

11.8.3 Other preparations

## Trust Guidelines























































































ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)











## NICE Guidance

Glaucoma: diagnosis and management (NG81)  
 Macular degeneration (age related) ranibizimab & pegaptanib (TA155)  
 Macular oedema (retinal vein occlusion) - dexamethasone (TA229)  
 Macular oedema (diabetic) - ranibizumab (TA274)  
 Macular oedema (retinal vein occlusion) - ranibizumab (TA283)  
 Macular degeneration (wet age-related) - aflibercept (1<sup>st</sup> line) (TA294)  
 Vitreomacular traction - ocriplasmin (TA297)  
 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)  
 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)  
 Aflibercept for treating diabetic macular oedema (TA346)  
 Cyclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)  
 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)  
 Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)  
 Holoclax for treating limbal stem cell deficiency after eye burns (TA467)  
 Aflibercept for treating choroidal neovascularisation (TA486)  
 Cenegermin for treating neurotrophic keratitis (TA532)  
 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)  
 Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)  
 Brolucizumab for treating wet age-related macular degeneration (TA672)  
 Faricimab for treating diabetic macular oedema (TA799)  
 Faricimab for treating wet age-related macular degeneration (TA800)  
 Brolucizumab for treating diabetic macular oedema (TA820)  
 Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)  
 Fluocinolone acetonide intravitreal implant for treating chronic DMO (updates & replaces TA301 / TA613) (TA953)



































































## GMMM Formulary












Formulary Homepage  
 Chapter 11: Eye (Complete)  
 GMMM Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMM Paediatric [Red/Amber/Green](#) Drug List











































11.3 Anti-infective eye preparations		GMMMG
<b>11.3.1 Antibacterials</b>		
<b>Chloramphenicol</b>		
0.5% eye drops, 1% eye ointment	 	
MHRA Drug Safety Update (Jul-21): Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years		
<b>Fusidic Acid (ophthalmic)</b>		
1% eye drops	 	
<b>Amikacin (ophthalmic)</b>  	 	<b>RESTRICTED</b> microbial keratitis. Consultant Ophthalmologist only
2.5% eye drops	 	<b>NOT STOCKED</b>
<b>Amphotericin</b>		
0.15% eye drops	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Azithromycin (ophthalmic)</b>		
	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
Azyter® 1.5% eye drops	  	
<b>Ceftazidime (ophthalmic)</b>		
	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
5% eye drops	 	<b>NOT STOCKED</b>
<b>Cefuroxime (ophthalmic)</b>		
 	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
5% eye drops	 	
<b>Cefuroxime (intracameral injection)</b>		
	  	<b>RESTRICTED</b> Consultant Ophthalmologist only
Ximaract® 50mg in 5mL intracameral injection		
<b>Chlorhexidine (ophthalmic)</b>		
 	 	<b>RESTRICTED</b> acanthamoeba keratitis. Consultant only
0.02% eye drops	 	
<b>Ciprofloxacin (ophthalmic)</b>		
	 	<b>RESTRICTED</b> microbial keratitis. Consultant Ophthalmologist only
0.3% eye drops	 	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
<b>Erythromycin (ophthalmic)</b>		
	 	<b>RESTRICTED</b> superficial eye infections
0.5% eye ointment	 	
<b>Gentamicin (ophthalmic)</b>		
 	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
1.5% eye drops (Use with cefuroxime eye drops)	 	
<b>Levofloxacin (ophthalmic)</b>		
	  	<b>RESTRICTED</b> Consultant only corneal ulcers/ keratitis
0.5% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
<b>Natamycin</b>		
	 	<b>RESTRICTED</b> fungal keratitis, conjunctivitis, fungal blepharitis
5% eye drops	 	
<b>Ofloxacin</b>		
	  	<b>RESTRICTED</b> Consultant Ophthalmologist only
0.3% eye drops	  	
MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour		
MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects		
MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk		
MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions & precautions for use due to rare reports of disabling & long-lasting / irreversible side effects...		
<b>Penicillin (ophthalmic)</b>		
 	 	<b>RESTRICTED</b> microbial keratitis. Consultant Ophthalmologist only
2,500 units/mL eye drops	 	
<b>Polyhexamethylene Biguanide (PHMB)</b>		
 	 	<b>NOT STOCKED</b>
0.02% eye drops	 	

<p><b>Polymyxin B Sulfate</b></p> <p>eye ointment</p>  	<p><b>RESTRICTED</b> gram negative bacteria, including pseudomonas</p>
<p><b>Propamide Isetionate</b></p> <p>Green</p> <p>0.1% eye drops</p>  	<p><b>RESTRICTED</b> Consultant Ophthalmologist only</p>
<p><b>Vancomycin (ophthalmic)</b></p> <p>U</p> <p>5% eye drops</p>  	<p><b>RESTRICTED</b> gram positives, including MRSA but not VRE</p> <p><b>NOT STOCKED</b></p>
<p><b>11.3.3 Antivirals</b></p>	
<p><b>Ganciclovir</b></p> <p>Green</p> <p>0.15% eye gel</p>  	
<p><b>Trifluorothymidine</b></p> <p>U Red</p> <p>1% eye drops</p>  	



11.4 Corticosteroid & other anti-inflammatory preparations		GMMMG
<b>11.4.1 Corticosteroids</b>		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
<b>Betamethasone</b>		
0.1% eye drops & ointment	 	
<b>Dexamethasone</b>		
0.1% eye drops & minims	 	
<b>Dexamethasone (intravitreal implant)</b>		<b>RESTRICTED</b> as per NICE TA229; TA460 & TA824
 		
Ozurdex® 700micrograms intravitreal implant	    	
<b>Fluocinolone Acetonide</b>		<b>RESTRICTED</b> as per NICE TA590 & TA953
 		
Iluvien® 190micrograms intravitreal implant	    	
<b>Prednisolone</b>		
0.5% & 1% eye drops; 0.5% minims	 	
<b>Fluorometholone</b>		
		
0.1% eye drops	 	
<b>Hydrocortisone sodium phosphate</b>		
Softacort® 3.35 mg/mL PF single use eye drops	  	
<b>Triamcinolone Acetonide</b>		<b>RESTRICTED</b> intralesional injection in skin grafts
 		
Kenalog® 40mg/mL injectable suspension	  	
<b>Triamcinolone Acetonide</b>		<b>RESTRICTED</b> uveitis; sympathetic ophthalmia
		
Triesence® 40mg/mL injectable suspension	  	
<b>Triamcinolone Acetonide</b>		<b>RESTRICTED</b> opacification of the vitreous humour
		
Intracinol® 40mg/mL ophthalmic suspension	  	
<b>Corticosteroids preparations with antibiotics</b>		
<b>Betamethasone / Neomycin Sulphate</b>		
0.1% / 0.5% eye drops (Betnesol-N®)	 	
<b>Dexamethasone / Neomycin Sulphate / Polymyxin B Sulphate</b>		
1 mg/mL : 3500 IU/mL : 6000 IU/mL (Maxitrol® eye drops & ointment)	 	
<b>11.4.2 Other anti-inflammatory preparations</b>		
<b>Sodium Cromoglicate</b>		
2% eye drops	 	
<b>Adalimumab</b>		<b>RESTRICTED Consultant Ophthalmologist only</b> Non-infectious Uveitis
 		
Amgevita® injection (see also sections 1.5.3, 10.1.3 & 13.5.3)	    	
<b>Antazoline with Xylometazoline</b>		
0.5% eye drops	 	
<b>Azelastine</b>		<b>RESTRICTED</b> allergic conjunctivitis, children only
0.05% eye drops	 	
<b>Ketotifen hydrogen fumarate</b>		
Ketofall® 0.25mg/mL PF eye drops	 	
<b>Lodoxamide</b>		<b>RESTRICTED</b> allergic conjunctivitis
0.1% eye drops	 	
<b>Olopatadine</b>		<b>RESTRICTED</b> Seasonal allergic conjunctivitis
1mg/mL eye drops	  	
<b>Potassium Ascorbate</b>		<b>RESTRICTED</b> management of chemical burns to the cornea
		
10% eye drops	 	

11.5 Mydriatics & cycloplegics		GMMMG
<b>Antimuscarinics</b>		
<b>Atropine Sulphate</b>		
1% minims	 	
<b>Cyclopentolate Hydrochloride</b>		
1% eye drops, 0.5% & 1% minims	 	
<b>Tropicamide</b>		
0.5% & 1% eye drops, 0.5% & 1% minims	 	
<b>Sympathomimetics</b>		
<b>Phenylephrine Hydrochloride</b>		<b>10% contraindicated in children &amp; the elderly</b>
2.5% & 10% minims	 	
<b>Sympathomimetics with tropicamide</b>		
<b>Phenylephrine Hydrochloride with Tropicamide</b>		<b>RESTRICTED Pre-operative mydriasis in cataract patients</b>
Mydriaser <sup>®</sup> 5.4mg / 280micrograms ophthalmic insert	  	

11.6 Treatment of glaucoma		GMMMG
<b>Beta-blockers</b>		NICE NG81
<b>Timolol</b>		
0.25% & 0.5% eye drops	 	
<b>Timolol once-daily</b>		
0.25% eye drops, <i>Tiopex</i> ® 0.1% gel, 0.5% long-acting ophthalmic gel	 	
<b>Betaxolol</b>		
0.25% & 0.5% eye drops, 0.25% minims	 	
<b>Levobunolol Hydrochloride</b>		
0.5% eye drops	 	
<b>Prostaglandin analogues and prostamides</b>		
<b>Bimatoprost</b>		
100 microgram/mL eye drops	  	
<b>Latanoprost</b>		
50 microgram/mL eye drops	 	
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
<b>Latanoprost (preservative free)</b>		
50 microgram/mL preservative free eye drops	  	
MHRA Drug Safety Update (Jul-15): Latanoprost (Xalatan): increased reporting of eye irritation since reformulation		
<b>Travoprost</b>		
40 microgram/mL eye drops	  	
<b>Prostaglandin analogues (combination products)</b>		
<b>Latanoprost / Timolol</b>		
50microgram/mL / 5mg/mL eye drops; preservative free eye drops	  	
<b>Sympathomimetics</b>		
<b>Brimonidine Tartrate</b>		
0.2% eye drops	  	
<b>Apraclonidine</b>		
<span style="background-color: green; color: white; padding: 2px;">Green</span> or <span style="background-color: red; color: white; padding: 2px;">Red</span>		<b>RESTRICTED</b> to delay laser treatment / surgery in uncontrolled glaucoma
0.5%; 1% eye drops	 	
<b>Carbonic anhydrase inhibitors &amp; systemic drugs</b>		
<b>Acetazolamide</b>		
<span style="background-color: green; color: white; padding: 2px;">Green</span>		
250mg tablets; <i>Diamox SR</i> ® 250mg capsules	 	
<b>Brinzolamide</b>		
10mg/mL eye drops	 	
<b>Brinzolamide / Brimonidine</b>		
<i>Simbrinza</i> ® 2% eye drops	  	<b>RESTRICTED</b> glaucoma patients in whom monotherapy provides insufficient IOP reduction
<b>Dorzolamide</b>		
2% eye drops; also preservative free	 	
<b>Dorzolamide / Timolol</b>		
<i>Cosopt</i> ® 2% eye drops; also preservative free	 	
<b>Miotics</b>		
<b>Pilocarpine</b>		
1%, 2% & 4% eye drops, 2% minims	 	
<b>Pilocarpine</b>		
4% ophthalmic gel	 	

## 11.7 Local anaesthetics



### Ocular Local anaesthetics

#### Lidocaine (Lignocaine) and Fluorescein (minims)

4% / 0.25% eye drops



#### Oxybuprocaine (minims)

0.4% eye drops



#### Proxymetacaine (minims)


0.5% eye drops



























































































#### Tetracaine (Amethocaine) (minims)

1% &amp; 2% eye drops



11.8 Miscellaneous ophthalmic preparations		GMMMG
<b>Other preparations</b>		
<b>Botulinum toxin type A</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only blepharospasm & strabismus
<i>Xeomin</i> ® injection	MMC BNF emc	
<b>Ciclosporin (eye)</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only
 2% eye drops	BNF emc	
<b>Ciclosporin (<i>Ikervis</i>®)</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only in line with NICE TA369
Green 1mg/mL eye drops	NICE MMC BNF emc	
<b>Ciclosporin (<i>Verkazia</i>®)</b>		<b>RESTRICTED Paediatrics</b> for vernal keratoconjunctivitis / severe allergic eye disease
Green 1mg/mL eye drops	MMC BNF emc	
<b>Mercaptamine</b>		<b>RESTRICTED</b> Specialist use only <b>NHSE</b>
Red  Cystadrops® eye drops	PbR x MMC BNF blueiteq emc	
<b>Sodium Chloride</b>		
 5% eye drops	BNF emc	
<b>Allogeneic Serum eye drops</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only
 eye drops (minims) (from NHS Blood & Transplant Service) (not a medicine)	MMC blueiteq	
<b>11.8.1 Tear deficiency, ocular lubricants &amp; astringents</b>		
<b>Acetylcysteine</b>		
 <i>Ilube</i> ® 5% eye drops	BNF emc	
<b>Alteplase</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only
25microgram in 0.1mL intravitreal injection	MMC BNF emc	
<b>Carbomers</b>		
<i>Viscotears</i> ® 0.2% eye drops	MMC BNF emc	
<b>Carmellose Sodium</b>		
<i>Celluvisc</i> ® 0.5% eye drops	BNF emc	
<b>Cationorm®</b>		
preservative free eye drops	MMC BNF emc	
<b>Hydroxyethylcellulose</b>		
<i>Minims</i> ® Artificial Tears preservative free eye drops	BNF emc	
<b>Hypromellose</b>		
0.3% eye drops	MMC BNF emc	
<b>Liquid Paraffin</b>		
<i>Lacri-Lube</i> ® ointment	BNF emc	
<b>Poly (carboxymethylglucose sulfate)</b>		<b>RESTRICTED</b> Consultant Ophthalmologist only <b>NOT STOCKED</b>
<i>Cacicol</i> ® eye drops (0.33mL)	MMC BNF emc	
<b>Polyvinyl Alcohol</b>		
<i>Liquifilm Tears</i> ® 1.4% eye drops	MMC BNF emc	
<b>Sodium Chloride (minims)</b>		
0.9% eye drops	BNF emc	
<b>Sodium Hyaluronate</b>		
<i>Hyo-Forte</i> ® 0.2% eye drops	MMC BNF emc	

<b>11.8.2 Ocular diagnostic &amp; peri-operative preparations &amp; photodynamic treatment</b>		
<b>Ocular diagnostic preparations</b>		
<b>Fluorescein Sodium</b>		
1% & 2% preservative free eye drops	 	
<b>Fluorescein Sodium</b> 		<b>RESTRICTED</b> Specialist use only fundus fluorescein angiography
100mg/mL injection	  	
<b>Indocyanine green (ICG)</b> 		<b>RESTRICTED</b> Specialist use only
Verdye® 5mg/mL injection	  	
<b>Ocular peri-operative drugs</b>		
<b>Acetylcholine Chloride</b>		
1% intraocular irrigation	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Apraclonidine</b>		
lopidine® 0.5% eye drops; 1% preservative free eye drops	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Bromfenac</b>		
Yellox® 0.9 mg/mL eye drops	  	<b>RESTRICTED</b> Consultant only for pseudophakic CMO
<b>Ketorolac Trometamol</b> 		
Acular® 0.5% eye drops	 	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Nepafenac</b>		
Nevanac® 1 mg/mL eye drops	  	<b>RESTRICTED</b> . 1 <sup>st</sup> line post cataract surgery in diabetics. 2 <sup>nd</sup> line CMO
<b>Povidone-Iodine</b>		
5% eye drops	  	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Heavy Silicone oil</b>		
Densiron® 68 - 10mL syringe	 	<b>RESTRICTED</b> intraocular tamponade of inferior retinal breaks
<b>Subfoveal choroidal neovascularisation</b>		
<b>Aflibercept</b>  		
Eylea® 40mg in 1mL injection	    	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Bevacizumab</b>   		
Avastin® 100mg in 4mL vial	    	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Brolucizumab</b>  		
Beovu® 120mg in 1mL injection	    	<b>RESTRICTED</b> Consultant Ophthalmologist only
MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals		
<b>Faricimab</b>  		
Vabysmo® 120mg/mL injection	    	<b>RESTRICTED</b> Consultant Ophthalmologist in line with NICE
<b>Ranibizumab</b>  		
Lucentis® / Ongavia® 10mg/mL injection	    	<b>RESTRICTED</b> Consultant Ophthalmologist only 
<b>Verteporfin</b>  		
Visudyne® 15mg vial	   	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>Vitreomacular traction</b>		
<b>Ocriplasmin</b>  		
Jetrea® 0.5 mg/0.2mL injection	    	<b>RESTRICTED</b> Consultant Ophthalmologist only
<b>11.8.3 Other preparations</b>		
<b>Voretigene</b>		
<b>Voretigene neparvec</b>  		
Luxturna® 2mL vial	    	<b>RESTRICTED</b> Consultant Ophthalmologist in line with NICE
<b>Insulin eye drops</b>		
<b>Insulin (soluble) eye drops</b>  		
Humulin S® in Systane® lubricant eye drops		<b>RESTRICTED</b> Consultant Ophthalmologist

## Section 12: Ear, nose & oropharynx

Supported by the  
formulary ([click here](#))



### 12.1 Drugs acting on the ear

- 12.1.1 Otitis externa
- 12.1.3 Removal of ear wax

### 12.2 Drugs acting on the nose

- 12.2.1 Drugs used in nasal allergy
- 12.2.2 Topical nasal decongestants
- 12.2.3 Nasal preparations for infection

### 12.3 Drugs acting on the oropharynx

- 12.3.1 Drugs for oral ulceration & inflammation
- 12.3.2 Oropharyngeal anti-infective drugs
- 12.3.4 Mouthwashes, gargles & dentifrices
- 12.3.5 Treatment of dry mouth

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79)  
Sore throat (acute): antimicrobial prescribing (NG84)  
Otitis media (acute): antimicrobial prescribing (NG91)  
Tinnitus: assessment and management (NG155)  
Otitis media with effusion in under 12s (NG233)  
Allergic rhinitis (CKS)

## GMMM Formulary

Formulary Homepage  
Chapter 12: Ear, nose & oropharynx (Complete)  
GMMM Adult [Red/Amber/Green](#); DNP and [Grey](#) Drug List  
GMMM Paediatric [Red/Amber/Green](#) Drug List



## 12.1 Drugs acting on the ear



### 12.1.1 Otitis externa

#### Astringent preparations

##### Aluminium Acetate

ear drops



#### Anti-inflammatory preparations

##### Betamethasone Sodium Phosphate

Betnesol® 0.1% ear drops



##### Prednisolone Sodium Phosphate

Predsol® 0.5% ear drops



#### Anti-inflammatory with antibacterial preparations

##### Dexamethasone / Neomycin Sulphate

Otomize® 0.1% / 3250u per mL ear spray



##### Dexamethasone / Framycetin Sulphate / Gramicidin

Sofradex® 0.05% / 0.5% / 0.005% ear/eye drops



##### Flumetasone Pivalate / Clioquinol

Locorten-Vioform® 0.02% / 1% ear drops



##### Hydrocortisone / Gentamicin

1% / 0.3% ear drops



##### Hydrocortisone / Neomycin Sulfate / Polymyxin B Sulphate

Otosporin® 1% : 3400u/mL : 10,000u/mL ear drops



#### Analgesic / Anti-inflammatory / local anaesthetic preparations

##### Phenazone with Lidocaine

Otigo® 40mg/g / 10mg/g ear drops



**RESTRICTED**  
paeds in line with NICE NG91

#### Anti-infective preparations

##### Ciprofloxacin

Green

Cetraxal® 0.2% ear drops



MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects

MHRA Drug Safety Update (Dec-20): Systemic &amp; inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk

MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling &amp; potentially long-lasting or irreversible side effects

##### Clotrimazole

1% ear drops



### 12.1.3 Removal of ear wax

##### Chlorobutanol / Arachis oil

Cerumol® ear drops



##### Olive oil ear drops

DNP

ear drops





























##### Sodium Bicarbonate

DNP

5% ear drops



12.2 Drugs acting on the nose		GMMMG
<b>12.2.1 Drugs used in nasal allergy</b>		
<b>Antihistamines</b>		
<b>Azelastine Hydrochloride</b>		
140micrograms nasal spray	NICE  	
<b>Corticosteroids</b>		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
<b>Beclometasone Dipropionate</b>		<b>1<sup>st</sup> line use</b>
50micrograms nasal spray	 	
<b>Betamethasone Sodium Phosphate</b>		
0.1% nose drops	 	
<b>Mometasone Furoate</b>		<b>1<sup>st</sup> line use nasal polyps</b>
50micrograms nasal spray	MMC  	
<b>Fluticasone Furoate</b>		
Avamys® 27.5micrograms nasal spray	MMC  	
<b>Fluticasone Propionate / Azelastine Hydrochloride</b>		<b>RESTRICTED 3<sup>rd</sup> line use</b>
Green Dymista® 50micrograms / 137micrograms nasal spray	NICE MMC  	
<b>Cromoglicate</b>		
<b>Sodium Cromoglicate</b>		
4% nasal spray	 	
<b>12.2.2 Topical nasal decongestants</b>		
<b>Sympathomimetics</b>		
<b>Ephedrine Hydrochloride</b>		<b>1<sup>st</sup> line use</b>
0.5%; 1% nasal drops	 	
<b>Sodium Chloride</b>		
0.9% nasal drops	 	
<b>Xylometazoline Hydrochloride</b>		
0.1% nasal drops	 	
<b>Antimuscarinics</b>		
<b>Ipratropium Bromide</b>		Rhinorrhoea associated with allergic & non-allergic rhinitis
0.03% nasal spray	 	
<b>12.2.3 Nasal preparations for infection</b>		
<b>Chlorhexidine Dihydrochloride / Neomycin</b>		<b>1<sup>st</sup> line use staphylococcal infections</b>
Naseptin® 0.1% / 0.5% nasal cream	MMC  	
<b>Mupirocin</b>		<b>RESTRICTED MRSA / post nasal cautery</b>
2% nasal ointment	MMC  	

## 12.3 Drugs acting on the oropharynx



### 12.3.1 Drugs for oral ulceration & inflammation

#### Local Analgesics

#### Benzylamine Hydrochloride

Green

0.15% oral rinse; 0.15% spray



#### Carmellose Sodium

30g protective paste



#### Corticosteroids

#### Hydrocortisone

muco-adhesive buccal tablets



### 12.3.2 Oropharyngeal anti-infective drugs

#### Oropharyngeal fungal infections

#### Miconazole

DNP

2% oral gel



MHRA Drug Safety Update (Sep-17): Miconazole (Daktarin): over-the-counter oral gel contraindicated in patients taking warfarin

#### Nystatin

DNP

100,000 units/mL oral suspension



### 12.3.4 Mouthwashes, gargles & dentifrices

#### Chlorhexidine Gluconate

0.2% mouthwash; 1% dental gel



### 12.3.5 Treatment of dry mouth

#### Local treatment

#### AS Saliva Orthana®

spray; lozenges



#### BioXtra®

oral gel



#### Systemic treatment

#### Pilocarpine

5mg tablets



**RESTRICTED Consultant use only**  
following irradiation for head & neck cancer

#### Treatment of Dental Caries

#### Silver Diamine Fluoride (SDF) 38%

liquid



## Section 13: Skin

Supported by the  
formulary (click here)



### 13.2 Emollient & barrier preparations

13.2.1 Emollients

13.2.2 Barrier preparations

### 13.3 Topical local anaesthetics & antipruritics

### 13.4 Topical corticosteroids

### 13.5 Preparations for eczema & psoriasis

13.5.1 Preparations for eczema

13.5.2 Preparations for psoriasis

13.5.3 Drugs affecting the immune response

Cytokine Modulators

### 13.6 Acne & Rosacea

13.6.1 Topical preparations for acne

13.6.2 Oral preparations for acne

### 13.7 Preparations for warts & calluses

### 13.8 Sunscreens & camouflagers

13.8.1 Sunscreen preparations

### 13.9 Shampoos & other preparations for scalp/hair conditions

### 13.10 Anti-infective skin preparations

13.10.1 Antibacterial preparations

13.10.2 Antifungal preparations

13.10.3 Antiviral preparations

13.10.4 Parasitocidal preparations

13.10.5 Preparations for minor cuts & abrasions

### 13.11 Skin cleansers, antiseptics & desloughing agents

13.11.1 Alcohols & saline

13.11.2 Chlorhexidine salts

13.11.4 Iodine

13.11.6 Oxidisers & dyes

13.11.7 Desloughing agents

### 13.12 Antiperspirants

### 13.13 Topical circulatory preparations

### 13.14 Miscellaneous preparations

### Non-Formulary Items

## Trust Guidelines


ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
 NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Biosimilar Medicines (KTT15)  
 Atopic eczema in children (CG57)  
 Psoriasis: assessment and management (CG153)  
 Pressure Ulcers (CG179)  
 Pubic lice CKS (2011)  
 Scabies CKS (2011)  
 Acne vulgaris CKS (2014)  
 Head lice CKS (2015)  
 Surgical site infections: prevention and treatment (NG125)  
 Atopic dermatitis (eczema) - topical steroids (TA81)  
 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)  
 Psoriasis - efalizumab and etanercept (TA103) EMA (efalizumab)  
 Psoriasis - infliximab (TA134)  
 Psoriasis - adalimumab (TA146)  
 Alitretinoin for the treatment of severe chronic hand eczema (TA177)  
 Psoriasis - ustekinumab (TA180)  
 Melanoma (stage III or IV) - ipilimumab (TA268)  
 Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)  
 Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)  
 Secukinumab for treating moderate to severe plaque psoriasis (TA350)  
 Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)  
 Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)  
 Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)  
 Apremilast for treating active psoriatic arthritis (TA433)  
 Ixekizumab for treating moderate to severe plaque psoriasis (TA442)  
 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)  
 Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)  
 Brodalumab for treating moderate to severe plaque psoriasis (TA511)  
 Guselkumab for treating moderate to severe plaque psoriasis (TA521)  
 Dupilumab for treating moderate to severe atopic dermatitis (TA534)  
 Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)  
 Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)  
 Risankizumab for treating moderate to severe plaque psoriasis (TA596)  
 Baricitinib for treating moderate to severe atopic dermatitis (TA681)  
 Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)  
 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)  
 Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)  
 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)  
 Difelikefalin for treating pruritus in people having haemodialysis (TA890)  
 Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)  
 Bimekizumab for treating active psoriatic arthritis (TA916)  
 Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)  
 Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)  
 Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

## GMMMG Formulary

Formulary Homepage  
 Chapter 13: Skin (Complete)  
 GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
 GMMMG Paediatric [Red/Amber/Green](#) Drug List

13.2 Emollient & barrier preparations		GMMMG
<b>13.2.1 Emollients</b>		
<b>Non-Proprietary emollient preparations</b>		
MHRA Drug Safety Update (Aug-20): Emollients and risk of severe and fatal burns: new resources available MHRA Drug Safety Update (Jul-20): Safe use of emollient skin creams to treat dry skin conditions MHRA Drug Safety Update (Dec-18): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients MHRA Patient Info Leaflet (Jul-20): Skin creams - risk of fire and burns		
<b>Aqueous cream BP</b>		
cream	 	
<b>Emulsifying ointment BP</b>		
ointment	 	
<b>Liquid &amp; white soft paraffin</b>		
ointment	 	
<b>Paraffin, white soft BP</b>		
white petroleum jelly	 	
<b>Paraffin, yellow soft BP</b>		
yellow petroleum jelly	 	
<b>Proprietary emollient preparations</b>		
<b>Diprobase®</b>		
cream; ointment	 	
<b>Doublebase®</b>		
gel	 	
<b>Hydromol®</b>		
cream; ointment	  	
<b>Oilatum®</b>		
	 	
<b>Preparations containing urea</b>		
<b>Balneum® Plus</b>		
	 	
<b>With antimicrobials</b>		
<b>Dermol® &amp; Dermol® 500</b>		
	  	<b>RESTRICTED</b> patients unable to tolerate 1 <sup>st</sup> / 2 <sup>nd</sup> line antimicrobial washes
<b>13.2.1.1 Emollient bath and shower preparations</b> <span style="float: right;">DNP</span>		
<b>Emollient bath and shower preparations without antimicrobials</b>		
When used for the management of eczema in children or adults. This recommendation does not apply to the use of standard emollients when used in the bath or shower as a soap substitute		DNP
<b>With antimicrobials</b>		
<b>Dermol® 600</b>		
<span style="border: 1px solid black; padding: 2px;">Grey</span> <span style="background-color: green; color: white; padding: 2px;">Green</span>		
bath emollient	 	
<b>Oilatum® Plus</b>		
bath emollient	 	<b>2<sup>nd</sup> line</b> MRSA decolonisation therapy
<b>13.2.2 Barrier preparations</b>		
<b>Proprietary barrier preparations</b>		
<b>Metanium®</b>		
ointment	 	<b>2<sup>nd</sup> line</b> only at parental request
<b>Sudocrem®</b>		
cream	 	<b>2<sup>nd</sup> line</b> only at parental request





























**13.3 Topical local anaesthetics & antipruritics****13.3 Topical local anaesthetics & antipruritics****Crotamiton**

cream; lotion












**Mepyramine Maleate**












































































2% w/w cream































13.4 Topical corticosteroids		GMMMG
Corticosteroid only preparations		NICE TA81
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions		
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration		
HYDROCORTISONE		Potency
<b>Canesten HC®</b>		Mild
hydrocortisone 1% plus clotrimazole 1% cream	 	
<b>Daktacort®</b>		Mild
hydrocortisone 1%, miconazole nitrate 2% cream; ointment	 	
<b>Eurax-Hydrocortisone®</b>		Mild
hydrocortisone 0.25%, crotamiton 10% cream	 	
<b>Fucidin H®</b>		Mild
hydrocortisone 1%, fusidic acid 1% cream	 	
BETAMETHASONE ESTERS		Potency
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions		
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
<b>Betamethasone valerate</b>		Moderate
0.025% ointment, cream	 	
<b>Betnovate-RD®</b>		Moderate
Betamethasone valerate 0.025% cream; ointment	 	
CLOBETASONE BUTYRATE		Potency
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions		
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
<b>Eumovate®</b>		Moderate
0.05% cream; ointment	 	
BETAMETHASONE ESTERS		Potency
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions		
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
<b>Betamethasone valerate</b>		Potent
0.1% ointment; cream; lotion; scalp lotion	 	
<b>Betnovate®</b>		Potent
0.1% cream; ointment; scalp application; lotion	 	
<b>Betamethasone valerate / Clioquinol</b>		Potent
0.1% / 3% ointment; cream	 	
<b>Betamethasone valerate / Neomycin sulfate</b>		Potent
0.1% / 0.5% cream; ointment	 	
<b>Diprosalic®</b>		Potent
Betamethasone dipropionate 0.05%, salicylic acid 3% ointment	 	
<b>Fucibet®</b>		Potent
Betamethasone valerate 0.1% plus fusidic acid 2% cream	 	
<b>Betnovate®</b>		Potent
ointment 25% in coal tar	 	DERMATOLOGY ONLY
























<b>CLOBETASOL PROPIONATE</b>		<b>Potency</b>
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions		
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions		
<b>Dermovate®</b> clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	 	Very potent
<b>Dermovate NN®</b> clobetasol propionate 0.05% / neomycin / nystatin cream	 	Very potent
<b>Etrivex®</b> clobetasol propionate 500micrograms/g shampoo	  	Very potent <b>RESTRICTED - 1<sup>st</sup> Care referral</b>
<b>DIFLUCORTOLONE VALERATE</b>		<b>Potency</b>
<b>Diflucortolone valerate</b>  0.3% oily cream	  	Very potent <b>RESTRICTED Consultant Gynaecologist</b>












13.5 Preparations for eczema & psoriasis		GMMMG
<b>13.5.1 Preparations for eczema</b>		
<b>Alitretinoin</b>   10mg; 30mg capsules     		<b>RESTRICTED</b> Dermatology Consultants only
MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women		
<b>13.5.2 Preparations for psoriasis</b>		
<b>Topical preparations for psoriasis</b>		<b>NICE CG153</b>
<b>Calcipotriol</b> Dovonex® ointment; with Betamethasone (Dovobet® 0.05% ointment)  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Dithranol</b>   (unlicensed preps) Dithocream® 0.1% & 0.25% cream  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Salicylic acid</b> Zinc & Salicylic acid paste BP (Lassar's Paste)  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Tacalcitol</b> Curatoderm® lotion; ointment  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Tars</b>		
<b>Coal tar paste BP</b> paste  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Coccolis®</b> scalp ointment  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Oral retinoids for psoriasis</b>		
<b>Acitretin</b>  10mg; 25mg capsules  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Dimethyl Fumarate</b>   30mg; 120mg tablets      		<b>RESTRICTED</b> 3 <sup>rd</sup> /4 <sup>th</sup> line as per NICE/GMMMG Referral to SRFT
<b>13.5.3 Drugs affecting the immune response</b>		
<b>Abrocitinib</b>   Cibingo® 50mg; 100mg; 200mg tablets      		<b>RESTRICTED</b> Dermatology Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality		
<b>Azathioprine</b>  25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3)  		<b>RESTRICTED</b> Dermatology Consultants only
<b>Ciclosporin</b>  25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2)    		<b>RESTRICTED</b> Dermatology Consultants only
<b>Methotrexate</b>  2.5mg tablets (see also sections 8.1.3 & 10.1.3)   		<b>RESTRICTED</b> Dermatology Consultants only
<b>Pimecrolimus</b>  1% cream    		<b>RESTRICTED</b> Dermatology Consultants only
<b>Sirolimus</b>  Hyfor® 0.2% gel   		<b>RESTRICTED</b> Dermatology Consultants only
<b>Tacrolimus (specially made by SRFT)</b>  0.03%; 0.1% ointment     		<b>RESTRICTED</b> Dermatology Consultants only
<b>Upadacitinib</b>   Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3)      		<b>RESTRICTED</b> Dermatology Consultants only in line with NICE
MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality		

<b>Cytokine Modulators</b>		(see also section 10.1.3)
<b>Adalimumab</b>   injection (see also sections 1.5.3, 10.1.3 & 11.4.2)	     	<b>RESTRICTED</b> Dermatology Consultants only
<b>Apremilast</b>   10mg; 20mg; 30mg tablets	    	<b>RESTRICTED</b> 3 <sup>rd</sup> /4 <sup>th</sup> line as per NICE/GMMMG
<b>Bimekizumab</b>   <i>Bimzelx</i> ® injection (see also section 10.1.3)	     	<b>RESTRICTED</b> in line with NICE
<b>Brodalumab</b>   <i>Kyntheum</i> ® 140mg/mL injection	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Certolizumab</b>   <i>Cimzia</i> ® 200mg injection (see also section 10.1.3)	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Dupilumab</b>   <i>Dupixent</i> ® 150mg/mL injection (see also section 3.4.2)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Etanercept</b>   injection (see also section 10.1.3)	     	<b>RESTRICTED</b> Dermatology Consultants only
<b>Guselkumab</b>   100mg/mL injection	    	<b>RESTRICTED</b> in line with NICE
<b>Infliximab</b>   100mg injection (see section 10.1.3)	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Ixekizumab</b>   80mg/1mL injection (see also section 10.1.3)	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Risankizumab</b>   75mg; 150mg injection	     	<b>RESTRICTED</b> Specialist use only in line with NICE
<b>Secukinumab</b>   150mg/1mL injection	     	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Tildrakizumab</b>   100mg injection	    	<b>RESTRICTED</b> Dermatology only in line with NICE
<b>Ustekinumab</b>   injection (see section 10.1.3)	     	<b>RESTRICTED</b> Dermatology NICE TA180 & 455 / Gastro 3 <sup>rd</sup> line Crohn's

13.6 Acne & Rosacea		GMMMG
13.6.1 Topical preparations for acne		NICE CKS: Acne
For mild to moderate acne, use topical benzyl peroxide or a topical retinoid 1 <sup>st</sup> line. Topical antibiotic should be reserved for patients who have not responded to other topical preparations.		
<b>Benzyl peroxide &amp; azelaic acid</b>		
<b>Benzoyl Peroxide</b> DNP	 	1 <sup>st</sup> line
4% cream; 5% gel		
<b>Azelaic acid</b>	 	2 <sup>nd</sup> line
Skinoren® 20% cream		
<b>Topical antibacterials for acne</b>		
<b>Clindamycin</b>	 	2 <sup>nd</sup> / 3 <sup>rd</sup> line
Dalacin T® 1% topical lotion		
<b>Erythromycin</b>	 	2 <sup>nd</sup> / 3 <sup>rd</sup> line
Zineryt® 40mg/mL erythromycin; zinc acetate 12mg/mL lotion		
<b>Topical retinoids &amp; related preparations for acne</b>		
<b>Adapalene</b>	 	1 <sup>st</sup> line
Differin® 0.1% cream; 0.1% gel		
<b>Topical retinoids with antibacterial</b>		
<b>Isotretinoin with Erythromycin</b>	 	<b>RESTRICTED</b> Dermatology Consultants only
Isotrexin® 500micrograms/1g : 20mg/1g gel		
13.6.2 Oral preparations for acne		NICE CKS: Acne
Oral antibiotics should be reserved for moderate to severe acne or where topical preparations have failed. Please refer to Chapter 5.		
<b>Lymecycline</b>	  	<b>RESTRICTED</b> GP referral only
408mg capsules (see also section 5.1.3)		
<b>Hormone treatment for acne</b>		
<b>Co-cyprindiol</b>	 	<b>RESTRICTED</b> GP referral only
Cyproterone acetate 2mg / ethinylestradiol 35micrograms tablets		
<b>Oral retinoid for acne</b>		
<b>Isotretinoin</b> Red	 	<b>RESTRICTED</b> Dermatology Consultants only
5mg; 10mg; 20mg; 40mg capsules		
<p>MHRA Drug Safety Update (Oct-23): Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight on initiation of treatment in under 18s</p> <p>MHRA Drug Safety Update (Apr-23): Isotretinoin (Roaccutane ▼): new safety measures, including additional oversight on initiation of treatment in under 18s</p> <p>MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼, and acitretin ▼): temporary monitoring advice during COVID-19 pandemic</p> <p>MHRA Drug Safety Update (Nov-20): Isotretinoin (Roaccutane ▼): contribute to expert review</p> <p>MHRA Drug Safety Update (Aug-20): Isotretinoin (Roaccutane ▼): reminder of important risks and precautions</p> <p>MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women</p> <p>MHRA Drug Safety Update (Oct-17): Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido</p> <p>MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders</p>		

















13.7 Preparations for warts & calluses		GMMMG
<b>13.7 Preparations for warts &amp; calluses</b>		
<b>Salicylic acid</b> DNP ointment; liquid	 	
<b>Silver Nitrate</b> pencil	 	<b>RESTRICTED</b> Dermatology Consultants only
<b>Silver Nitrate</b> 75% applicator	  	<b>RESTRICTED</b> ENT - nasal cauterly
<b>Anogenital warts</b>		
<b>Podophyllotoxin</b> 0.15% cream	 	<b>1<sup>st</sup> line</b>
<b>Imiquimod</b> Green 5% cream	  	<b>RESTRICTED</b> GUM Consultant only










13.8 Sunscreens & camouflagers		GMMMG
13.8.1 Sunscreen preparations		
Photodamage		
<b>Methyl-5-Aminolevulinate</b>  160mg/g cream   		<b>RESTRICTED</b> Dermatology Consultants & Vulval Intraepithelial Neoplasia (VIN) only
<b>Diclofenac Sodium</b> Solaraze® 3% gel  		<b>RESTRICTED</b> Dermatology Consultants
<b>Fluorouracil / Salicylic acid</b> Actikerall® 0.5% / 10% cutaneous solution   		<b>RESTRICTED</b> Dermatology Consultants as per MMC

13.9 Shampoos & other preparations for scalp / hair conditions		GMMMG
<b>Shampoos</b>		
<b>Ketoconazole</b>		<b>RESTRICTED</b> persistent / severe seborrhoeic dermatitis / dandruff
<i>Nizoral</i> ® 2% shampoo	 	
<b>Capasal</b> ®		<b>RESTRICTED</b> Dermatology Consultants only
coal tar 1%, coconut oil 1% &, salicylic acid 0.5% shampoo	 	
<b>Ceanel Concentrate</b> ®		<b>RESTRICTED</b> Dermatology Consultants only
cetrimide 10%, undecenoic acid 1% & phenylethyl alcohol 7.5% shampoo	 	
<b>Other scalp preparations</b>		
<b>Polytar</b> ®		
40mg/mL coal tar scalp shampoo	 	
<b>Hirsutism</b>		
<b>Eflornithine</b>		<b>RESTRICTED</b> Dermatology Consultants only
<i>Vaniqa</i> ® 11.5% cream	  	

13.10 Anti-infective skin preparations		GMMMG
<b>13.10.1 Antibacterial preparations</b>		
<b>Topical antibacterials should generally be avoided for the treatment of infections</b>		
<b>13.10.1.1 Antibacterial preparations only used topically</b>		
<b>Mupirocin</b>		
2% cream; ointment	MMC BNF emc	
<b>Fusidic acid</b>		<b>RESTRICTED</b> superficial impetigo
2% cream; ointment	BNF emc	
<b>Metronidazole</b>		<b>RESTRICTED</b> topical treatment of rosacea
0.75% topical gel; cream	BNF emc	
<b>Silver Sulfadiazine</b>		<b>RESTRICTED</b> Treatment/prophylaxis of burns
1% w/w cream	BNF emc	
<b>13.10.2 Antifungal preparations</b>		
<b>Amorolfine</b>		<b>1<sup>st</sup> line</b> antifungal for nail infections
5% nail lacquer	MMC BNF emc	
<b>Benzoic acid ointment, compound, BP</b>		<b>1<sup>st</sup> line</b> treatment of ringworm
benzoic acid 6% / salicylic acid 3% / in emulsifying ointment	BNF emc	
<b>Clotrimazole</b>		<b>1<sup>st</sup> line</b> fungal skin infections
1% cream	BNF emc	
<b>Miconazole</b>		<b>2<sup>nd</sup> line</b> fungal skin infections
2% cream	BNF emc	
<b>Terbinafine</b>		<b>2<sup>nd</sup> line</b> fungal skin infections
1% cream	BNF emc	
<b>13.10.3 Antiviral preparations</b>		
<b>Aciclovir</b>		<b>1<sup>st</sup> line</b>
5% cream	BNF emc	
<b>13.10.4 Parasitocidal preparations</b>		
		<b>NICE CKS: Head lice</b>
		<b>NICE CKS: Pubic lice</b>
		<b>NICE CKS: Scabies</b>
<b>Ivermectin</b>		
<b>U</b> tablets	MMC BNF emc	
<b>Malathion</b>		
0.5% aqueous solution	BNF emc	
<b>Permethrin</b>		
1% crème rinse; 5% dermal cream	BNF emc	
MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition...		
<b>13.10.5 Preparations for minor cuts &amp; abrasions</b>		
<b>Proflavine cream, BPC</b>		
0.1% cream	BNF emc	
<b>Brulidine</b>		<b>RESTRICTED</b> Theatres only
0.15% w/w cream	emc	
<b>Preparations for boils</b>		
<b>Magnesium Sulfate</b>		
paste, BP	emc	
<b>Skin tissue adhesive</b>		
<b>Histoacryl®</b>		<b>RESTRICTED</b> Theatres only
0.5mL skin adhesive	BNF emc	



13.11 Skin cleansers, antiseptics & desloughing agents		GMMMG
<b>13.11.1 Alcohols &amp; saline</b>		
<b>Isopropyl Alcohol 70%</b>	 	
<b>Sodium Chloride</b>	 	
0.9% irrigation solution		
<b>13.11.2 Chlorhexidine salts</b>		
<b>Chlorhexidine Gluconate</b>	 	
<b>13.11.4 Iodine</b>		
<b>Alcoholic Iodine solution BP</b>	 	
<b>Iodine weak solution</b>	 	
<b>Povidone-Iodine</b>	 	
<b>13.11.6 Oxidisers &amp; dyes</b>		
<b>Hydrogen Peroxide solution, BP</b>	 	<b>RESTRICTED</b> Specialist use only
3% solution; 6% solution		
<b>Potassium Permanganate</b>	 	<b>RESTRICTED</b> Specialist use only
400mg tablets for cutaneous solution		
National Patient Safety Alert (Apr-22): Inadvertent oral administration of potassium permanganate		
<b>13.11.7 Desloughing agents</b>		
<b>CONTACT THE TISSUE VIABILITY TEAM on x64042</b>		

13.12 Antiperspirants		GMMMG
<b>Aluminium salts</b>		
<b>Aluminium Chloride Hexahydrate</b>  20% solution		
 		
<b>Glycopyrronium Bromide</b>		
<b>Glycopyrronium Bromide</b>  <i>Robinul</i> ®		
<b>Glycopyrrolate</b>		<b>RESTRICTED</b> <b>Diabetes Consultants only</b> <b>(gustatory sweating)</b>
 0.5% cream		
  		
  		

### 13.13 Topical circulatory preparations



#### Topical circulatory preparations

**Hirudoid®**

0.3% cream; 0.3% gel



## 13.14 Miscellaneous preparations



### 8-Methoxypsoralen



10mg tablets

MMC

emc

**RESTRICTED**  
Dermatology Consultants only

### Fumaric Acid Esters



Fumaderm® tablets

MMC

emc

**RESTRICTED**  
Dermatology Consultants only

### Glucarpidase



Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 10.4)

PbR X

MMC

BNF

emc

**RESTRICTED**  
2<sup>nd</sup> line rescue therapy

NHS  
England

### Hyaluronic acid / Lidocaine



Juvederm® / Belotero® injection

MMC

emc

**RESTRICTED**  
vocal cord paralysis

**Non-Formulary Items****Ingenol Mebutate****WITHDRAWN***Picato*® 150 micrograms/g gel (face & scalp); 500 micrograms/g gel (trunk & extremities)MHRA Drug Safety Update (Feb-20): Ingenol mebutate gel (*Picato* ▼): suspension of the licence due to risk of skin malignancyMHRA Drug Safety Update (Oct-19): Ingenol mebutate gel (*Picato* ▼): increased incidence of skin tumours seen in some clinical studies

## Section 14: Immunological products & vaccines

Supported by the  
formulary ([click here](#))



### 14.4 Vaccines & antisera

- Bacillus Calmette-Guérin (BCG) vaccines
- Botulism antitoxin
- COVID-19 vaccine
- Diphtheria vaccines (children under 10yrs old)
- Diphtheria vaccines (children over 10yrs old & adults)
- Haemophilus type B conjugate vaccine
- Hepatitis A vaccine
- Hepatitis B vaccine
- Human papilloma virus vaccine
- Influenza vaccine
- Measles, Mumps & Rubella (MMR) vaccine
- Meningococcal vaccines
- Pneumococcal vaccines
- Poliomyelitis vaccines
- Rabies vaccines
- Tetanus vaccines
- Typhoid vaccines
- Varicella-zoster vaccines

### 14.5 Immunoglobulins

- 14.5.1 Normal immunoglobulin
- 14.5.2 Disease-specific immunoglobulins
- 14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin  
Immunoglobulin follow up form  
Immunoglobulin Prescribing and Administration Guidelines  
Immunoglobulin Prescribing Flow Chart  
Immunoglobulin request form  
National Demand Programme for Immunoglobulin - Clinical Info  
[Non-formulary Conversion Table](#)

## NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

## GMMM Formulary

Formulary Homepage  
Chapter 14: Immunological products & vaccines (**ON HOLD**)  
GMMM Adult **Red/Amber/Green**; DNP and Grey Drug List  
GMMM Paediatric **Red/Amber/Green** Drug List

## Other Links

National Immunoglobulin Database  
DH: Clinical guidelines for immunoglobulin use (2<sup>nd</sup> edition update)  
Immunoglobulin handbook (HPA)

## 14.4 Vaccines & antisera

MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunosuppressed

### **Bacillus Calmette-Guérin (BCG) vaccines**

#### **Bacillus Calmette-Guérin (BCG) vaccine**

injection



**BCG vaccine diagnostic agent** (Tuberculin purified protein derivative (PPD))

injection



#### **Botulism antitoxin**

#### **Botulism antitoxin**

injection



**RESTRICTED**  
Emergencies only

#### **COVID-19 vaccine**

**UK HSA: The Green book Ch14a**

#### **Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)**

**12 years of age and older**

Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)



**pending availability of XBB1.5**

#### **Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)**

**12 years of age and older**

Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)



#### **Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)**

**5 to 11 year olds**

Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)



#### **AstraZeneca COVID-19 vaccine**

**DISCONTINUED**

Vaxzevria® injection



#### **Moderna Biotech COVID-19 vaccine**

**DISCONTINUED**

Spikevax® injection



#### **Novavax COVID-19 vaccine**

**PAUSED by JCVI**

Nuvaxovid® injection



MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023

MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023

MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023

MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022

MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022

MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022

MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022

MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022

MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022

MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022

MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022

MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022

MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022

MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022

MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022

MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021

MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021

MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021

MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021

MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021

MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021

MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021

MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021

MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021

MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZeneca): current advice

MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19

### **Diphtheria vaccines (children under 10yrs old)**

#### **PediaceI®**

injection



#### **Infanrix-IPV+Hib®**

injection



#### **Infanrix-IPV®**

injection





















#### **Repevax®**

injection





<b>Diphtheria vaccines (children over 10yrs old &amp; adults)</b>		
<b>Revaxis®</b>		
injection	 	
<b>Haemophilus type B conjugate vaccine</b>		
<b>Haemophilus Influenzae B vaccine</b>		
Hiberix® injection	 	
<b>Haemophilus Influenzae B &amp; Meningitis C vaccine</b>		
Menitorix® injection	 	
<b>Hepatitis A vaccine</b>		
<b>Hepatitis A vaccine single component</b>		
Havrix Monodose®; Havrix Junior Monodose®; Vaqta® Paediatric injection	 	
<b>Hepatitis B vaccine</b>		
<b>Hepatitis B single component</b>		
Engerix B®; Engerix B® Paediatric injection	 	
<b>Hepatitis B single component</b>		
HBvaxPRO®; HBvaxPRO® Paediatric injection	 	
<b>Human papilloma virus (HPV) vaccine</b>		
<b>Human Papilloma Virus (HPV) quadrivalent vaccine</b>		<b>RESTRICTED</b>
Gardasil® injection	  	<b>Paediatric Immunology Consultant</b>

<b>Influenza vaccine</b>		
<b>Influenza vaccine</b>		
injection, intranasal	 	
<b>Measles, Mumps &amp; Rubella (MMR) vaccine</b>		
<b>Measles, Mumps &amp; Rubella vaccine</b>		
injection	 	
<b>Meningococcal vaccines</b>		
<b>Meningococcal Polysaccharide A, C, W135 &amp; Y vaccine</b>		
injection	 	
<b>Meningococcal group B vaccine</b>		<b>RESTRICTED</b> childhood immunisation schedule & high risk patients
Bexsero® injection	  	
<b>Meningococcal group C vaccine</b>		
injection	 	
<b>Pneumococcal vaccines</b>		
<b>Pneumococcal Polysaccharide vaccine</b>		
injection	 	
<b>Poliomyelitis vaccines</b>		
<b>Poliomyelitis vaccine inactivated</b>		
	 	
<b>Rabies vaccines</b>		
<b>Rabies vaccine inactivated</b>		<b>RESTRICTED</b> Not Stocked
Rabipur® injection	 	
<b>Tetanus vaccines</b>		
<b>Tetanus vaccine adsorbed</b>		
injection	 	
<b>Typhoid vaccines</b>		
<b>Typhoid polysaccharide vaccine</b>		
Typhim Vi® injection	 	
<b>Varicella-zoster vaccines</b>		
<b>Varicella-Zoster live attenuated vaccine</b>		
Varivax® injection	 	

<b>14.5 Immunoglobulins</b>		<b>IVIG Request Form</b>
<b>14.5.1 Normal immunoglobulin</b> <span style="color:red">Red</span> (for ITP & home treatment programmes)		
<b>For intramuscular use</b>		
<b>Normal immunoglobulin injection</b> <span style="color:red">Red</span> <span style="color:blue">££</span>		<b>RESTRICTED</b> Specialist use only IVIG Request Form
injection	PbR X <span style="color:purple">BNF</span> <span style="color:blue">emc</span>	
<b>For subcutaneous use</b>		
<b>Normal immunoglobulin injection</b> <span style="color:red">Red</span> <span style="color:blue">££</span>		<b>RESTRICTED</b> Specialist use only IVIG Request Form
injection	PbR X <span style="color:green">MMC</span> <span style="color:purple">BNF</span> <span style="color:blue">emc</span>	
<b>For intravenous use</b>		
<b>Human normal immunoglobulin</b> <span style="color:red">Red</span> <span style="color:blue">££</span>		<b>RESTRICTED</b> Specialist use only IVIG Request Form
injection	PbR X <span style="color:green">MMC</span> <span style="color:purple">BNF</span> <span style="color:blue">emc</span>	
<b>14.5.2 Disease-specific immunoglobulins</b>		
<b>Hepatitis B immunoglobulin</b>		
<b>Hepatitis B immunoglobulin</b>		<b>RESTRICTED</b> Not Stocked
injection	<span style="color:purple">BNF</span> <span style="color:blue">emc</span>	
<b>Tetanus immunoglobulin</b>		
<b>Tetanus immunoglobulin</b>		
injection	<span style="color:purple">BNF</span> <span style="color:blue">emc</span>	
<b>Varicella-Zoster immunoglobulin</b>		
<b>Varicella-Zoster immunoglobulin</b> <span style="color:green">Green</span>		<b>RESTRICTED</b> Not Stocked
injection	<span style="color:purple">BNF</span> <span style="color:blue">emc</span>	
<b>Cytomegalovirus (CMV) immunoglobulin</b>		
<b>Human normal immunoglobulin (CMV)</b>		<b>RESTRICTED</b> Specialist use only
injection	<span style="color:green">MMC</span> <span style="color:purple">BNF</span> <span style="color:blue">emc</span>	
<b>14.5.3 Anti-D (Rh<sub>0</sub>) immunoglobulin</b>		
<b>Anti-D (Rh<sub>0</sub>) immunoglobulin</b> <span style="color:red">Red</span>		
injection	<span style="color:purple">NICE</span> <span style="color:green">MMC</span> <span style="color:purple">BNF</span> <span style="color:blue">emc</span>	

## Section 15: Anaesthesia

Supported by the  
formulary ([click here](#))



### 15.1 General anaesthesia

- 15.1.1 Intravenous anaesthetics
- 15.1.2 Inhalational anaesthetics
- 15.1.3 Antimuscarinic drugs
- 15.1.4 Sedative & analgesic post-operative drugs
  - 15.1.4.1 Benzodiazepines
  - 15.1.4.2 Non-opioid analgesics
  - 15.1.4.3 Opioid analgesics
  - 15.1.4.4 Other drugs for sedation
- 15.1.5 Neuromuscular blocking drugs
  - Non-depolarising neuromuscular blocking drugs
  - Depolarising neuromuscular blocking drugs
- 15.1.6 Drugs for reversal of neuromuscular blockade
  - Anticholinesterases
  - Other drugs for reversal of neuromuscular blockade
- 15.1.7 Antagonists for central & respiratory depression
- 15.1.8 Drugs for malignant hyperthermia

### 15.2 Local anaesthesia

- Local Anaesthetic Toxicity
- Other agents

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
Paediatric Anaesthesia Website  
Children's Pain Management Website  
PICU Emergency Drugs Calculator  
[Non-formulary Conversion Table](#)

## NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

## GMMMG Formulary

Formulary Homepage  
Chapter 15: Anaesthesia (**ON HOLD**)  
GMMMG Adult **Red/Amber/Green**; DNP and Grey Drug List  
GMMMG Paediatric **Red/Amber/Green** Drug List

## 15.1 General anaesthesia

### 15.1.1 Intravenous anaesthetics

#### Etomidate

injection



#### Ketamine

Red

injection



#### Propofol

injection; infusion



#### Thiopental Sodium

injection



### 15.1.2 Inhalational anaesthetics

#### Volatile liquid anaesthetics

#### Desflurane

anaesthetic agent



**RESTRICTED**  
Theatres only

#### Isoflurane

anaesthetic agent



#### Methoxyflurane

Penthrox® inhalation vapour



**RESTRICTED**  
ED only

#### Sevoflurane

anaesthetic agent



#### Nitrous oxide

#### Nitrous Oxide



#### Nitrous Oxide 50% & Oxygen 50%

Entonox®



### 15.1.3 Antimuscarinic drugs

#### Atropine Sulfate

600microgram/1mL injection



Adults 600microgram/1mL  
I.M. or I.V.

#### Glycopyrronium Bromide

200micrograms/1mL; 600micrograms/3mL injection



Adults 200-400microgram I.V.

#### Hyoscine Hydrobromide

400microgram/mL injection



### 15.1.4 Sedative & analgesic post-operative drugs

#### 15.1.4.1 Benzodiazepines

#### Diazepam

tablets; liquid; injection; rectal tube (see also sections 4.1.2 &amp; 4.8.2)



#### Lorazepam

tablets; injection (see also sections 4.1.2 &amp; 4.8.2)



#### Midazolam

Green

oromucosal solution; injection; infusion (see also section 4.8.2)



#### Temazepam

tablets; oral solution (see also section 4.1.1)



### 15.1.4.2 Non-opioid analgesics

#### Ketorolac Trometamol

injection























































































#### Parecoxib

injection




























**RESTRICTED**  
Theatres only - acute postop. pain

<b>15.1.4.3 Opioid analgesics</b>		
<b>Alfentanil</b>		
 injection	 	
<b>Fentanyl</b>		
 injection (see also section 4.7.2)	 	
<b>Remifentanyl</b>		<b>RESTRICTED</b> Specialist use only
 injection	  	
<b>15.1.4.4 Other drugs for sedation</b>		
<b>Dexmedetomidine</b>		<b>RESTRICTED</b> Specialist use only
infusion	  	
<b>15.1.5 Neuromuscular blocking drugs</b>		
<b>Non-depolarising neuromuscular blocking drugs</b>		
<b>Atracurium Besilate</b>		
injection	 	
<b>Cisatracurium</b>		<b>RESTRICTED</b> Consultant only
injection	  	
<b>Mivacurium</b>		
injection	 	
<b>Rocuronium Bromide</b>		
injection	 	
<b>Vecuronium Bromide</b>		
injection	 	
<b>Depolarising neuromuscular blocking drugs</b>		
<b>Suxamethonium Chloride</b>		
injection	 	
<b>15.1.6 Drugs for reversal of neuromuscular blockade</b>		
<b>Anticholinesterases</b>		
<b>Neostigmine Metilsulfate</b>		
injection	 	
<b>Neostigmine Metilsulfate with Glycopyrronium Bromide</b>		
injection	 	
<b>Other drugs for reversal of neuromuscular blockade</b>		
<b>Sugammadex</b>		<b>RESTRICTED - Consultant</b> (Emergency) use in Theatres only Complete Trust incident & audit forms
<i>Bridion</i> ® injection	  	
<b>15.1.7 Antagonists for central &amp; respiratory depression</b>		
<b>Doxapram Hydrochloride</b>		
injection (see also section 3.5.1)	 	
<b>Flumazenil</b>		
injection	 	
<b>Naloxone Hydrochloride</b>		
injection	 	
<b>15.1.8 Drugs for malignant hyperthermia</b>		
<b>Dantrolene Sodium</b>		
injection	 	
MHRA Drug Safety Update (Jul-14): Intravenous dantrolene: risk of undissolved crystals		

15.2 Local anaesthesia	AAGBI SAFETY GUIDELINE
<b>15.2 Local anaesthesia</b>	
<b>Lidocaine Hydrochloride</b>	
<b>Lidocaine</b>	
0.5%, 1% & 2% injection	 
<b>with adrenaline</b>	
<b>Lidocaine with Adrenaline</b>	
1%, 2% injection	 
<b>for surface anaesthesia</b>	
<b>Lidocaine with Chlorhexidine</b>	
<i>Instillagel</i> ® 2% gel	 
<b>Lidocaine with Phenylephrine</b>	
<i>Co-phenylcaine</i> ® 5% / 0.5% spray	  
<b>Lidocaine with Prilocaine</b>	
<i>EMLA</i> ® 5% cream	 
<b>Lidocaine</b>	
4% topical solution	 
<b>Lidocaine</b>	
<i>Laryngojet</i> ® 4% (160mg/4mL) jet spray	 
<b>Lidocaine</b>	
5% ointment	 
<b>Lidocaine</b>	
<i>Xylocaine</i> ® 10% spray	 
<b>Lidocaine</b>	
<span style="border: 1px solid black; padding: 2px;">Green</span> <span style="border: 1px solid black; padding: 2px;">DNP</span>	
<i>Versatis</i> ® 700mg medicated plaster	  
<b>Bupivacaine Hydrochloride</b>	
<b>Bupivacaine Hydrochloride</b>	
0.25% Infusion (500mL)	 
<b>Bupivacaine Hydrochloride with Glucose</b>	
<i>Marcain Heavy</i> ® 0.5% Injection	 
<b>with adrenaline</b>	
<b>Bupivacaine and Adrenaline</b>	
0.25% with 1:200,000 injection	 
<b>Bupivacaine and Adrenaline</b>	
0.5% with 1:200,000 injection	 
<b>with other ingredients</b>	
<b>Bupivacaine and Fentanyl</b>	
 0.125% with 1mg/500mL infusion	 
<b>Bupivacaine and Sodium Chloride</b>	
0.08% in 0.9%	 
<b>Bupivacaine Hydrochloride with Glucose</b>	
20mg with 320mg/4mL spinal injection	 
<b>Levobupivacaine</b>	
<b>Levobupivacaine</b>	
<i>Chirocaine</i> ® 25mg/10mL; 50mg/10mL; 75mg/10mL injection; epidural 250mg/200mL	  
<b>Levobupivacaine with Fentanyl</b>	
 0.1% with 2microgram/mL epidural	 

**RESTRICTED**  
Consultant / specialist pain team only



<b>Prilocaine Hydrochloride</b>		
<b>Prilocaine Hydrochloride</b>		
<i>Citanest</i> ® 1% injection	 	
<b>Prilocaine Hydrochloride</b>		
<i>Prilotekal</i> ® 2% injection	  	
<b>Prilocaine with Felypressin</b>		
<i>Octapressin</i> ® 3% cartridges (30mg/mL Citanest with 0.54micrograms/mL)	 	
<b>Ropivacaine Hydrochloride</b>		
<b>Ropivacaine</b>		<b>For Consultant use on CDU (elective CS), Theatre 1 (ortho) &amp; wards 1 &amp; 2 (following surgery in Th. 1)</b>
injection; infusion	  	
<b>Tetracaine (Amethocaine)</b>		
<b>Tetracaine</b>		<b>RESTRICTED children under 1yr by specific doctor request or /V team</b>
4% gel	  	
<b>Local Anaesthetic Toxicity</b>		<b>AAGBI SAFETY GUIDELINE</b>
<b>Intralipid 20%</b>		
20% injection	 	
<b>Other agents</b>		
<b>Cocaine</b>		
 5% solution	 	
<b>Ethyl Chloride</b>		
<i>Cryogesic</i> ® spray	  	
<b>Mepivacaine Hydrochloride</b>		
3% injection	 	
<b>Neomycin Sulfate / Fluocinolone Acetonide / Lidocaine Hydrochloride</b>		<b>RESTRICTED Paediatrics. Intra-urethral steroid ointment</b>
<i>Nefluan</i> ® 10g gel	 	

## Section 16: Miscellaneous

Supported by the  
formulary ([click here](#))



### 16.1 Organ Perfusion Fluids

16.1.1 Cardiac Perfusion Fluids

16.1.2 Kidney / Pancreas / Liver perfusion fluids

16.1.3 Contrast Agents

## Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)  
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)  
NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)  
[Non-formulary Conversion Table](#)

## NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

## GMMMG Formulary

Formulary Homepage  
GMMMG Adult [Red/Amber/Green](#); DNP and Grey Drug List  
GMMMG Paediatric [Red/Amber/Green](#) Drug List

16.1 Organ Perfusion fluids		
<b>16.1.1 Cardiac perfusion fluids</b>		
Aspartate / Glutamate Solution <b>U</b> 100mL	MMC	
Bretschneiders Histidine-Tryptophan-Ketoglutarate (HTK) <b>U</b> Custodiol Cardioplegia® solution (1000mL)	MMC	emc⊕
Cardioplegia in Ringer's Solution <b>U</b> 1000mL	MMC	
Cardioplegic ULTH Formula A <b>U</b> 500mL	MMC	
Cardioplegic ULTH Formula B <b>U</b> 500mL	MMC	
Sterile Concentrate for Cardioplegia Infusion  20mL	MMC	emc⊕
<b>16.1.2 Kidney / Pancreas / Liver perfusion fluids</b>		
Cold Storage Solution (UW Solution)  Belzer UW® (1000mL)	MMC	emc⊕
Kidney Perfusion Fluid  Soltran® (1000mL)	MMC	emc⊕
Lung Perfusion Solution  Perfadex® (1000mL)	MMC	emc⊕
Machine Perfusion Solution  Belzer MPS® UW machine perfusion solution (1000mL)	MMC	emc⊕
<b>16.1.3 Contrast Agents</b>		
Gadobutrol  Gadovist® (1.0mmol/mL) injection	MMC	emc⊕
Gadoteric acid  Dotarem® (0.5mmol/mL) injection	MMC	emc⊕
Gadoxetic acid  Primovist® (0.25mmol/mL) injection	MMC	emc⊕
Perflutren  Luminity® (150microlitres/mL) lipid microspheres for injection	MMC	emc⊕
Sulphur Hexafluoride  SonoVue® (8microlitre/mL) injection	MMC	emc⊕